



Index

- 5-HT *See* Serotonin (5-HT)
5-HT_{1A} autoreceptors, 2159
5-Hydroxytryptophan (5-HTP), 2266
16th century, history of psychiatry, 2596–2597
17th century, history of psychiatry, 2597–2598
18th century, history of psychiatry, 2599–2601
19th century, history of psychiatry, 2601–2608
20th century, history of psychiatry, 2608–2619
- α_2 -adrenergic agonists, ADHD, 757–758
AA *See* Alcoholics Anonymous (AA)
AACAP *See* American Academy of Child and Adolescent Psychiatry (AACAP)
Aberrant behaviors, 1396
Abortion, spontaneous, 2362
Abreaction, to dissociative amnesia therapy, 1188
Abridged somatization disorder *See* Undifferentiated somatoform disorder
Abstinence, 1802
Abulia, 564
Abuse assessment screen (AAS), 2537, 2538
Academic achievement skills, 603
Acamprosate, 1426
ACC *See* Anterior cingulate cortex (ACC)
Acceptance and commitment therapy (ACT), 1846
Acceptance-based models, PTSD, 1151
Accountable care organizations (ACOs), 1794, 1795
Acetaminophen, 2198
Acetylcholine (ACh), 311
Acetylcholinesterase inhibitors, Alzheimer's disease, 401
Acetyl-L-carnitine (ALCAR), 2267
ACOs *See* Accountable care organizations (ACOs)
Acquired immune deficiency syndrome (AIDS), 1223
assessment issues, 1692
associated features, 1692
comorbidity and course, 1692
diagnostic features, 1691–1692
differential diagnosis, 1692
epidemiology, 1692
etiology and pathophysiology, 1692–1693
and major depressive disorder, 912–913
treatment, 1693
Acromegaly, 562
ACT *See* Assertive community treatment (ACT)
Active therapy (Ferenczi), 1820
Activity scheduling, 1846–1849
Acupuncture
anxiety disorders, 2270
cocaine use disorder, 1591
mood disorders, 2267
smoking, 1630
Acute and posttraumatic stress disorder, 1903–1904
Acute bereavement, supportive psychotherapy, 1873
Acute bipolar disorder *See* Bipolar disorder (BD)
Acute extrapyramidal symptoms (EPS), 2110, 2112
Acute grief, 2457
Acute major depression, 2060
Acute mania *See* Mania, mood stabilizers
Acute phase treatment, schizophrenia, 825–827
Acute sleep disruption, 1264–1265
Acute stress disorder (ASD), 1194
assessment, 1158
comorbidity, 1158
course, 1158
cultural presentations, 1158
definition, 1157–1158
diagnostic features, 1157–1158
differential diagnosis, 1158
epidemiology, 1158
etiology, 1159
gender, 1158
pathophysiology, 1159
and posttraumatic stress disorder, 1146
treatment, 1159
Acute Stress Disorder Interview (ASDI), 1158
Acute Stress Disorder Scale (ASDS), 1158
ADA *See* Americans with Disabilities Act (ADA)
Adaptive functioning
and behavior assessment
appearance, 576
attitude and cooperation, 576
motor behavior, 576–577
neuropsychological assessment, 603
Adaptive servoventilation (ASV), 1286
Addiction
animal models of reward, 369–370
anti-reward systems, 373–374
binge-intoxication stage, 371–373
brain circuitry neuroadaptations, 371–372
characterization, 359
compulsive disorders, 360
cycle, 360–362
definition, 359

- Addiction (*continued*)
 development, 362
 DSM-5 classification, 666
 impaired inhibitory control, 374–375
 impulse control disorders, 360
 medicine, 1549
 molecular genetic evidence, 376
 neurobiology, 359
 patterns, 360–361
 preoccupation/anticipation stage, 371–372, 374–375
 psychiatric comorbidity, 367–368
 transcription factors, 375–376
 transduction factors, 375
 withdrawal/negative affect stage, 371, 373–374
- Ademyelination-dominated
 polyneuropathy, 1519
- ADHD *See*
 Attention-deficit/hyperactivity disorder (ADHD)
- Adherence to medication, psychiatric disorders
 indirect measures, 2385–2386
 intervention strategies, 2393–2395
 medication compliance measurement, 2384–2385
 patterns, medication noncompliance, 2384
 prevalence, poor adherence to medication, 2384
 risk factors, noncompliance, 2386–2391
 shared decision-making, 2382–2383
 specific patient populations, 2391–2393
 theoretical models, health behavior, 2383–2384
- ADI-R *See* Autism Diagnostic Interview-Revised (ADI-R)
- Adjourning/termination model, group development, 1931
- Adjustment disorder (AD), 916
 assessment, 1160
 cases, 1160–1162
 comorbidity, 1160
 course, 1160
 culture and, 645–646
 definition, 1159–1160
 diagnostic features, 1159–1160
 differential diagnosis, 1160
 epidemiology, 1160
- Adolescent
 behavioral problems, 1772
 cannabis check-up, 1463
 critical exposure period, 368–369
 development
 biological, 194–198
 brain, 197–199
 cognitive, 199–202
 cognitive maturation, 192
 conceptual framework, 194
 consolidation of identity, 192
 emotional, 202–205
 gene–environment interactions, 207–209
 historical perspectives, 193–194
 ideal task accomplishment, 193
 phases, 193
 physical and emotional maturity, 192
 protective factors, 207–209
 risk factors, 207–209
 sexual thoughts, 192
 social, 204–207
 generalized anxiety disorder, 2164
 initial psychiatric evaluation, 629–638
 social anxiety disorder, 2168
- Adolescent-onset Huntington's disease, 1701
- Adrenal dysregulation, 912
- Adrenarche process, 195
- Adult ADHD, 750
- Adult attachment interview (AAI), 470
- Adult development
 conceptual framework, 213–216
 developmental and cohort effects, 216–217
 developmental formulations, 220–222
 Eriksonian model, 222–224
 grief, 224–225
 identity formation, 225–226
 integrated model, 220
 protective factors, 217–219
 resilience, 217–219
 risk factors, 217–219
 transitions and developmental crises, 225
 young adulthood, 219–220
- Adult-onset cases, Huntington's disease, 1700–1701
- Adult psychopathology, 286–287
- Advanced sleep phase type (ASPT), 1288, 1292
- Advocacy
 definition, 1983
 organizations, 1983–1986
 psychiatric evaluation, 637–638
- Affective cohesion, 1925–1926
- Affordable Care Act (ACA), 1545–1546
- Agencies, sharing information with, 637
- Agenesis, of corpus callosum, 684
- Age-related diminution, 234
- Aggregation toxicity, 1498
- Aggression *See also* Violence
 dysfunctional anger and, 2512–2513
 biological aspects, 2513
 neurotransmitters aspects, 2512–2513
- ID/IDD, 700
- neurologically based impairments, 2512
 reactive *vs.* deliberate, 2508
 suicidal ideation, 2496
 treatment
 nonpharmacological options, 2513–2514
 pharmacological options, 2514–2516
- Aggressive obsessions, 1098–1099
- Agitation management
 attitude change, 2480
 BARS, 2480
 culture change, 2480
 de-escalation, 2482–2484
 definition, 590, 2479
 environment change, 2480–2481
 evaluation
 attitude, 2481
 evaluation and management
 balance, 2482
 genuineness, 2481
 nonverbal communication, 2482
 initial management, 2481
 measurement scales, 2480
 modern guidelines, 2481
 oral antipsychotics, 2485
 psychopharmacology, 2484–2485
 restraints rate, 2480
 seclusion and restraint, 2485
 violent sequelae, 2479–2480
- Agnosias, 545
- Agonist replacement approach, 2332
- Agoraphobia, 1057
 assessment, 1059–1061
 and body dysmorphic disorder, 1132
 clinician–patient relationship issues, 1072
 cognitive behavioral therapy and, 1069–1071
 comorbidity patterns, 1062–1064
 costs, 1064
 course, 1064
 cultural presentations, 1065
 developmental presentations, 1065
 diagnostic features, 1059
 differential diagnosis, 1061
 DSM-5 definition, 1059
 environmental factors, 1068–1069
 epidemiology, 1061–1062
 gender presentations, 1065
 generalized anxiety disorder, 1081
 genetic factors, 1068
 and major depressive disorder, 1063
 neurobiological factors, 1066–1068
 personality disorders, 1064
 pharmacological treatments, 1071
 psychological factors, 1065–1066
 psychosocial treatment, 1069–1071
 refractory patient treatment, 1072
 selective serotonin reuptake inhibitors, 1068, 1071
 sequential treatments, 1071
 serotonin noradrenaline reuptake inhibitors, 1068
 simultaneous treatments, 1071
 social and environmental factors, 1068–1069
 special factors influencing treatment, 1072–1073
 substance use disorders, 1063–1064

- treatment goals, 1069
with vs. without panic attacks, 1058
- Agranulocytosis, antipsychotic drugs, 2117
- AHI *See* Apnea hypopnea index (AHI)
- Akathisia, 828, 2110, 2112
- Alabama Parenting Questionnaire, 1353
- Alcohol
alcohol use disorder treatment, 2335–2337
effects, 370
medically supervised withdrawal, 2334–2335
substance use disorders, 360–361, 1772–1773
suicidal ideation, 2495
violence and, 2510
- Alcoholics Anonymous (AA), 1924, 1928, 1986–1987
- Alcohol-induced disorders
anxiety disorder, 1408–1409
bipolar disorder, 1408
depressive disorder, 1408
intoxication, 1407
neurocognitive disorder, 1409, 1689–1690
psychotic disorder, 1408
sexual dysfunction, 1409
sleep disorder, 1409
withdrawal, 1407–1408
- Alcohol use disorder, 600
AUDIT, 1411–1412
candidate gene studies, 1404
cholinergic neurotransmission, 1407
clinical manifestations, 1404
comorbidity, 1416–1418
course and specifiers, 1404
diagnostic criteria, 1403
ethnic and cultural issues and treatment, 1428–1429
etiological subtypes, 1405–1406
GABAergic neurotransmission, 1406–1407
gender and developmental presentations, 1414–1415
geriatric patients, 1428
glutamatergic neurotransmission, 1407
- ICD-10 and DSM-5 diagnostic criteria, 1402–1404
issues in clinician–patient relationship, 1429
linkage studies, 1405
management algorithm, 1420
medical consequences, 365
natural history, 1418–1419
neuropharmacology, 1406
opioidergic neurotransmission, 1406
prevalence, 1402, 1415–1416
psychiatric history and examination, 1412–1414
serotonergic neurotransmission, 1406
treatment, 1419–1429
- Alcohol use disorders identification test (AUDIT), 1396
- Alexithymia
supportive psychotherapy, 1873
terminology, 731
- Algolagnic disorder, 1750
- Alienation, 2597
- Aliphatic class, of phenothiazines, 2094
- Aliphatic phenothiazines,
schizophrenia, 823
- Allegiance effect, 1824
- Allergic reactions, 2069
- Allopregnanolone, 969
- Alpha-2 adrenergic agonists, 1360
- Alprazolam
GAD treatment, 2165
premenstrual dysphoric disorder, 973
- Alternative/indigenous treatment and healing methods, 2044
- Alternative model, 571–572
- Altman Self-Rating Mania Scale (ASRS), 862
- Alzheimer's disease (AD), 1662
anatomical profile, 400
assessment issues, 1674–1675
associated features, 1674
clinical features, 400
cognitive enhancers
comorbidity and course, 1675
definition, 398
dementia management, geriatric psychiatry, 2442
diagnosis, 401
diagnostic features, 1674
differential diagnosis, 1675
early-onset and late-onset forms, 400
epidemiology, 1661–1662
etiology, 1675–1676
genetic analysis, 401–402
medications, 1677
medications and behavioral disturbance in geriatrics, 2446
pathogenesis, 400–401
pathology, 400–401
pathophysiology, 1675–1676
psychosis, 400
treatment, 401, 1676–1677
- Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADASc), 2236
- Alzheimer's-type dementia,
chromosomal disorders, 679
- Amenorrhea, 1231, 1233, 1234
- American Academy of Child and Adolescent Psychiatry (AACAP), 673
- American Medical Association (AMA), 1985
- American Psychiatric Association (APA), 673, 1985
- American Society of Addiction Medicine (ASAM), 1420
- Americans with Disabilities Act (ADA), 692
- Amisulpride, 2094–2095
- Amnesia
anterograde, 526–527
assessment issues, 1669
associated features, 1668–1669
chronic, 1670–1671
comorbidity and course, 1669
diagnostic features, 1668
differential diagnosis, 1669
epidemiology, 1669
episodic, 1669–1670
psychogenic, 525, 532
PTA, 527
retrograde, 526–527
treatment, 1671
- Amniocentesis, 689
- Amotivational syndrome, 1460, 1461
- AMP *See* Amphetamine (AMP)
- AMPA receptor modulators, 2247
- Amphetamine (AMP), 1280
ADHD, stimulants in children, 2205
somatic treatments, 755–756
- Amphetamine-type stimulants (ATS)
definition, 1561
METH (*see* Methamphetamine (METH))
- Amygdala, 198
- Amyloid-based interventions
anti-aggregation agents, 2250–2251
colostrinin, 2251
curcumin, 2251
docosahexaenoic acid, 2251
flurbiprofen, 2250
immunotherapy, 2249–2250
metal chelators, 2251
nonsteroidal anti-inflammatory drugs, 2250
peroxisome proliferator-activated receptor- γ agonists, 2251–2252
R-enantiomer, 2250
secretase inhibitors, 2250
statins, 2251
- Amyloid precursor protein (APP), 1676
- Anaclitic depression, 922
- Analysis of variance (ANOVA), 2586, 2587, 2589
- Analyst's listening process, in psychoanalytic psychotherapy, 1803
- Ancient times, history of psychiatry, 2593–2594
- Anencephaly, 684
- Angelman syndrome, 680
- Anger
DSM-5 diagnoses, 557–558
emotional expression, 564–565
vs. violence and aggression, 2508
- Anhedonia, 249
- Animal models
anxiety disorders, 333–334
experimental
cognitive and behavioral endophenotypes, 279–282
etiologic factors, 277

- Animal models (*continued*)
 genetic, environmental, and experiential etiologies, 285–287
 Huntington's disease, 276
 iterative pathogenic process, 277–278
 neuropathological/pharmacological phenotypes, 282–285
 phenotypes, 277–279
 Rett's syndrome, 276
 susceptibility genes, 277
 obsessive-compulsive disorder, 1111–1112
 of reward, addiction, 369–370
- Animal trials, antidepressants development, 2059
- Animism, 164
- Annihilation event, 621
- Anorexia nervosa, 645, 2598
 assessment, 1233
 body image, 1233
 comorbidity, 1236
 course, 1236
 definition, 1233
 differences in presentation, 1237
 differential diagnosis, 1236–1237
 DSM-IV-TR criteria, 1233
 epidemiology, 1235
 etiology/pathophysiology, 1237–1238
 family-based treatment for, 1773
 family treatment, 1240
 history, 1231, 1233
 laboratory findings, 1235
 medical problems, 1234
 physical examination, 1235
 physiological effects, 1233–1235
 prevention, 1240
 psychosocial treatments, 1239–1240
 somatic treatment, 1240
 supportive psychotherapy, 1879
 treatment, 1238–1240
 treatment-refractory patients, 1240
 weight restoration, 1239
- Anosmia, 1518
- Anosognosia, 1660, 1672
- ANOVA *See* Analysis of variance (ANOVA)
- Anterior attention system, 161
- Anterior cingulate cortex (ACC), 1358
- Anterograde amnesia, 526–527, 1668
- Anti-aggregation agents, 2250–2251
- Anti-cataplectic drugs, 1280
- Anticholinergic drugs, 1256
- Anticonvulsants
 acute bipolar depression
 divalproex/valproate, 2141–2142
 lamotrigine, 2142–2143
 topiramate, 2143
 aggression treatment, 2515
 generalized anxiety disorder, 2165–2166
 insomnia, 2200
- maintenance therapy, acute bipolar depression
 carbamazepine, 2148
 divalproex/valproate, 2147–2148
 lamotrigine, 2146–2147
 lithium and valproate combination, 2148
- major depressive disorder, 939
- mood stabilizers for mania
 carbamazepine, 2137–2138
 divalproex sodium/valproate, 2136–2137
- obsessive-compulsive disorder, 2183
- panic disorder, 2174
- posttraumatic stress disorder, 2177–2178
- social anxiety disorder, 2169
- Antidepressants
 ADHD, 758
 comparative trials, 2058–2059
 dementia in geriatrics, 2447
 development of, 2052, 2059
 discovery of, 2052
 drug–drug interactions, 2070
 drugs, 246
 eating disorders, 1240, 1244, 1245
 efficacy determination, 2055–2059
 first-generation
 efficacy determination, 2058
 gender, 2063–2064
 idiopathic effects, 2069–2070
 manic depressive disorder, 878
 mechanisms of actions, 2052–2053
 taxonomy and relation to, 2053–2055
 monoamine hypothesis of depression, 2052–2053
 patient preparation, 2064–2072
 perinatal depression
 congenital malformations, 2368–2375
 epidemiology, 2361–2362
 fetal death, 2362–2363
 fetal growth, 2367–2368
 gestational age and preterm birth, 2363–2367
 neonatal and post-neonatal demise, 2375
 neonatal behavioral syndrome, 2375–2378
 neurodevelopmental effects, 2378–2379
 persistent pulmonary hypertension, 2378
 spontaneous abortion, 2362
- postpartum depression, 2433
- pregnancy, psychiatric symptoms, 2429
- premenstrual dysphoric disorder, 970–972
- race and ethnicity, 2064
- receptors, 2053
- recommendations for use, 2081
- schizophrenia, 835
- sedating
 mirtazapine, 2200
 trazodone, 2199–2200
 tricyclic antidepressants, 2199
- selection, 2060–2063
- side effects, 2065–2069
- suicidal ideation treatment, 2498–2499
- theoretical basis for treatment, 2052–2055
- treatment, 352–354, 2060–2072, 2072–2081
- in United States, 2057
- uses, 2060–2061
- Antiepileptic drugs (AEDs) *See* Anticonvulsants
- Anti-excitotoxic therapies, 2253
- Antihypertensives, insomnia, 2200–2201
- Antimanic mood stabilizers, 2139
- Antioxidants, 2252
- Antipsychotic drugs (APDs) *See also* Atypical antipsychotics
 aggression treatment, 2514
 autistic disorder, in children, 2099
 bipolar disorder, 2097
 borderline personality disorder, 2097–2098
 cardiovascular effects, 2115–2116
 chemical structures of (*see* First-generation antipsychotics (FGAs))
 dementia
 behavioral disturbances, 2098
 in geriatrics, 2446–2447
- DNA microarray expression profiling, 2093
- dopamine D₂ receptor modulation, 2091
- drug interactions, 2108–2109
- dyslipidemia, 2115
- endocrine and sexual effects, 2113–2114
- EPS symptoms, 2110, 2112–2113
- gastrointestinal effects, 2116
- gene expression, 2094
- generalized anxiety disorder, 2166–2167
- H₁ receptors blockade, 2093
- hematological effects, 2117
- hepatic effects, 2116–2117
- history of, 2089, 2091
- Huntington's disease, 2098
- intracellular signal transduction (Akt, GSK-3, Wnt), 2093
- major depression with psychotic features, 2097
- medication cost, 2117–2118
- metabolic syndrome, 2115
- neuroleptic malignant syndrome, 2113
- neuroprotection, 2094
- neurotransmitter receptor affinities of, 2091, 2092
- nonpsychotic disorders, in children, 2099

- obsessive-compulsive disorder, 2183–2184
- ocular effects, 2117
- oral, agitation management, 2485
- panic disorder, 2174
- Parkinson's disease, 2098
- pervasive developmental disorders, 2098–2099
- pharmacology of, 2094–2097
- plasma levels, 2108
- posttraumatic stress disorder, 2178–2179
- and pregnancy, 2109–2110
- pregnancy, psychiatric symptoms risk, 2430
- research and treatment, 2118–2119
- schizoaffective disorder, 843–844
- schizophrenia, 2099–2101
- acute phase treatment, 825–827, 2102–2105
 - affective symptoms, 2101
 - aripiprazole, 825
 - asenapine, 825
 - cognitive impairments, 2100–2101
 - CPM with, 833–835
 - dibenzodiazepine, 823
 - dibenzoxazepine, 823
 - diphenylbutylpiperidines, 823
 - haloperidol, 823
 - iloperidone, 825
 - lurasidone, 825
 - maintenance treatment, 827, 2105–2107
 - negative symptoms, 2099–2100
 - olanzapine, 824
 - paliperidone/9-hydroxy risperidone, 825
 - phenothiazines, 823
 - positive symptoms, 2099
 - prodromal stage of, 2101–2102
 - quality of life, 2101
 - quetiapine, 824
 - risks and side effects, 828, 830–832
 - risperidone, 824
 - suicidal behavior, 2101
 - thioxanthenes, 823
 - ziprasidone, 824–825
- sedation, 2117, 2200
- selection, 2118
- serotonin receptor modulation, 2091, 2093
- side-effect profiles of, 2110, 2111
- substance-related disorders, 2098
- suicidal ideation treatment, 2499
- Tourette's disorder, 2097
- type 2 diabetes mellitus, 2114–2115
- weight gain and obesity, 2114
- Anti-reward systems, cocaine, 1567
- Antisocial personality disorder (ASPD), 1351, 1355, 1368, 1398, 1709
- assessment issues, 1720–1721
- comorbidity, 1721
- course, 1721
- diagnostic and associated features, 1720
- differential diagnosis, 1721
- epidemiology, 1721
- etiology and pathophysiology, 1721–1722
- treatment, 1722–1723
- Anti-stigma techniques, 1986
- Anxiety, 262, 600, 909–910, 932, 1019, 1356, 1773
- agoraphobia, 320, 322
 - alcohol-induced, 1408–1409
 - animal models, 333–334
 - autism, 385
 - autism spectrum disorder, 736
 - behavioral inhibition, 326–327
 - bipolar disorder and, 990
 - breathing control exercises, 1848
 - caffeine-induced, 1450–1451
 - cannabis-induced, 1462
 - categories, 320
 - clinical presentation, 556–559
 - complementary and alternative medicine
 - herbal medicines, 2268–2270
 - mind–body techniques, 2270–2274
 - nutritional medicines, 2270
 - culture and, 643
 - and depression
 - approach-avoidance conflict, 281–282
 - stress and maladaptive contingency learning, 286–287
 - DSM-5 classification, 557–559, 664
 - emotional expression, 554–559
 - etiology, 554–556
 - extinction and safety conditioning, 333
 - fear, 330–333
 - gene–environment interactions, 327–330
 - generalized anxiety disorder, 322
 - genetic contributions, 326
 - gross stress reactions, 321
 - herbal medicines
 - Galphimia glauca* (Galphimia), 2270
 - Matricaria recutita* (Chamomile), 2270
 - Melissa officinalis*, 2269
 - Passiflora incarnata* (Passionflower), 2269
 - Piper methysticum* (Kava), 2268–2269
 - Valeriana officinalis* (Valerian), 2269
 - hypnosis, 1901–1903
 - ID/IDD, 699–700
 - interpersonal situations, 321
 - intimate partner violence, 2543
 - IPT, 1866
 - manic depressive disorders with, 864
 - medical condition, 1082
 - in medical conditions, 556
 - mind-body techniques
 - acupuncture, 2270
 - meditation, 2270–2271
 - meditative movement, 2271–2274
 - and mood disorders, 1077–1078
 - motivation/interpretive biases, 446
 - nutritional medicines, 2270
 - obsessive-compulsive disorder, 320, 322–323, 1103
 - panic disorder, 322
 - pathophysiology, 323–324
 - phobias, 323
 - physical manifestations, 585–587, 586
 - physiological manifestations, 554
 - posttraumatic stress disorder, 320, 323
 - response-oriented approach, 555
 - social anxiety disorder, 323 (*see also* Social anxiety disorder)
 - social phobia, 321
 - spectrum, 554
 - suicidal ideation, 2495
 - supportive psychotherapy, 1878
 - symptoms, 564
 - theories, 555–556
 - therapeutic targets, 324–325
 - trait-state conception, 555
 - violence, 2509
- Anxiety-like symptoms, medical disorders with, 589
- Anxiety Sensitivity Index-3, 1021, 1060
- Anxiolytic drugs
 - azapyrones, 2159
 - barbiturates, 2159
 - differential diagnosis, 2160
 - DSM-IV-TR, 2159
 - γ -aminobutyric acid, 2159
 - medication usage, pharmacological properties, 2161
 - monoamine oxidase inhibitors, 2159
 - psychotropic medications effects, 2160
 - selective serotonin reuptake inhibitors (SSRIs), 2159
 - tricyclic antidepressants, 2159
 - venlafaxine, 2159
- APA *See* American Psychiatric Association (APA)
- Apathy, 932, 1660
- characteristics, 565
 - DSM-5 diagnoses, 557–558
 - emotional expression, 564
- Aplastic anemia, 1521
- Apnea hypopnea index (AHI), 1282
- Appreciative inquiry (AI), 494
- Arginine vasopressin receptors 1a (AVPR1a), autism, 387
- Aripiprazole, 2095
- acute bipolar depression, 2140–2141
 - aggression treatment, 2515
 - maintenance therapy, 2149
 - schizophrenia, 825
- Armodafinil, 1280, 2144
- Army Alpha and Army Beta Tests, 530
- Arousal/regulatory systems domain, 669

- Arrhythmia, 1439
 ASDI *See* Acute Stress Disorder Interview (ASDI)
 ASDS *See* Acute Stress Disorder Scale (ASDS)
 Asenapine, 2095
 mania, mood stabilizers, 2135
 schizophrenia, 825
 ASPD *See* Antisocial personality disorder (ASPD)
 Asperger syndrome, 390, 391, 722
 ASPT *See* Advanced sleep phase type (ASPT)
 Assertive community treatment (ACT)
 case management model, 1964–1965
 description, 1965–1966
 efficacy and benefits, for SMI patients, 1966–1967
 implementation and current availability, 1967–1968
 integrated health and social care component of, 1967
 involuntary outpatient commitment, 1966
 program, 2567
 schizophrenia, 840
 team-based approach, 1966
 Associative deficit hypothesis (ADH), 233
 Atomoxetine (ATX), 1280
 ADHD, 757
 for tics, 788
 Attachment theory, 22–23
 adult attachment interview, 470
 basics of model, 470–471
 definition, 470
 extensive research, 471
 formulation and treatment, 471–472
 historical context, 470
 and object relations theory, 114
 Attention
 alerting system, 437
 and behavioral flexibility, 250–251
 definition, 441
 difficulties in psychiatric disorders, 437–439
 and executive functions, 439–440
 executive system, 437
 filters and capture, 437
 implications for therapeutic intervention, 439
 neural basis, 437
 neuropsychological assessment, 602
 orienting system, 437
 Attention-deficit/hyperactivity disorder (ADHD), 188, 633, 709, 1174, 1368
 α_2 -adrenergic agonists, 757–758
 adherence to medication, psychiatric disorders, 2392
 adult, 750
 antidepressants, 758
 assessment issues, 749
 associated features, 749
 atomoxetine, 757
 bipolar disorder, 990
 candidate genes for, 752
 cannabis dependence, 1466
 children with, 1356
 clinician–patient relationship, 761–762
 cocaine use disorder, 1595–1596
 combined treatments, 760
 comorbidity, 750–751, 760–761
 complementary and alternative medicine
 herbal medicines, 2281
 mind–body techniques, 2281–2282
 nutritional medicines, 2280–2281
 course, 751
 developmental effects, 761
 developmental, gender, and cultural presentations, 751
 diagnostic features, 748–749
 differential diagnosis, 751–752
 epidemiology, 750
 genetic factors, 752
 laboratory measures, 750
 manic depressive disorders with, 864
 mind–body techniques
 meditation, 2281
 neurotherapy, 2281–2282
 modafinil, 758
 neurobiological factors, 752–754
 neuropsychological assessment, 605, 750
 nutritional medicines
 dietary elimination strategies, 2280–2281
 omega-3 fatty acids, 2280
 phosphatidylserine, 2280
 psychological factors, 754
 psychosocial treatments, 758–760
 psychostimulants, 755–757
 rating scales, 749
 social/environmental factors, 754–755
 somatic treatments, 755
 stimulants in children
 amphetamines, 2205
 clinical use, 2221–2226
 indications, 2210
 medications, 2205–2208
 methylphenidates, 2205
 OROS-MPH, 2209
 pharmacology, 2208–2210
 review of efficacy data, 2210–2218
 serotonin (5-HT), 2209
 side effects, 2218–2221
 symptoms, 735–736, 1356
 tobacco use disorder, 1619
 treatment algorithms and practice guidelines, 761
 treatment goals, 755
 treatment-refractory patients, 760
 Attitudes, 9–10
 Attributable risk, psychiatric epidemiology, 412
 Attributional style, cognitive model, 1839
 Attribution theory, 454–460
 ATX *See* Atomoxetine (ATX)
 Atypical antipsychotics, 1360, 2080 *See also* New-generation antipsychotics (NGAs)
 for acute bipolar depression
 aripiprazole, 2140–2141
 lurasidone, 2141
 olanzapine-fluoxetine combination and olanzapine, 2139–2140
 quetiapine, 2140–2141
 ziprasidone, 2141
 maintenance therapy
 aripiprazole, 2149
 olanzapine, 2148–2149
 paliperidone, 2150–2151
 quetiapine adjunctive to
 lithium/divalproex, 2149–2150
 risperidone, 2150
 ziprasidone adjunctive to
 lithium/valproate, 2150
 mania, mood stabilizers
 aripiprazole, 2135
 asenapine, 2135
 atypical antipsychotics, 2133
 olanzapine, 2133
 paliperidone, 2134
 quetiapine, 2134
 risperidone, 2133–2134
 role in treatment, 2136
 tolerability and safety issues, 2135–2136
 ziprasidone, 2135
 treatment-resistant depression, 2324
 Atypical depression, 2061
 AUDIT *See* Alcohol use disorders identification test (AUDIT)
 Auditory hallucinations, 543
 Australian Clinical Guidelines for Early Psychosis, 1999
 Authoritarian personality, 453
 Autism
 alternative medicine, 393
 anxiety, 385
 ASD (*see* Autistic spectrum disorder (ASD))
 autoimmune disorders, 385–386
 AVPR1a, 387
 behavioral features, 383–384
 behavioral treatment, 391–392
 calcium ion channels, 388
 comorbid features, 385–386
 DHCR7, 388
 diagnosis features, 384–385
 distal-less 2/5, 388
 Engrailed2, 388
 epidemiology, 382–383
 etiology, 386–388
 FMR1, 387
 FRAXA, 387
 functional neuroimaging, 390–391
 gastrointestinal disorders, 385

- ion channels, 388
 main intervention approaches, 392
 MeCP2, 388
 medical features, 385–386
 Met tyrosine kinase, 387
 microscopic neuropathology, 389–390
 neuroligins, 387
 neuropathology, 388–390
 OXTR, 387
 phenylalanine hydroxylase, 388
 psychopharmacological treatments, 393
 PTEN, 387
 seizures, 385
 serotonin transporter, 387
 SHANK3, 387
 sodium ion channels, 388
 structural MRI studies, 388–389
 treatment delivery, 392
 tuberous sclerosis, 387
- Autism Diagnostic Interview-Revised (ADI-R), 727
- Autism spectrum disorder (ASD), 437, 709–710, 1172
 ADHD symptoms, 735–736
 anxiety, 736
 assessment issues, 726–727
 associated features, 725–726
 autoimmune disorders, 386
 CAM, 736–737
 children, 383
 clinician–patient relationship, 739–741
 combined treatment, 738
 comorbidity, 728, 1014
 compulsions and interfering repetitive behaviors, 735
 course, 728
 developmental, gender, and cultural presentations, 729
 diagnostic features, 384, 723–725
 differential diagnosis, 729
 DSM-IV/DSM-IV-TR subtypes, 722–723
 DSM-5 diagnostic criteria for, 724
 epidemiology, 727
 genetic factors, 729–730
 impairments, 383
 intelligence quotient scores, 726
 irritability, 733–735
 neurobiological factors, 730–731
 prevalence, 385
 psychological factors, 731
 psychosocial treatments, 737–738
 randomized, controlled trials, 734
 sleep disturbance, 736
 social cognition, 443, 445–446
 social/environmental factors, 731–732
 somatic treatment, 732–733
 special factors influencing treatment, 738–739
 symptom rating scales, 727
 treatment goals, 732
 treatment-refractory patients, 738
- Autistic disorder
 in children, antipsychotic medication, 2099
 DSM-IV-TR diagnostic criteria for, 724
- Autoerotic deaths, 1513
- Autoimmune disorders
 autism, 385–386
 delirium, 1656
- Automatic thoughts
 description, 1837
 modification
 cognitive-behavior rehearsal, 1845
 examining the evidence procedure, 1843–1845
 generating alternatives, 1845
 imagery techniques, 1842–1843
 mood shifts, 1842
 role-playing, 1842
 Socratic questioning, 1842
 thought recording, 1843
 negative thoughts, 1837–1839
- Autosomal dominant inheritance disorder, 681
- Autosomal recessive inheritance disorder, 681–682
- Avatars, 2022
- Aversive techniques, tobacco use disorder, 1629
- Avoidant behavior, 580–581
- Avoidant personality disorder (AVPD), 1027, 1732–1734
- Avoidant/restrictive food intake disorder (ARFID), 1247
- Azapyrones, 2159
- BABS *See* Brown Assessment of Beliefs Scale (BABS)
- Baclofen, 1590, 1652, 2352
- Bad trips, hallucination, 1484
- Barbiturates
 anxiolytic drugs, 2159
 injection of, 1553
 phenobarbital withdrawal equivalents, 1557
- BARS *See* Behavioral Activity Rating Scale (BARS)
- BD *See* Bipolar disorder (BD)
- BDD *See* Body dysmorphic disorder (BDD)
- Beck Anxiety Inventory, 1060
- Beck Depression Inventory, 1060
- BED *See* Binge-eating disorder (BED)
- Behavioral Activity Rating Scale (BARS), 2480
- Behavioral Assessment Scales for Children (BASC-2), 1351
- Behavioral avoidance tasks (BATs), generalized anxiety disorder, 1010
- Behavioral disorders, 676, 695
- Behavioral genetics, 342–343
- Behavioral inhibition, 326–327
- Behaviorally induced insufficient sleep, 1278
- Behavioral marital therapy (BMT), 1771–1772
- Behavioral models
 antidepressants development, 2059
 posttraumatic stress disorder, 1150–1151
- Behavioral or psychological symptom of dementia (BPSD), 2444–2445
- Behavioral parent training (BPT), 1361
- Behavioral tests, anxiety disorder, 1023
- Behavioral theory
 classical conditioning, 478–479
 operant conditioning, 479
 overview, 478–479
 panic disorder, 485–486
 PTSD, 486
 schizophrenia, 486
- Behavioral therapy (BT), 1361
 ADHD, 759
 ID/IDD, 702
 OCD, 1119–1120
 Skinner and Wolpe, 1821
 tobacco use disorder, 1629
- Behavioral tolerance, drinking, 1403–1404
- Behavioral treatment, autism, 391–392
- Behavioral variant FTD (bv-FTD), 402–403
- Behavior exchange contracts, 1848–1849
- Behaviors
 avoidant patterns, 580–581
 compulsive patterns, 579–580
 emotional expression, 547–551
 impulsive patterns, 577–579
 mental status examination, 504
 motor, 576–577
 problematic patterns, 577–581
 suicidal ideation and, 2492
 violence (*see* Violence)
- Behçet syndrome, 1666
- Bender–Gestalt Test, 509
- Beneficence, 73
- Benzodiazepine, 1300, 1550
 aggression treatment, 2515
 alcohol withdrawal, 1421
 dementia in geriatrics, 2447–2448
 GAD treatment, 2165
 generic and trade names, 1551
 hypnotics, 2195–2196
 intoxicating effects, 1555
 medication
 generalized anxiety disorder, 2165
 obsessive-compulsive disorder, 2182
 panic disorder, 2173–2174
 social anxiety disorder, 2169
 phencyclidine intoxication, 1477
 phenobarbital withdrawal equivalents, 1557
 pregnancy, psychiatric symptoms risk, 2430–2431
 receptor agonists, 1274
 receptors, 1551

- Bereavement, 905 *See also* Grief
- Beta-blocker medication
 aggression treatment, 2516
 obsessive-compulsive disorder, 2182–2183
 posttraumatic stress disorder, 2177
 social anxiety disorder, 2169
- BFRBD *See* Body-focused repetitive behavior disorder (BFRBD)
- Big Data, 2022–2023
- Binge drinking, 360–361, 1402
- Binge-eating disorder (BED)
 assessment, 1245–1246
 comorbidity, 1246
 course, 1246
 definition, 1245
 differential diagnosis, 1246
 epidemiology, 1246
 etiology/pathophysiology, 1246
 history, 1245
 laboratory findings, 1246
 physical examination, 1246
 psychosocial treatment, 1246
 with purging, 1233, 1240–1245
 somatic treatment, 1246
 treatments, 1246
- Binge-intoxication stage, addiction, 371
 motivation substrate-positive, 372–373
 salience and reward circuitry, 372
- Binswanger's disease, 1664, 1684–1685
- Biofeedback therapy, encopresis, 1260
- Biogenic spectrum model, 573–574
- Biological context, 172
- Biological development
 adolescents, 194–198
 human, 104–106
 infant, 138, 140–141, 143–144, 145, 149
 preschool, 161–162
 school-age, 181–182
- Biopsychosocial model, 126
- Bipolar disorder (BD), 263–264, 1398
See also Manic depressive disorder;
 Mood stabilizers
 ADHD, 990
 adherence to medication, psychiatric disorders, 2391–2392
 alcohol-induced, 1408
 anticonvulsants/AEDs, 2141–2143
 antipsychotic medication, 2097
 anxiety disorders, 990
 assessment issues, 989–990
 associated features, 989
 atypical antipsychotics for acute bipolar depression, 2139–2141
 bipolar depression, 991, 994
 case, 996
 combined treatments, 995
 comorbidity, 990, 991
 conduct disorder, 991
 couple- or family-centered care, 1945
 course, 991–992
 diagnostic features, 988–989
 differential diagnosis, 992
 DSM-5 classification, 664, 988
 epidemiology, 990–991
 gambling, 1640
 genetic factors, 992
 lithium, 2143
 major depressive disorder, 907
 mood stabilizers for
 antimanic mood stabilizers, 2139
 armodafinil, 2144
 clinical approach, 2138
 ketamine, 2144
 maintenance therapy, 2144–2151
 modafinil, 2143–2144
 neurobiological factors, 992–993
 OCD, 1102
 oppositional defiant disorder, 991
 psychological factors, 993
 psychosocial treatments, 995
 rapid cycling, 2151–2153
 social/environmental factors, 993–994
 somatic treatments, 994–995
 special factors influencing treatment, 996
 substance use disorders, 991
 treatment goals, 994
 treatment-refractory patients, 995–996
 treatment-resistant depression, 2315
- Bipolar I disorder
 clinical case, 887
 phenomenology, 858–859
 psychosis and rapid cycling, 859–860
 screening for manic depressive disorder, 860–867
- Bipolar II disorder, 887–888
- Bipolar Spectrum Diagnostic Scale (BSDS), 860
- Blogs, 2018
- Blonanserin, 2095
- Blood alcohol level (BAL), 1407
- Blood oxygenation-level dependent (BOLD), 436
- The Blue Brain Project, 2021–2022
- Body dysmorphic disorder (BDD)
 associated features, 1130–1131
 clinician–patient relationship issues, 1134
 combined treatments, 1134
 comorbidity, 1131
 course, 1131
 cultural presentations, 1131–1132
 developmental presentations, 1131–1132
 diagnostic features, 1129–1133
 differential diagnosis, 1132–1133
 DSM-5 diagnostic criteria, 1130
 dysmorphic concern and, 1132–1133
 epidemiology, 1131
 etiology and pathophysiology, 1133
 gender presentations, 1131–1132
 issues, 1131
 OCD and, 1096, 1107
 physical signs and symptoms, 593
 psychosocial treatments, 1133–1134
 somatic treatment, 1133
 special factors influencing treatment, 1134
 treatment-refractory patients, 1134
- Body-focused repetitive behavior disorder (BFRBD), 1135
- Body mass indices (BMIs), 196
- BOLD *See* Blood oxygenation-level dependent (BOLD)
- Borderline personality disorder (BPD), 12, 294, 467, 1180, 1368, 1398, 1708, 2620
 antipsychotic medication, 2097–2098
 course, 1724–1725
 diagnostic and associated features, 1724
 differential diagnosis, 1724
 epidemiology, 1724
 etiology and pathophysiology, 1725
 hypnosis, 1899
 suicidal ideation, 2496
 treatment, 1725–1726
- Boston process approach, 604–605, 607
- Bottom-up processing model system, 1181
- BPD *See* Borderline personality disorder (BPD)
- Brain-derived neurotrophic factor (BDNF), 311, 329, 344, 921
- Brain development, adolescents, 197–199
- Brain–gut axis, 1912
- Brain imaging, 514–515
 functional imaging modalities, 620–624
 molecular imaging, 624
 psychiatric populations, 624–627
 structural imaging modalities, 617–620
- Brain reading, 2022
- Brain stem evoked potentials (BSEPs), 612
- Brain stimulation, in psychiatry
 applications
 in health and disease, 2294–2295
 neuroimaging and neurophysiology, 2295
 mechanisms of action
 acute vs. chronic effects, 2293–2294
 electrical stimulation, 2292
 neuroplasticity, 2294
 vs. psychopharmacology, 2292–2293
 response, 2294
 relative focality and invasiveness of, 2294
 tools
 DBS, 2305–2306
 ECT, 2295–2298
 MST, 2301–2302
 tDCS, 2302–2303

- TMS, 2298–2301
VNS, 2303–2305
- Brain stimulation reward, 370
- Breast cancer patients
 personality traits/coping style, 2409
 psychoanalytic psychotherapy, 1811
- Breastfeeding and postpartum
 depression, 2433
- Breathalyzer, 1397
- Breathing control exercises, CBT, 1848
- Breathing-related sleep disorders
 (BRSD), 1279
 assessment issues, 1283
 associated features, 1283
 clinician–patient relationship issues,
 1285
 combined treatments, 1285
 comorbidity, 1283–1284
 course, 1284
 developmental/gender/cultural
 presentations, 1284
 diagnosis, 1282–1283
 differential diagnosis, 1284
 epidemiology, 1283
 etiology/pathophysiology, 1284
 factors influencing treatment, 1285
 genetic factors, 1284
 neurobiological factors, 1284
 psychological factors, 1284
 psychological treatments, 1285
 social/environmental factors, 1284
 somatic treatment, 1284–1285
 treatment, 1284–1285
- Brevity, 1822
- Brief Dimensional Scales for Anxiety
 Disorders, 1060
- Brief psychodynamic therapy
 characterization of, 1823
 disorders treated with, 1824
 meta-analyses of, 1823–1824
 therapist interventions, 1823
- Brief psychotherapy
 availability, 1822
 average duration of, 1820
 common factors
 change process, sequencing of,
 1831–1832
 focal aims, 1830–1831
 patient inclusion criteria, 1830
 therapist and patient activity, 1831
 time-effectiveness, 1829–1830
 contextual therapies, 1828–1829
 cost-effectiveness, 1822–1823
 history of, 1820–1822
 learning therapies, 1827–1828
 relational therapies, 1825–1827
- Brief psychotic disorder
 clinical signs and symptoms, 845
 course and prognosis, 845
 diagnosis, 844–845
 differential diagnosis, 845
 epidemiology, 845
 etiology, 845
 treatment, 845–846
- Brief Romantic Relationship Interaction
 Coding Scheme (BRRICS), 1769
- Briquet's syndrome *See* Somatization
 disorder
- Broad-based rating scales, 1351
- Broaden-and-build theory, positive
 emotions, 491
- Brokerage approach, 1965
- Bromocriptine, 973, 1688
- Brown Assessment of Beliefs Scale
 (BABS), 1100
- BRSD *See* Breathing-related sleep
 disorders (BRSD)
- BSEPs *See* Brain stem evoked potentials
 (BSEPs)
- BT *See* Behavior therapy (BT)
- Bulimia nervosa, 2595
 assessment, 1241
 comorbidity, 1242
 course, 1242
 definition, 1240–1241
 differential diagnosis, 1242
 epidemiology, 1241–1242
 etiology/pathophysiology, 1242–1243
 factors influencing treatment, 1245
 history, 1240, 1242
 laboratory findings, 1241
 neurobiological factors, 1243
 physical examination, 1241
 physiological disturbances, 1241
 psychological factors, 1243
 psychosocial treatments, 1244
 social/environmental factors, 1243
 somatic treatment, 1244–1245
 treatment, 1243–1245
- Bulletin board systems (BBS),
 2017–2018
- Bullying, 184–185
- Buprenorphine
 for detoxification, 2340–2341
 induction procedure for, 2343–2345
 maintenance, 2345
 opioid use disorder, 1536, 1538,
 1539–1540
 prognostic factors for, 2344
 required physician qualification to
 prescribe, 2343
- Bupropion
 ADHD, 758
 cannabis dependence, 1465
 obsessive-compulsive disorder, 2182
 panic disorder, 2173
 social anxiety disorder, 2168
 tobacco use disorder, 1627
 treatment-resistant depression, 2321
- Bureau of Justice Statistics (BJS), 2564
- Bupirone, 2159
 alcohol withdrawal, 1424
 generalized anxiety disorder, 2165
 major depressive disorder, 940
 obsessive-compulsive disorder, 2182
 panic disorder, 2174
 social anxiety disorder, 2169
 treatment-resistant depression, 2324
- Buss–Perry Aggression scale, 1353
- Butyrophenones, 823, 2094
- Bv-FTD *See* Behavioral variant FTD
 (Bv-FTD)
- B vitamins, mood disorders, 2266
- Bystander effect, 454
- Caffeine
 content of foods and medications,
 1435, 1436
 induced anxiety disorder, 1450–1451
 induced sleep disorder, 1451–1453
 intoxication
 assessment issues, 1437
 comorbidity, 1438
 course, 1438–1439
 diagnostic features, 1436–1437
 differential diagnosis, 1439
 epidemiology, 1437–1438
 genetic factors, 1439
 neurobiological and behavioral
 factors, 1439–1440
 treatment, 1440
 in United States, 1435
 use disorder
 definition, 1445
 diagnosis, 1445–1447
 etiology and pathophysiology,
 1447–1449
 treatment, 1449–1450
 withdrawal
 assessment issues, 1441
 associated features, 1441
 comorbidity, 1442–1443
 course, 1443
 diagnostic features, 1440–1441
 differential diagnosis, 1443
 epidemiology, 1441–1442
 genetic factors, 1443
 neurobiological and behavioral
 factors, 1444
 signs and symptoms, 1440
 treatment, 1444
- Calcium channel blockers, 2253
- Calcium ion channels, autism, 388
- CAM *See* Complementary and
 alternative medicine (CAM)
- Camellia sinensis*, schizophrenia, 2275
- cAMP response element binding protein
 (CREB), 375
- Canadian Network for Mood and
 Anxiety Treatments (CANMAT)
 pharmacotherapy guidelines, 2325
- Cancer
 mental disorders and psychological
 symptoms, 2408–2409
 outcome, 2409
 personality traits/coping style, 2409
 psychological factors, 2409
 treatment of, 913, 2074
- Candidate dopamine (DA) genes, 752
- Candidate gene studies
 alcohol dependence, 1404
 cocaine use, 1564

- Cannabis, 370–371
 abuse and dependence, 1458–1460
 description, 1458
 in eastern and western World, 1458–1459
 endocannabinoid system, 1460–1462
 frequency of use and amount used, 1460
 intoxication delirium, 1461–1462
 pharmacotherapy, 1465–1466
 synthetic cannabinoids, 1462–1463
 treatment, cannabis-related disorders, 1463–1465
 withdrawal syndrome, 360
- Capgras' syndrome, 544
- CAR *See* Cortisol awakening response (CAR)
- Carbamazepine
 alcohol withdrawal, 1421
 maintenance therapy, acute bipolar depression, 2148
 mood stabilizers for mania, 2137–2138
 pregnancy, psychiatric symptoms risk, 2430
- Carbidopa, 1300
- Carbohydrate-deficient transferrin (CDT), 1413
- Cardiac arrhythmia
 cocaine use, 1576
 inhalant abuse, 1520
- Cardiomyopathy, 1577
- Cardiopulmonary abnormalities, 688–689
- Cardiovascular patients, treatment of, 2073–2074
- CAS *See* Child Anxiety Scale (CAS)
- Cataplexy, 1277, 1280
- Catatonia, 525, 794, 906–907, 946
- CATCH22 syndrome *See* Velocardiofacial syndrome (VCFS)
- Catechol *O*-methyltransferase (COMT), 869, 1382, 1621
 HPPD, 1492, 1493
 STPD, 1719
- Categorical model, personality style, 571–572
- CATIE trial, 826
- CBIT *See* Comprehensive behavioral intervention for tics (CBIT)
- CBT *See* Cognitive behavioral therapy (CBT)
- CD *See* Conduct disorder (CD)
- CDI *See* Children's Depression Inventory (CDI)
- Central nervous system (CNS), malformation of, 683–684
- Central sleep apnea (CSA)
 assessment issues, 1286
 associated features, 1286
 clinician–patient relationship issues, 1287
 comorbidity, 1286
 course, 1286
- diagnostic features, 1285–1286
 differential diagnosis, 1286
 epidemiology, 1286
 etiology/pathophysiology, 1286
 treatment, 1286–1287
 treatment-refractory patients, 1287
- Cerebellum, schizophrenia, 310–311, 806
- Cerebral palsy (CP), 675–676
- Cerebrolysin, 2248
- Cerebrospinal fluid evaluation, 514
- Cerebrovascular disease
 major depressive disorder, 911–912
 stimulant use disorders, 1577–1578
- CFI *See* Cultural Formulation Interview (CFI)
- CGH *See* Comparative genomic hybridization (CGH)
- Change talk, 1882
- Chemical dependency, supportive psychotherapy, 1873
- Chemotoxicity, 618
- Cheyne–Stokes breathing (CSB), 1286
- Child- and family-focused cognitive behavioral therapy (CFF-CBT), 995
- Child Anxiety Scale (CAS), 634
- Child Behavior Checklist (CBCL), 632, 1355
- Childhood disintegrative disorder, 384, 723
- Childhood gender nonconformity, 170
- Childhood-onset fluency disorder (COFD)
 associated features, 715
 comorbidity, 715
 course, 715–716
 definition and diagnostic features, 715
 developmental, gender, and cultural presentation, 716
 differential diagnosis, 716
 epidemiology, 715
 genetic factors, 716
 neurobiological factors, 716
 outcome, 717
 psychological factors, 716
 social/environmental factors, 716
 somatic treatment, 716–717
 treatment goals, 716
- Childhood onset schizophrenia (COS), 306, 2102
- Child maltreatment, 153, 187
- Children, 14
 caffeine withdrawal, 1441
 disability identification, 636
 generalized anxiety disorder, 2164
 initial psychiatric evaluation, 629–638
 major depressive disorder, 914
 psychiatric evaluation, 630–631
 social anxiety disorder, 2168
- Children's Aggression Scale, 1353
- Children's Depression Inventory (CDI), 634
- CHIME framework, 1960
- Chinese classification, of mental disorders, 648
- Chi-square, research design, 2586
- Chloral hydrate, 2200
- Cholesterol emboli syndrome, 1654
- Cholinergic neurotransmission, 1407
- Cholinergic treatment approaches
 adverse effects, 2245
 cholinesterase inhibitors, 2241
 donepezil, 2243, 2245
 galantamine, 2244–2245, 2246
 indirect cholinergic-enhancing strategies, 2241
 muscarinic agonists and antagonists, 2241
 nicotinic agonists, 2241
 precursor loading, 2241
 rivastigmine, 2243–2244
 tacrine, 2242, 2245
 vastigmine, 2245
- Cholinesterase inhibitors, 2241
- Choreoacanthocytosis, 1665
- Chorionic villus sampling (CVS), 689
- Chromosomal anomalies, prenatal causes, 677–680
- Chronic amnesia, 1670
- Chronic care models (CCMs), 885
- Chronic drinking, 1403
- Chronic extrapyramidal symptoms, 2112–2113
- Chronic obstructive pulmonary disease (COPD), 2413
 tobacco use disorder, 1618
- Chronic pain, 911
- Chronology, of historical events, 2625–2630
- Chronotherapy, depressive disorder, 935
- Chvostek's sign, 586
- CIDI *See* Composite International Diagnostic Interview (CIDI)
- Cigarette smoking, 1449 *See also* Tobacco use disorders
- Circadian genes, 1265
- Circadian regulation of sleep, 1265
- Circadian rhythms, 1264–1266
- Circadian rhythm sleep-wake disorders (CRSWD)
 assessment issues, 1289–1290
 associated features, 1289
 case study, 1292–1293
 clinical algorithm, 1289
 clinician–patient relationship issues, 1292
 combined treatments, 1292
 comorbidity, 1290
 course, 1290
 developmental/gender/cultural presentations, 1290
 diagnostic features, 1288–1289
 differential diagnosis, 1290–1291
 epidemiology, 1290
 etiology/pathophysiology, 1291
 factors influencing treatment, 1292

- genetic factors, 1291
 neurobiological factors, 1291
 psychological factors, 1291
 psychological treatment, 1292
 social/environmental factors, 1291
 somatic treatment, 1291–1292
 treatment, 1291–1292
 treatment-refractory patients, 1292
- Circular interactional pattern, 1765
- Circumplex model, emotions, 551
- Citalopram, 1117
 anxiety disorders, 2163
- Citizens Commission on Human Rights (CCHR), 1985
- Civil law issues
 competency and treatment refusal, 87–88
 confidentiality and privilege, 89–90
 disability and fitness evaluations, 92–93
 hospitalization decisions, 86–87
 informed consent, 88
 involuntary hospitalization, 86
 malpractice, 90–91
 physician–patient boundary violations, 92
 supervising, 91–92
 treatment of minors, 88–89
- Civil Rights of Institutionalized Persons Act (CRIPA), 692
- CJD *See* Creutzfeldt-Jakob disease (CJD)
- Classical conditioning, 478–479
- Classification systems
 categorical *vs.* dimensional, 658–659
 DSM-I and DSM-II, 659
 DSM-III, 659
 DSM-III-R, 660
 DSM-IV, 660
 DSM-IV-TR, 661
 DSM-V, 661–662
 etiological *vs.* descriptive, 657–658
 goals of, 657
 ICD-10/ICD-11, 661
 syndrome *vs.* symptom, 658
- Clearance (CL), definition of, 2032–2033
- Client-operated services, 1983, 1988
- Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), 2099
- Clinical case management model, 1965
- Clinical global impression of change (CGIC), 2237
- Clinical practice guidelines (CPGs), for early intervention, 1999
- Clinician–patient relationship, 63–64
 ADHD, 761–762
 issues in, 739–741
- Clomipramine, 1136, 1139
 OCD, 1116–1117
- Clonidine
 attention-deficit/hyperactivity disorder, 757–758
 opioid use disorder, 1537
- Cloninger's alcoholism typology, 1405–1406
- Cloninger's seven-factor model, 572–573
- Clozapine, 2095
 schizophrenia, 823–824
- Clubhouse model, for SMI, 1968–1969
- CMV *See* Congenital cytomegalovirus (CMV)
- Cocaethylene, 1594
- Cocaine
 and amphetamines, 2350–2353
 intoxication, 1574
 synthesis, 1561
 use disorder
 acupuncture, 1591
 antisocial personality disorder, 1596
 attention-deficit/hyperactivity disorder, 1595–1596
 biological therapies, 1585–1587
 candidate genes, 1564
 cardiovascular disease, 1576–1577
 cocaine-alcohol abuse and cocaethylene, 1594
 course and natural history, 1570–1572
 dopaminergic agents and agonist therapy, 1587–1590
 epidemiology, 1562
 genetic vulnerability to, 1563–1565
 immunotherapy, 1590–1591
 mental disorder diagnosis, 1593
 metabolic acceleration, 1591
 mood disorders, 1595
 neurobiological mechanisms, 1565–1567
 pharmacogenetic factors, 1591
 psychiatric disorders, 1594–1595
 psychotic disorder, 1596
 substance use disorders, 1593–1594
 transcriptional and epigenetic regulation, 1570
 treatment, 1580–1582
 withdrawal, 1574–1575
- Cockcroft–Gault equation, 2033, 2132
- Codeine, 1533
- Coercive process, 1761, 1769
- COFD *See* Childhood-onset fluency disorder (COFD)
- Cognitive adaptation training (CAT), 838–839
- Cognitive and behavioral endophenotypes
 approach-avoidance conflict, 281–282
 prefrontal cortex, 279
 schizophrenia, 280–281
- Cognitive and behavioral therapies
 activity scheduling, 1846–1849
 assumptions of, 1836
 behavioral model
 chain of events, 1840
 expanded BA model, 1840–1841
 stimulus–response relationships, 1840
 behavior exchange contracts, 1848–1849
 breathing control exercises, 1848
 cognitive model
 attributional style, 1839
 automatic thoughts (*see* Automatic thoughts)
 cognitive errors, 1838
 depression, 1836
 of psychiatric illness, 1838
 schemas, 1838–1839, 1845–1846
 schematic illustration, 1837
 collaborative empiricism, 1841
 contingency contract, 1848
 continuation and maintenance phase, 1852–1853
 efficacy of, 1853–1854
 exposure, 1849–1850
 flooding, 1850
 graded task approach, 1848
 mastery-pleasure exercises, 1848
 psychoeducation, 1841–1842
 relaxation training, 1849
 social skills training, 1850
 systematic desensitization, 1849
 treatment
 augmentation, 1852
 duration of, 1852
 gender issues, 1851
 indications for, 1850
 intensity of, 1851–1852
 outcome assessment, 1852
 patient preparation, 1851
 phases of, 1851
 race and ethnicity, 1851
 selection of, 1850–1851
- Cognitive assessment
 dementia in geriatrics, 2442–2443
 psychological evaluation, 633–634
- Cognitive behavioral analysis system of psychotherapy (CBASP), 1822
- Cognitive behavioral couple therapy (CBCT), 1952
- Cognitive behavioral family therapy, 1951–1952
- Cognitive behavioral group therapy (CBGT), 838
- Cognitive behavioral therapy (CBT), 108–110, 293–294, 1361, 1812
 acute stress disorder, 1159
 ADHD, 759
 agoraphobia and, 1069–1071
 anorexia nervosa, 1244
 for anxiety disorders, 1773
 behavioral theory, 478–479
 body dysmorphic disorder and, 1133–1134
 for cannabis use, 1463–1464
 cocaine use, 1582–1583
 cognitive psychology, 436–437
 cognitive theory, 479–482
 conceptualization, 482–485

- Cognitive behavioral therapy (CBT)
(continued)
 efficacy, 477
 generalized anxiety disorder, 1085
 vs. interpersonal psychotherapy,
 1866–1867
 longitudinal conceptualization, 485
 MDD, 987
 motivational interviewing, 1883, 1884
 OCD, 1120–1121
 overview, 478
 panic disorder, 485–486
 posttraumatic stress disorder, 1154
 principles, 478
 psychosocial treatments, 1012–1013
 PTSD, 474, 486
 schizophrenia, 486–487
 sexual violence, management of,
 2545–2546
 suicidal ideation treatment,
 2499–2500
 techniques, 480
 for tics, 785
 tobacco use disorder, 1629
 torture, therapeutic considerations,
 2557
 trauma-focused, 477
 treatment planning, 482–485
 trichotillomania, 1136
- Cognitive-behavior rehearsal, 1845
- Cognitive capacities, 43
- Cognitive compensation, 1975
- Cognitive delays, 120
- Cognitive development
 adolescents, 199–202
 human, 107–111
 infant, 141–142, 144, 145–146, 149
 preschool children, 163–165
 school-age children, 181–183
- Cognitive dissonance, 459
- Cognitive dysfunction, 308
- Cognitive enhancement
 herbal cognitive enhancers,
 2277–2278
 herbal medicines
Ginkgo biloba, 2277–2278
Melissa officinalis, 2278
Panax ginseng, 2278
Salvia lavandulaefolia, 2278
Salvia officinalis, 2278
 nutritional medicines, 2278–2279
 omega-3 fatty acids, 2278–2279
 phosphatidylserine, 2279
 vitamins, 2278
- Cognitive enhancers, AD
 AMPA receptor modulators, 2247
 amyloid-based interventions
 anti-aggregation agents,
 2250–2251
 colostrinin, 2251
 curcumin, 2251
 docosahexaenoic acid, 2251
 flurbiprofen, 2250
 immunotherapy, 2249–2250
- metal chelators, 2251
- nonsteroidal anti-inflammatory
 drugs, 2250
- peroxisome proliferator-activated
 receptor-g agonists,
 2251–2252
- R-enantiomer, 2250
- secretase inhibitors, 2250
- statins, 2251
- anti-excitotoxic therapies, 2253
- antioxidants, 2252
- behavior effect, 2247
- cholinergic treatment approaches,
 2240–2246
 adverse effects, 2245
 cholinesterase inhibitors, 2241
 donepezil, 2243, 2245
 galantamine, 2244–2245, 2246
 indirect cholinergic-enhancing
 strategies, 2241
 muscarinic agonists and
 antagonists, 2241
 nicotinic agonists, 2241
 precursor loading, 2241
 rivastigmine, 2243–2244
 tacrine, 2242, 2245
 vastigmine, 2245
- combined therapies, 2253
- etiopathology and implications for
 treatment
 dominant theories, 2237–2238
 neuropathology, 2237
 pathogenic cascade hypothesis,
 2238
- glutamatergic therapies
 cholinesterase inhibitor and
 memantine, 2247
 memantine, 2246
- growth hormone-releasing hormone,
 2248
- histamine, 2247–2248
- history and background, 2236
- inflammatory processes, 2252
- metabolic enhancement, 2249
- neurotransmitter-based approaches,
 2238–2240
- neurotrophic factors
 cerebrolysin, 2248
 estrogens, 2249
 glucocorticoid antagonists, 2249
 leteprenim, 2248
 nerve growth factor (NGF),
 2248
 paliroden, 2249
 xaliproden, 2248
- regulatory and methodological issues
 Alzheimer's Disease Assessment
 Scale-Cognitive Subscale
 (ADASc), 2236
 clinical global impression of
 change (CGIC), 2237
 FDA, 2236
- somatostatin, 2248
- Tau-based therapies, 2252
- treatment approach, approved
 compounds, 2247
 valproate and lithium, 2252
- Cognitive errors, 1838
- Cognitive evaluation and management,
 geriatric psychiatry, 2441
- Cognitive impairment, 816–817
 depression in geriatrics, 2449
- Cognitive impairment associated with
 schizophrenia (CIAS), 2100
- Cognitively impaired persons,
 psychiatric disorders, 2393
- Cognitive model
 major depressive disorder, 922–924
 panic disorder, 1065–1066
 posttraumatic stress disorder, 1151
- Cognitive neuroscience
 contributions, 436
 developments, 435
- Cognitive psychology
 attention (*see* Attention)
 influences, 436–437
 social cognition (*see* Social cognition)
 traditional neuropsychological tests,
 435
- Cognitive remediation (CR), 1975
 ADHD, 760
- Cognitive schemas, 459
- Cognitive screening, neuropsychological
 assessment, 602
- Cognitive system domain, 669
- Cognitive theory
 hopelessness, 482
 information processing biases,
 481–482
 overview, 479–482
 panic disorder, 486
 PTSD, 486
 schizophrenia, 486–487
- Cognitive therapy, 1821–1822
 alcohol withdrawal, 1422
 generalized anxiety disorder, 1086
- Cohesion, 1925, 1926
- Collaborative care (CC)
 collaborative care team
 care manager or care coordinator,
 2466
 consulting psychiatrist, 2466–2467
 primary care provider, 2465–2466
 roles, 2465
 consulting psychiatrist, educator,
 2469–2470
 core principles, 2465
 DIAMOND program, 2470
 evidence base for, 2464–2465
 IMPACT study, 2464
 implementing effective programs,
 2470
 Mental Health Integration Program,
 2470
 psychiatric consultation, 2467–2469
 RESPECT-MIL program, 2470
- Collaborative Care approach, 1794
- Collaborative empiricism, 1841

- Collaborative Longitudinal Personality Disorders Study (CLPS), 128
- Collaborative Study on Genetics of Alcoholism (COGA), 1405
- Colostrinin, amyloid-based interventions, 2251
- Communication deviance (CD), 1760–1761, 1764, 1769
- Communication disorder
- childhood-onset fluency disorder, 715–717
 - DSM-III and, 706
 - DSM-IV-TR and, 706–707
 - language disorder, 707–713
 - pragmatic communication disorder, 717–719
 - social communication disorder, 717–719
 - speech sound disorder, 713–715
 - stuttering, 715–717
 - unspecified, 719
- Communicative development, infant, 142, 144, 146–147, 150
- Community Health Centers (CHCs), 1791
- Community living needs
- assertive community treatment, 1964–1968
 - citizenship and partnership, 1960
 - cognitive compensation, 1975
 - cognitive remediation, 1975
 - disabilities, 1960
 - family consultation, 1974
 - family education, 1974–1975
 - family psychoeducation, 1971–1975
 - homelessness, 1976–1977
 - housing, 1976–1978
 - interventions
 - recommendations of, 1962, 1963
 - social skills training, 1964
 - recovery
 - description of, 1960
 - features of, 1961, 1962
 - goals of, 1960
 - and prognostic outlook, 1960–1961
 - and rehabilitation, 1961–1962
 - severe mental illness, 1959, 1960
 - social cognition, 1975–1976
 - social conditions, importance of, 1961
- Community mental health teams (CMHTs), 1990
- Community treatment of offenders, 2570
- Comorbidity
- ADHD, 750–751, 760–761
 - autism spectrum disorder, 728
 - childhood-onset fluency disorder, 715
 - in correctional setting, 2570–2571
 - developmental coordination disorder, 780
 - dyslexia, 769
 - language disorder, 709
 - mathematics disorder, 772
 - speech sound disorder, 714
 - stereotypic movement disorder, 782
 - stuttering, 715
 - TIC disorders, 784
- Comparative genomic hybridization (CGH), 681
- Competency
- parental, child protection cases, 701
 - to stand trial, 700
 - to testify, 700
- Complementary and alternative medicine (CAM), 736–737
- anxiety disorders
- herbal medicines, 2268–2270
 - mind–body techniques, 2270–2274
 - nutritional medicines, 2270
- attention-deficit/hyperactivity disorder
- herbal medicines, 2281
 - mind–body techniques, 2281–2282
 - nutritional medicines, 2280–2281
- cognitive enhancement
- herbal cognitive enhancers, 2277–2278
 - nutritional medicines, 2278–2279
- doctor–patient relationship, 2282
- herb–drug interactions, 2282
- insomnia
- melatonin, 2276–2277
 - mind–body techniques, 2277
 - Valeriana officinalis* (Valerian), 2276
- mental disorders, 696–697
- mood disorders
- herbal medicines, 2262–2264
 - mind–body techniques, 2267–2268
 - nutritional medicines, 2264–2267
- schizophrenia
- herbal medicines, 2275
 - mind–body techniques, 2275–2276
 - nutritional medicines, 2274–2275
- Complete blood count, 511
- Complex attention, 1659
- Complicated bereavement, 905
- Complication model, depression, 560
- Composite International Diagnostic Interview (CIDI), 420
- psychiatric epidemiology, 412–413
- Comprehension, 1660
- Comprehensive behavioral intervention for tics (CBIT), 785–786
- Compulsive behavior, 579–580
- Compulsive disorders, 360
- Computed tomography (CT), 803
- advantages and limitations, 618
 - findings, neuropsychiatric disorders, 618
 - vs. MRI, 620, 621
 - structural imaging modalities, 617–618
- Computer-assisted CBT (CCBT), 1842
- Computer-assisted therapy, 2018
- Concomitant psychotropic medications (CPM), 833–835
- Concreting process, 1914
- Condensed hypnotic approach, 1905–1906
- Conditioned place preference, 370
- Conduct disorder (CD)
- assessment issues, 1351, 1353–1354
 - associated features, 1351
 - bipolar disorder and, 991
 - case study, 1362
 - clinical assessment, 1351
 - clinician–patient relationship issues, 1362
 - combined treatments, 1361–1362
 - comorbidity, 1354
 - course, 1354–1355
 - developmental/gender/cultural presentations, 1355–1356
 - diagnostic features, 1350–1351
 - diagnostic interviews, 1353
 - differential diagnosis, 1356
 - discrimination of, 1356
 - DSM-5 classification, 666
 - epidemiology, 1354
 - etiology/pathophysiology, 1356–1359
 - factors influencing treatment, 1362
 - genetic factors, 1356–1357
 - laboratory measures, 1354
 - neurobiological factors, 1357–1358
 - neuropsychological assessment, 1353
 - psychological factors, 1358
 - psychosocial treatments, 1361
 - rating scales, 1351–1353
 - risk for, 1351
 - social/environmental factors, 1358–1359
 - somatic treatments, 1359–1361
 - subtypes, 1351
 - treatment, 1359–1363
 - algorithms/practice guidelines, 1362
 - goals, 1360
 - treatment-refractory patients, 1362
- Confabulation, 1913, 1914
- Confidentiality, 78–79
- Conflict
- interactional ratings, 1770
 - measurement, 1770
 - nonspecific-parent adolescent conflict, 1772
 - resolution, 1766
- Conflict Tactics Scale, 1770
- Confounding bias, psychiatric epidemiology, 416
- Confusional arousals, 1293
- Congenital central alveolar hypoventilation, 1287
- Congenital cytomegalovirus (CMV), 684

- Congenital malformations
antidepressants, perinatal depression, 2368–2375
pregnancy, psychiatric symptoms risk, 2428–2429
- Congenital rubella, 684
- Congenital toxoplasmosis, 684
- Connectome, 105–106
- Conners Adult ADHD Rating Scale, 750
- Consciousness
alterations, 524
Glasgow Coma Scale, 524
levels, 524–525
nature, 523–524
physiology of alterations, 526
qualitative changes, 525–526
stimulus-response approach, 524
- Constructional apraxia, 1659
- Consultation, child and adolescent psychiatry
collaborative interdisciplinary care, 2423–2424
developmental considerations, 2424
developmental neurobiological considerations, 2424
ethical considerations, 2425
pediatric hospital settings, diagnosis and treatment, 2424
pediatric subspecialties, 2425
principles, 2423
rehabilitation and disabilities, 2425
research, 2425
staff self-care, 2425
- Contamination obsessions, 1098
- Contextual emotion regulation therapy (CERT), MDD, 987
- Contingency contract, 1848
- Contingency management therapy, cocaine use, 1583
- Continuation period, of treatment, 2077–2078
- Continuous positive airway pressure (CPAP) therapy, 1284
- Conversion disorder, 592, 1906–1908
case study, 1217–1218
course, 1215
definition, 1213
diagnostic features, 1213–1214
differential diagnosis, 1215–1216
epidemiology, 1214–1215
etiology/pathophysiology, 1216
treatment, 1216–1217
- Conversion hysteria, 1214
- Conversion reaction, 1214
- Coping cards, 1845
- Coprophilia, 1751
- Copy number variants, schizophrenia, 801
- Core conflictual relationship theme (CCRT), 1821
- Coronary artery disease, 2410–2411
major depressive disorder, 912
- Correctional mental healthcare and economics, 2571
- Correctional psychiatry, 96–97
challenges in, 2570–2571
criminal justice, 2566–2567
homelessness, 2566
legal considerations, 2567
mental healthcare in, 2567–2570
mental health collaborative interventions, 2566–2567
mental illness in, 2564–2566
police-based interventions, 2567
police-mental health team, 2567
- Correlation matrix, 2588
- Cortical gyrus anomalies-lissencephaly, 684
- Corticobasal ganglionic degeneration, 1698
- Corticobasal syndrome (CBS), 402
- Cortisol awakening response (CAR), 1358
- Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS), 2099
- Council for Information on Tranquillisers, Antidepressants and Painkillers (CITAp), 1555
- Counterresistance, 1801
- Countertransference, 1800, 1801
reactions, 24–25
- Couple- and family-centered interventions, 1943–1944
- Couple- or family-centered psychiatric care, 1945–1947
- Covi Anxiety Scale, 2163
- CP *See* Cerebral palsy (CP)
- Crack cocaine, 1561
- Craving, substance dependence, 1394
- Creutzfeldt–Jakob disease (CJD), 405, 1664, 1694–1695
- Cri du chat syndrome, 679
- Criminal justice system, 2566–2567
population of, 2565
- Criminal law issues
children and adolescents, 96
competency, 93–94
correctional psychiatry, 96–97
diminished capacity and mitigating factors, 96
insanity defense, 94–95
- CRIPA *See* Civil Rights of Institutionalized Persons Act (CRIPA)
- Cripiprazole, 2135
- Critical time intervention (CTI), for SMI persons, 1977
- Crocus sativus* (Saffron), 2264
- Cross-disorder studies, 263
- CRSWD *See* Circadian rhythm sleep-wake disorders (CRSWD)
- CSA *See* Central sleep apnea (CSA)
- CSB *See* Cheyne–Stokes breathing (CSB)
- CT *See* Computed tomography (CT)
- Cuban Glossary of Psychiatry, Third Edition (GC-3), 348
- Cultural context
careful assessment, 56
clinician–patient relationship, 63–64
competence, 64–65
cultural competence, 57
demography, 56
electronic communication, 58
ethnicity, 58
ethnocultural identity, 56
gender, 58–59
identity, 60–61
interpreters and culture brokers, 65–67
limits of, 68–69
overall assessment, 64
psychiatric disorders, 56
psychosocial environment, 62–63
race, 58
small-scale societies, 57
social class, 58
stigma of mental illness, 67–68
strengths and limitations, 57
symptoms and illness, 61–62
- Cultural Formulation, 647–648
- Cultural Formulation Interview (CFI), 648, 2043
- Cultural identity, 60–61
- Cultural idioms of distress, 647
- Cultural issues
anorexia nervosa, 1237
in treatment, 713
- Cultural presentations
acute stress disorder, 1158
adjustment disorder, 1160
agoraphobia, 1065
disruptive mood dysregulation disorder, 998
GAD, 1080–1081
major depressive disorder, 984
posttraumatic stress disorder, 1147
- Cultural syndromes, 647
- Culture
adjustment disorders, 645–646
anxiety disorders, 643
cultural formulation, 647–648
depersonalization, 645
dissociative disorders, 644–645
distress, 646–647
in DSM and ICD classifications, 639–640
eating disorders, 645
GC-3, 648
GLADP, 648–349
ICD-10, national and regional adaptations, 648
IGDA, 649
mental disorders, Chinese classification, 648
mood disorders, 642–643
neurocognitive disorders, 640
personality disorders, 646

- in personalized diagnostic systems, 649
- physical signs and symptoms, 584–585
- PID, 649–650
- schizophrenia, 641–642
- sexual disorders, 645
- somatoform disorders, 643–644
- substance-related disorders, 640–641
- Culture-bound syndromes, 643, 646–647
- Cumulative incidence, 411
- Curcumin, AD cognitive enhancers, 2251
- CUTLASS trial, 826
- CVS *See* Chorionic villus sampling (CVS)
- Cyber bullying, 207
- Cyclic adenosine monophosphate (cAMP) signaling, 372
- Cyclic AMP-CREB cascade, 350–351
- Cyclothymic disorder, 888–889
- CYP2C19, 2046, 2047
- CYP2D6, 2045–2047, 2070
- Cytochrome p450 (CYP) enzymes, 2070
- Cytochrome P450 system, 2029–2032
- Cytokines, schizophrenia, 802
- D7-dehydro-cholesterol reductase (DHCR7)
- autism, 388
- D-amino-acid oxidase activator (*DAOA*), 800
- Danzol, 973
- DASS *See* Depression Anxiety Stress Scales (DASS)
- DAST *See* Drug abuse screening test (DAST)
- DAT *See* Dopamine transporters (DAT)
- Daytime enuresis, 1250
- DBD *See* Disruptive behavior disorders (DBD)
- DBS *See* Deep brain stimulation (DBS)
- DBT *See* Dialectical behavior therapy (DBT)
- DDs *See* Dissociative disorders (DDs)
- DE *See* Delayed ejaculation (DE)
- Death and bereavement
- and grief, 2456–2461
- The Onion*, 2453–2454
- work with terminally ill patients
- advance directives, 2454–2455
- management, 2455–2456
- Death penalty, 701
- Deaux's theory, 458
- Deceitful patient, 52–53
- Decentration, 163
- Decisional balance activity, in MI, 1887–1888
- Declarative learning and memory, 603
- Declarative memory, 527 *See also* Explicit memory
- Decoding, of brain activity, 2022
- Deep brain stimulation (DBS), 2305–2306
- major depressive disorder, 935
- OCD, 1122
- De-escalation, agitation management, 2482–2484
- Default mode network (DMN), in ADHD, 753
- Defense mechanisms, 25, 1801
- description of, 1799
- DeFries-Fulker (DF) regression method, 773
- Delayed ejaculation (DE)
- assessment issues, 1317
- associated features, 1317
- case study, 1319
- combined treatments, 1319
- comorbidity, 1317
- course, 1317–1318
- developmental/cultural presentations, 1318
- diagnosis, 1317–1318
- differential diagnosis, 1318
- epidemiology, 1317
- etiology/pathophysiology, 1318
- genetic factors, 1318
- neurobiological factors, 1318
- psychological factors, 1318
- psychological treatments, 1318–1319
- social/environmental factors, 1318
- somatic treatments, 1318
- treatment, 1318–1319
- Delayed sleep phase type (DSPT), 1288, 1292
- “Deliberate” vs. “implicit”
- emotion-regulation strategies, 252
- Delinquency, 1772
- Delirious mania, 1650
- Delirium, 525
- assessment issues, 1649–1650
- associated features, 1649
- comorbidity and course, 1650
- dementia in geriatrics, 2445
- diagnostic features, 1647–1649
- differential diagnosis, 1650–1651
- epidemiology, 1650
- intracranial disorders, 1654–1656
- major depressive disorder, 916
- medication-induced, 1651–1652
- metabolic, 1652–1653
- postoperative, 1656
- substance withdrawal, 1653–1654
- symptoms of, 1648
- toxic, 1651
- treatment, 1657
- Delusional disorder, 821, 1208
- clinical cases, 851
- clinical signs and symptoms, 842
- course and prognosis, 850
- diagnosis, 848–849
- differential diagnosis, 843
- epidemiology, 849–850
- etiology, 850
- history, 848
- treatment, 850–851
- Delusional patient, 48–49
- Dementia, 690
- assessment issues, 1661
- associated features, 1661
- behavioral disturbances in, 2098
- caregiver burden reduction strategies, 1947
- causes, 399
- comorbidity and course, 1662
- definition, 398–399
- diagnostic features, 1658–1661
- differential diagnosis, 1662
- epidemiology, 1661–1662
- etiology, 1662–1666
- flexible battery in, 604
- geriatric psychiatry management
- antidepressants and, 2447
- antipsychotic medications in dementia, 2446–2447
- behavioral disturbance
- management, 2444–2445
- benzodiazepines and, 2447–2448
- caregivers, 2443
- cognitive assessment, 2442–2443
- delirium and, 2445
- driving and, 2443
- evaluation, 2442
- medical comorbidity and, 2444
- mood stabilizers in, 2447
- nonpharmacologic management, 2445
- pharmacologic management, 2443–2444, 2446, 2448
- lacunar, 1683–1684
- major depressive disorder, 912, 916
- multi-infarct, 1683
- neuropsychiatric populations, 627
- pathophysiology, 1662–1666
- praecox, 791
- treatment, 1666–1667
- Dementia with Lewy bodies (DLB)
- anatomical profiles, 404
- clinical features, 404
- diagnosis, 404
- genetics, 404
- treatment, 404
- Dependent personality disorder (DPD), 1709, 1734–1736
- Depersonalization/derealization disorder (DPDRD)
- diagnosis, 1190–1191
- treatment, 1191
- Depression, 50–51, 252, 253, 920, 2060
- adherence to medication, psychiatric disorders, 2391
- alcohol-induced, 1408
- anorexia nervosa relationship, 1236, 1237
- clinical presentation, 561–563
- cognitive and behavioral therapies, 1836
- complication model, 560
- definition of, 1860
- depression ratings case study, 457–460

- Depression (*continued*)
 DSM-5 diagnoses, 557–558
 emotional expression, 559–563
 etiology, 559–561
 geriatric psychiatry management
 clinical presentation, 2448
 and cognitive impairment, 2449
 electroconvulsive therapy, 2450
 and medical comorbidity,
 2448–2449
 psychotherapy, 2449–2450
 suicide, 2449
 treatment, 2449
 hopelessness model of, 454
 intimate partner violence, 2543
 major
 assessment issues, 907–909
 associated features, 905–907
 comorbidity, 909–913
 course, 913–914
 cultural and ethnic differences, 915
 diagnostic features, 904–905
 differential diagnosis, 915–917
 epidemiology, 909
 gender-related differences,
 914–915
 genetic factors, 917–918
 issues in clinician–patient
 relationship, 943
 neurobiological factors, 918–922
 psychological factors, 922–924
 research vs. clinical diagnosis,
 903–904
 social/environmental factors,
 924–925
 treatment, 925–943
 in medical conditions, 562
 medically ill and geriatric patients,
 2226–2227
 models, 560
 monoamine hypothesis of, 2052–2053
 motivation/interpretive biases, 446
 Parkinson's disease, 1699–1700
 pathoplasty model, 560
 persistent (*see* Persistent depressive
 disorder)
 physical manifestations, 587–588
 placebo effect, 455
 positive reinforcement and, 479
 resilience factors that protect
 children, 1947–1948
 spectrum model, 559, 560
 stimulants, adults
 abuse potential, 2228
 acceleration of response, 2227
 acute effects, 2226
 augmentation in depression, 2227
 chronic effects, 2226
 dextroamphetamine vs.
 methylphenidate,
 2227–2228
 in late-life depression, 2227
 medically ill and geriatric patients,
 2226–2227
 modafinil for depression,
 2228–2229
 side effects and safety, 2228
 supportive psychotherapy, 1878
 symptoms, 564
 vegetative symptoms of, 587
 vulnerability model, 560
 Depression Anxiety Stress Scales
 (DASS), 1078
 Depressive symptoms disorders,
 1423–1424
 Dermatological disorders, 1911–1912
 Descriptive-based classification systems,
 657–658
 Desmopressin, 1255
 Detoxification, opiates, 2337–2341
 Detrended fluctuation analysis (DFA),
 of EEGs, 1917
 Detrusor-dependent enuresis, 1252
 Developmental coordination disorder,
 779
 assessment issues and comorbidity,
 780
 course, 780
 development, gender, and cultural
 presentations, 780–781
 diagnostic criteria, 780
 differential diagnoses, 781
 epidemiology, 780
 etiology and pathophysiology, 781
 treatment, 781
 Developmental disorders, 691
 Developmental neurobiology, 306–307
 Developmental psychopathology,
 188–189
Deviant Children Grown Up, 414
 Dexamethasone suppression test (DST),
 921
 Dexamphetamine, 1588, 1591
 Dextroamphetamine, 1588, 1591
 vs. methylphenidate, 2227–2228
*Diagnostic and Statistical Manual of
 Mental Disorders (DSM)*
 anxiolytic drugs, 2159
 culture in, 639–640
 gender diagnoses in, 1339–1340
*Diagnostic and Statistical Manual of
 Mental Disorders*, first edition
 (DSM-I), 659
*Diagnostic and Statistical Manual of
 Mental Disorders*, second edition
 (DSM-II), 659
*Diagnostic and Statistical Manual of
 Mental Disorders*, third edition
 (DSM-III), 659, 793
 communication disorder, 706
 epidemiological assessment of,
 646
*Diagnostic and Statistical Manual of
 Mental Disorders*, third edition,
 revision (DSM-III-R), 321
 anxiety disorder, 1076–1077
 panic disorder, 1057, 1058
 somatoform disorders, 643
*Diagnostic and Statistical Manual of
 Mental Disorders*, fourth edition
 (DSM-IV), 660, 793
 autism spectrum disorder, 722–723
 cultural formulation outline, 647–648
 ID/IDD, 674
*Diagnostic and Statistical Manual of
 Mental Disorders*, fourth edition,
 text revision (DSM-IV-TR), 661
 anxiolytic drugs, 2159
 autism spectrum disorder, 722–723
 communication disorder, 706–707
 diagnostic criteria for autistic
 disorder, 724
 ID/IDD, 674
 phobia, 1024
 postpartum depression, 2432
 posttraumatic stress disorder, 1143
*Diagnostic and Statistical Manual of
 Mental Disorders*, fifth edition
 (DSM-5), 584
 ADHD, 749
 agoraphobia, 1059
 anger, 557–558
 anxiety, 557–558, 664
 apathy, 557–558
 bipolar disorder, 664, 988
 body dysmorphic disorder, 1130
 CFI in, 648
 Cultural Issues Subgroup of, 647
 depression, 557–558, 664
 and diagnostic codes, 662–663
 diagnostic criteria for ASD, 724
 diagnostic groupings, 663
 disruptive, impulse-control, and
 conduct disorders, 666
 disruptive mood dysregulation
 disorder, 1000
 dissociative disorders, 644, 665
 elimination disorders, 665
 euphoria, 557–558
 fear, 557–558
 feeding and eating disorders, 665
 gender dysphoria, 666
 ID/IDD, 674–675
 illness anxiety disorder, 593
 insomnia, psychiatric patients, 2202
 major depressive disorder, 982
 neurocognitive disorders, 666
 neurodevelopmental disorders,
 663–664
 obsessive-compulsive disorders,
 664–665
 OCD and, 1093, 1095
 panic disorder, 1058–1059, 1073
 paraphilic disorders, 667
 pathological possession trance, 644
 personality disorders, 553–554,
 666–667
 premenstrual dysphoric disorder, 966
 RDoC project, 668–669
 relational problems, 1759–1760
 schizophrenia, 664, 794
 sexual dysfunctions, 666

- sleep-wake disorders, 665–666
 somatic symptom and related disorders, 665
 substance-related and addictive disorders, 666
 substance use disorders, 359–360
 trauma- and stressor-related disorders, 665
 Diagnostic Interview Schedule (DIS), 412
 Dialectical behavior therapy (DBT), 294, 495, 1378, 1812, 1846
 BPD, 1726
 suicidal ideation treatment, 2500
 DIAMOND program, 2470
 Dibenzodiazepine, 823
 Dibenzoxazepine, 823
 DID *See* Dissociative identity disorder (DID)
 Dietary elimination strategies, 2280–2281
 Differential score approach, 605–606
 Diffuse optical imaging (DOI), 624
 Diffuse plaque, 1676
 Diffusion of responsibility, 454
 Diffusion tensor imaging (DTI), 619, 803
 white matter tracts, 621
 Di-George syndrome *See* Velocardiofacial syndrome (VCFS)
 Digit span test, 532
 Digressive speech, 537
 Dimensional model
 emotions, 551
 personality style, 571–574
 Dimethyltryptamine (DMT), 1481
 Dim-light melatonin onset (DLMO), 1289
 Diphenylbutylpiperidines, 823
 Diphenylbutylpiperidines, schizophrenia, 823
 DIS *See* Diagnostic Interview Schedule (DIS)
 Disability-adjusted life-years (DALYs), 1402
 Disaster psychiatry
 at-risk groups, 2525–2526
 description, 2521–2522
 disaster-related distress and dysfunction, 2526
 individual and community responses, 2522–2525
 psychological first aid core actions, 2528
 types, 2522
 Discontinuation syndrome, 931
 Discord, motivational interviewing, 1888–1889
 Discriminant validity, generalized anxiety disorder, 1077
 Disinhibited social engagement disorder (DSED)
 assessment issues, 1174
 associated features, 1174
 case study, 1176
 clinician–patient relationship issues, 1176
 combined treatment, 1176
 comorbidity, 1174
 course, 1174
 developmental/gender/cultural presentations, 1174
 diagnosis, 1174–1175
 differential diagnosis, 1174
 epidemiology, 1174
 etiology/pathophysiology, 1175
 factors influencing treatment, 1176
 genetic factors, 1175
 neurobiological factors, 1175
 psychological factors, 1175
 psychosocial treatment, 1175–1176
 social/environmental factors, 1175
 somatic treatment, 1175
 treatment, 1175–1176
 treatment-refractory patients, 1176
 Disorder of sexual development (DSD), 1341
 Disorders Interview Schedule for DSM-IV: Lifetime Version (ADIS-IV-L), 1078
 Disrupted in Schizophrenia (DISC1), 799
 Disruption, 683
 Disruptive behavior disorders (DBD), 1350, 1351
 DSM-5 classification, 666
 stimulants in children
 clinical use, 2221–2226
 indications, 2210
 medications, 2205–2208
 pharmacology, 2208–2210
 review of efficacy data, 2210–2218
 side effects, 2218–2221
 Disruptive mood dysregulation disorder (DMDD), 981, 1354
 assessment issues, 997
 associated features, 997
 case, 999
 combined treatments, 999
 comorbidity, 997
 course, 997–998
 cultural presentations, 998
 developmental presentations, 998
 diagnostic features, 996–997
 differential diagnosis, 998
 DSM-5 diagnostic criteria, 1000
 epidemiology, 997
 gender presentations, 998
 genetic factors, 998
 neurobiological factors, 998
 psychological factors, 998
 psychosocial treatment, 999
 social/environmental factors, 998
 somatic treatment, 999
 treatment goals, 998–999
 Dissociation, 544–545
 Dissociative amnesia, 1178
 abreaction, 1188
 case study, 1187
 diagnosis, 1186–1188
 with dissociative fugue, 1189–1190
 hypnosis, 1188
 psychotherapy, 1188–1189
 screen technique, 1188–1189
 treatment, 1188–1189
 Dissociative disorders (DDs), 1178
 and biological processes, 1181–1182
 concept development, 1178–1179
 cultural context, 644–645, 1192–1193
 dissociative reactions, 1193–1194
 dissociative trance, 1191–1192
 DSM-5 classification, 665, 1194–1195
 epidemiology, 1179–1180
 ICD-10 diagnostic criteria, 1194–1195
 and information processing, 1181
 and memory systems, 1182
 possession trance, 1192
 symptoms, 1146
 and trauma, 1180–1181
 treatment, 1193, 1194
 Dissociative fugue
 diagnosis, 1189
 dissociative amnesia with, 1189–1190
 treatment, 1189–1190
 Dissociative identity disorder (DID), 644, 1178, 1898
 case study, 1184, 1185
 comorbidity, 1183–1184
 course, 1183
 diagnosis, 1182–1184
 epidemiology, 1182–1183
 hypnosis, 1184–1185, 1898
 integration, 1185
 memory retrieval, 1185
 psychological testing, 1184
 psychotherapy, 1184–1186
 rule of thirds, 1185
 somatic treatment, 1186
 traumatic transference, 1185–1186
 treatment, 1184–1186
 Dissociative trance disorder, 1191–1192
 Distal-less genes, autism, 388
 Distress, cultural concepts of, 643, 646–647
 Distributive justice, 73
 Disulfiram
 alcohol use disorder, 1422–1423
 cocaine use, 1586–1587
 Diurnal enuresis, 1251, 1256
 Divalproex
 acute bipolar depression, 2141–2142
 maintenance therapy, acute bipolar depression, 2147–2148
 mood stabilizers for mania, 2136–2137
 sodium, cannabis dependence, 1465
 Divided attention, 1659
 D-KEFS Trail Making Test, 605
 DLB *See* Dementia with Lewy bodies (DLB)

- DMDD *See* Disruptive mood dysregulation disorder (DMDD)
- Docosahexaenoic acid (DHA), 2251
- Doctor–patient relationship, 75–76, 79–80
- complementary and alternative medicine, 2282
 - confidentiality and privilege, 89–90
 - disability and fitness evaluations, 92–93
 - informed consent, 88
 - malpractice, 90–91
 - physician–patient boundary violations, 92
 - supervising, 91–92
 - treatment of minors, 88–89
- Doctor shopping, 1552
- DOI *See* Diffuse optical imaging (DOI)
- Dominant theories, 2237–2238
- Donepezil, 2243, 2245
- Dopamine, 308–309, 2053
- bipolar disorder, 869
 - depression, 920
 - gambling disorder, 1642
 - in schizophrenia, 810–811
 - side effects of, 2067, 2068
 - striatum, 807
- Dopamine D₂ receptor modulation, APDs, 2091
- Dopamine D4 receptor (DRD4) polymorphism, 1172
- Dopamine depletion hypothesis, 1568
- Dopamine-glutamate theory, schizophrenia, 813
- Dopamine reuptake inhibitors (DRIs), 2054
- Dopamine reuptake transporter (DAT), 1280
- Dopamine reward system, 127
- Dopaminergic agents
- cocaine use, 1587
 - METH addiction, 1591–1592
- Dopamine transporters (DAT), 753
- Dorsal striatum, 250
- Down syndrome (DS)
- prenatal causes, 677
 - and trisomy 21 karyotype, 679
- Doxepin, 1274
- DPDRD *See* Depersonalization/derealization disorder (DPDRD)
- DRD4 polymorphism *See* dopamine D4 receptor (DRD4) polymorphism
- Dreaming, 2620
- Dream interpretation, 1803
- DRIs *See* Dopamine reuptake inhibitors (DRIs)
- Drives, concept of, 1804
- Driving, in geriatrics, 2443
- Dronabinol, for cannabis dependence, 1465, 1466
- Drug abuse screening test (DAST), 1396
- Drug addiction, 249, 250
- Drug counseling, cocaine use, 1583–1584
 - Drug–drug interactions, 2070
 - Drug Enforcement Administration (DEA), 2194
 - Drug metabolism, genetically variable enzymes of, 2045
 - Drug-metabolizing enzyme expression
 - environmental factors, 2047–2048
 - external and internal factors, 2047
 - genetic polymorphism, 2045, 2047
 - Dry bed technique, 1254
 - DS *See* Down syndrome (DS)
 - DSD *See* Disorder of sexual development (DSD)
 - DSED *See* Disinhibited social engagement disorder (DSED)
 - DSPT *See* Delayed sleep phase type (DSPT)
 - DTI *See* Diffusion tensor imaging (DTI)
 - Dual agency, in correctional setting, 2571
 - Duloxetine, 2063, 2076
 - FDA approval, 2163
 - generalized anxiety disorder, 2163–2164
 - side effects, 2164
 - vs. venlafaxine XR, 2164
 - Duration of untreated psychosis (DUP), 1991, 1996
 - Duster sprays, 1509
 - Dyadic Adjustment Scale, 1770
 - Dynamic deconstructive psychotherapy (DDP), 1812
 - Dynamic unconscious model, 1179
 - Dynorphins, 1567
 - Dysesthesias, 1298
 - Dysfunctional information processing, 1837
 - Dyslexia
 - comorbidity, 769
 - course, 769–770
 - diagnostic features, 768–769
 - epidemiology, 769
 - genetic factors, 770
 - neurobiological factors, 770
 - psychological factors, 770
 - psychosocial treatments, 770–772
 - Dyslipidemia, 2115
 - Dysmorphophobia *See* Body dysmorphic disorder (BDD)
 - Dysthymic disorder, 1081 *See also* Persistent depressive disorder
 - Dystonia, 828, 2110, 2112
 - Dystrobrevin-binding protein 1 gene (*DTNBPI*), 800
- Early adolescence, 203
- Early intervention (EI), in mental healthcare
- by age group, 2000, 2001
 - care taking, 2001
 - chronicity, 2003–2004
 - clinical benefit, 2004
- by community/hospital/forensic settings, 2000, 2003
 - cultural benefit, 2005
 - description of, 1990, 1996
 - economic cost-benefit, 2004–2005
 - general practitioners and society, 1990
 - modalities, 2000
 - moral/equity/morale benefit, 2005
 - myths and realities, 1995–1996
 - NNI concept, 2003
 - NNT concept, 2003
 - NNW concept, 2003
 - phases of care, 2000
 - pioneering researchers/clinicians and contributions, 1997, 1998
 - practices of, 1997
 - prevention of, 1996
 - principles of, 1997, 1999
 - psychosis
 - antipsychosis agents, 1992
 - clinical high risk criteria, 1991
 - clinical staging, 1994–1995
 - cost-effectiveness of, 1992–1993
 - critical period, 1992
 - dose reduction/discontinuation study, 1992
 - evidence-based
 - bio-psycho-socio-cultural interventions, 1991
 - headspace programs, 1997
 - occurrences of, 1991
 - preventive interventions, 1994
 - “start low, go slow” prescribing approach, 1992
 - sub-threshold syndromes, 1994
 - symptomatic remission, 1992
 - ultra-high risk criteria, 1991
 - worldwide dissemination, 1993–1994
 - quaternary prevention, 2003
 - rational/logical benefit, 2004
 - service quality, 1999–2000
 - by specific mental disorders, 2000, 2002
 - wellness approach, 2004
 - workforce disciplines, 2000–2001
- Early/preresponse period, of treatment, 2076–2077
- Early Psychosis Prevention and Intervention Center (EPPIC) service
- acute care, 1993
 - cost functions of, 1993
 - early detection, 1993
 - features of, 1993
 - recovery-focused continuing care, 1993–1994
 - youth participation, 1994
- Early years, history of psychiatry, 2608–2610
- Eating disorders, 1231–1248, 1773
- body dysmorphic disorder and, 1132
 - case study, 1247–1248

- culture and, 645
 definition, 1231
 diagnosis, 1232
 DSM-IV-TR criteria, 1233
 DSM-5 classification, 665
 hypnosis, 1899, 1908
 IPT, 1865–1866
 ECA study *See* Epidemiologic Catchment Area (ECA) study
 Economics and correctional mental healthcare, 2571
 Ecstasy *See* 3,4-Methylenedioxy-methamphetamine (MDMA)
 ECT *See* Electroconvulsive therapy (ECT)
 ED *See* Erectile disorder (ED)
 Educational evaluation
 indications for, 635
 psychological, 635
 purpose of, 636
 Educational plan, psychological evaluation, 636
 EEG *See* Electroencephalogram (EEG)
 EFT *See* Emotionally focused couples therapy (EFT)
 Ego, 1799–1800
 Ego-dystonic disorder, 1708
 Ego observation impairment, 1873
 Ego psychology, 221
 basics of model, 464–465
 defense mechanisms, 464, 465
 definition, 464
 formulation and treatment, 465–466
 historical context, 464
 Oedipal conflict, 465
 primary/secondary process thinking, 464
 topographic model, 464
 unconscious conflict, 465
 Ego-strengthening technique, 1901
 Ego-syntonic disorder, 1708
 Ehlers–Danlos syndrome, 1439
 Elderly patients
 efficacy, 2072–2073
 pharmacodynamic concerns, 2072
 pharmacokinetic concerns, 2072
 Elderly psychiatric patient *See* Geriatric psychiatry
 Electrocardiogram, 514
 Electroconvulsive therapy (ECT), 861, 2080, 2295–2298
 depression in geriatrics, 2450
 major depressive disorder, 933–934
 psychiatric treatment for pregnancy, 2431
 suicidal ideation treatment, 2500
 Electroencephalogram (EEG), 514, 808
 neurophysiological assessment, 609–611
 noninvasive, 597
 Electrolytes, psychiatric patient, 513
 Electronic health record (EHR), 2020, 2021
 Electronic mail (e-mail), 80, 2016–2017
 Electronic medical record (EMR), 2020, 2021
 Electronic monitoring (EM), psychiatric disorders, 2386
 Elicit-provide-elicite technique, 1886–1887
 Elimination disorders, 665
 Embalming fluid, 1475
 Emergency care *See* Psychiatric emergency services (PESs)
 Emerging adulthood, 219
 Emotional delays, 120
 Emotional development
 adolescents, 202–205
 human, 111–114
 infant, 142, 144, 146, 149–150
 preschool children, 166–167
 school-age children, 183–184
 Emotional health, 231
 Emotionally focused couples therapy (EFT), 1949–1950
 Emotional over involvement, 1761
 Emotional sampling method (ESM), 204
 Emotions
 anxiety, 554–559
 apathy, 564, 565
 behavioral expression, 547–551
 categories, 547
 circumplex model, 551
 cognitive components, 547–551
 depression, 559–563
 dimensional models, 551
 empathy in psychopathy, 445
 euphoria, 563
 executive control, 440
 expression, 547
 Eysenck's biological theory, 551
 fear, 563–564
 hostility, 564–565
 influences on explicit memory, 442
 James-Lange theory, 547–548
 mood vs. affect, 551–553
 neurological components, 547–551
 personality disorders, 553–554
 rage, 564–565
 regulation, 549–550, 552
 schemas, 547
 in social interactions process, 444
 Empathic listening, 1803
 Empathy, 17, 45, 1877
 Empirically derived family relational constructs, 1760, 1761
 Encephalopathic pellagra, 1653
 Encephalopathy, 1515–1516
 Encopresis
 assessment, 1258–1259
 behavioral treatment, 1259
 biofeedback therapy, 1260
 case study, 1260–1261
 course, 1257
 definition, 1257
 diagnosis/differential diagnosis, 1257
 epidemiology, 1259
 etiology/pathophysiology, 1259
 history, 1257
 management, 1260
 phenomenology, 1257–1258
 physical treatment, 1260
 role of family in treatment, 1259–1260
 standard treatment, 1259
 Endocannabinoid system, 1460–1462
 Endocrine disorders, treatment of, 2074
 Endocrinology, 2411–2412
 End-of-life (EOL) care
 advance directives, 2454–2455
 management, 2455–2456
 Endophenotypes, 246–247, 271, 277
 major depressive disorder, 918
 Endophenotypic markers, 307–308
 Endoreactive dysthymia, 945
 End-stage renal disease, psychological factors in, 2414
 Engagement process, in MI, 1885–1886
 England, history of psychiatry, 2600–2601, 2605–2606
 Engrailed2 (EN2), 388
 Enuresis
 alternative treatment, 1256
 assessment, 1251–1252
 case study, 1256–1257
 complementary treatment, 1256
 course, 1250
 daytime, 1250
 definition, 1250
 diagnosis/differential diagnosis, 1250–1252
 diurnal, 1251, 1256
 etiology/pathophysiology, 1252–1253
 history, 1250
 mental status examination, 1251–1252
 nocturnal, 1250, 1252, 1253
 pharmacotherapy, 1255–1256
 physical examination, 1252
 psychosocial treatments, 1254–1255
 standard treatment, 1253–1254
 surgery, 1256
 treatment, 1253–1256
 Environmental factors
 ADHD, 754–755
 agoraphobia, 1068–1069
 anorexia nervosa, 1238
 autism spectrum disorder, 731–732
 bipolar disorder, 993–994
 childhood-onset fluency disorder, 716
 disruptive mood dysregulation disorder, 998
 generalized anxiety disorder, 1009–1010, 1084
 language disorder, 711
 major depressive disorder, 985–986
 mental disorders, 694
 posttraumatic stress disorder, 1151
 stuttering, 716

- Epidemiologic Catchment Area (ECA) study, 417, 795, 1096
 design, 418
 incidence, 418
 institutionalized sample, 418
 mental and substance use disorders, 418
 mental health services use, 418
 posttraumatic stress disorder, 1148
 prevalence, 418
- Epigenetics, 118–119, 347
 posttraumatic stress disorder, 1148–1149
 schizophrenia, 801–802
- Epilepsy
 delirium, 1656
 major depressive disorder, 911
- Episodic amnesia, 1669–1670
- Episodic memory, 527, 1182
- Erectile disorder (ED)
 assessment issues, 1319
 associated features, 1319
 case study, 1321
 combined treatments, 1321
 comorbidity, 1320
 course, 1320
 developmental/cultural presentations, 1320
 diagnosis, 1319–1320
 differential diagnosis, 1320
 epidemiology, 1319–1320
 etiology/pathophysiology, 1320
 genetic factors, 1320
 neurobiological factors, 1320
 psychological factors, 1320
 psychosocial treatments, 1321
 social/environmental factors, 1320
 treatment, 1320–1321
- Eriksonian model, 222–224
- Erikson's theory, 168
- EROs *See* Event-related oscillations (EROs)
- ERPs *See* Event-related potentials (ERPs)
- Escitalopram
 GAD in elderly patients, 2163
 generalized anxiety disorder, 2162, 2163
- Estelle v. Gamble*, 2567
- Estrogens, 2249
- Eszopiclone (Lunesta), 1554
- Ethnicity, 58
- Ethnicity issues, substance use disorders, 363, 365, 366
- Ethnobotanical hallucinogens, 1480–1482
- Ethnocultural allodynia, 1810
- Etiology-based classification systems, 657–658
- EUFEST, 826
- Eugenics, 2597
- Euphoria
 DSM-5 diagnoses, 557–558
 emotional expression, 563
- European First Episode Schizophrenia Trial (EUFEST), 2099
- Event-related oscillations (EROs), 597
- Event-related potentials (ERPs), 597, 808
- Evoking process, in MI
 decisional balance activity, 1887–1888
 elicit-provide-elicite technique, 1886–1887
 evocative questions and reflections, 1887
 importance and confidence rulers, 1888
 recognizing change talk, 1885
- Excoriation disorder
 diagnostic features, 1137–1138
 etiology and pathophysiology, 1138
 treatment, 1139
- Executive function, 161, 1659
 attention and, 439–440
 brain regions in, 438
 neuropsychological assessment, 602
 protective role, 440
 in psychiatric disorders, 440
- Exercise
 AD, 2253
 eating disorders, 1233, 1235
- Exhibitionistic disorder, 1750 *See also* Paraphilic disorders
- Experimental animal models
 cognitive and behavioral endophenotypes, 279–282
 etiologic factors, 277
 genetic, environmental, and experiential etiologies, 285–287
 Huntington's disease, 276
 iterative pathogenic process, 277–278
 neuropathological/pharmacological phenotypes, 282–285
 phenotypes, 277–279
 Rett's syndrome, 276
 susceptibility genes, 277
- Explanatory model (EM) approach, 2043
- Explanatory style, social psychology, 455
- Explicit memory, 233, 440–441, 527, 1182
 binding and retrieval, 442
 emotional influences, 442
 encoding, 441–442
- Exposure therapy, posttraumatic stress disorder, 1154
- Expressed emotion (EE)
 Camberwell Family Interview, 1770
 description of, 1762
 goal of, 1770
 partner, 1764–1765
 prevalence of, 1770
 schizophrenia, 839
- Expressive-supportive continuum, 1798–1799
- Expressive-supportive psychotherapy, 1811
- External prenatal causes
 maternal viral infections, 684
 pregnancy and placental insufficiency toxemia, 685
 toxic substances, 684–685
- Eyberg Child Behavior Inventory, 632
- Eye movement desensitization and reprocessing (EMDR)
 posttraumatic stress disorder, 1154–1155
 sexual violence, management of, 2546
- Eye-roll measurement, 1898
- Eye-roll sign, for hypnotizability, 1897, 1898
- Eysenck's biological theory, 551
- Facebook, 2018–2019
- Factitious delirium, 1651
- Factitious disorder, 1218, 1222, 1223
 imposed on others
 case study, 1229
 diagnosis, 1228–1229
 etiology/pathophysiology, 1229
 treatment, 1229
 imposed on self
 assessment, 1224
 associated features, 1223–1224
 case study, 1227–1228
 comorbidity patterns, 1224–1225
 course, 1225
 developmental/gender/cultural presentations, 1225
 diagnostic features, 1223
 differential diagnosis, 1225
 environmental factors, 1226
 epidemiology, 1224
 etiology/pathophysiology, 1225–1226
 genetic factors, 1225
 neurobiological factors, 1225
 psychological factors, 1225–1226
 social factors, 1226
 treatment, 1226–1227
 physical signs and symptoms, 591, 594
- Factor analysis, research design, 2588–2589
- Fagerström Test for Nicotine Dependence (FTND), 1616
- Fahr syndrome, 1666
- FAMCON interventions, 1945
- Family
 consultation, 1974
 context, 172–173
 education, 1974–1975
 genograms, 1953
 history, psychiatric interview, 504
 informants, 907–908
 interaction, psychological evaluation, 634–635
 relational problems, 1768
 resilience, 1947
- Family Accommodation Scale (FAS), 1769
- Family-centered mental health services, 1955–1956
- Family Environment Scale, 1353
- Family-focused therapy (FFT)

- bipolar disorder, 995
mood disorders, 1774
- Family Interaction Coding System, 1769
- Family/marital relational problem, treatment of
adolescent behavioral problems, 1772
alcohol and substance use problems, 1772–1773
anxiety disorders, 1773
delinquency, 1772
eating disorders, 1773
mood disorders, 1774
nonspecific parent–adolescent conflicts, 1772
parent–child difficulties, 1772
partner relational difficulties, 1771–1772
schizophrenia, 1773–1774
- Family psychoeducation (FPE)
case study, 1975
description of, 1972
elements of, 1972
family service models, 1973–1974
in mental health services, 1973
- Family therapy
anorexia nervosa, 1240
and couple therapy
clinical problem and treatment methods, 1949
cognitive behavioral couple therapy, 1952
cognitive behavioral family therapy, 1951–1952
common factors of, 1943–1944
couple- or family-centered psychiatric care, 1945–1947
description of, 1943
emotionally focused couples therapy, 1949–1950
family-based prevention programs, 1947–1948
family psychoeducation, 1944–1945
interactional patterns, 1948
postmodern family therapies, 1953–1955
psychodynamic therapy, 1952–1953
sexual problems, 1948
structural-strategic family therapy, 1950–1951
description of, 1943
gambling disorder, 1644
Farmer v. Brennan, 2567
- FAS *See* Fetal alcohol syndrome (FAS)
- Fatal familial insomnia, 1695–1696
- Fat emboli syndrome, 1655
- FDG *See* ¹⁸F-fluoro-deoxy-glucose (FDG)
- Fear, 1019
anxiety, 330–331
conditioning, 331–333
DSM-5 diagnoses, 557–558
emotional expression, 563–564
symptoms, 564
- Federal governments, effective mental health advocacy, 1986
- Feeding disorders, DSM-5 classification, 665
- Female orgasmic disorder (FOD)
assessment issues, 1322
associated features, 1321–1322
case study, 1323–1324
combined treatments, 1323
comorbidity, 1322
course, 1322
developmental/cultural presentations, 1322
diagnosis, 1321–1322
differential diagnosis, 1322
epidemiology, 1322
etiology/pathophysiology, 1322–1323
factors influencing treatment
genetic factors, 1322
neurobiological factors, 1322
neuropsychological assessment
psychological factors, 1323
psychosocial treatments, 1323
social/environmental factors, 1323
somatic treatments, 1323
treatment, 1323
- Female sexual interest/arousal disorder (FSIAD), 1322
assessment issues, 1324
associated features, 1324
case study, 1326
combined treatments, 1326
comorbidity, 1324
course, 1324
developmental/cultural presentations, 1324
diagnosis, 1324–1325
differential diagnosis, 1324–1325
epidemiology, 1324
etiology/pathophysiology, 1325
genetic factors, 1325
neurobiological factors, 1325
psychological factors, 1325
psychosocial treatments, 1325–1326
social/environmental factors, 1325
somatic treatments, 1325
treatment, 1325–1326
- Fentanyl, 1533, 1534
- Fetal alcohol spectrum disorders (FASDs), 365, 685, 1414
- Fetal alcohol syndrome (FAS), 365, 684
- Fetal death, perinatal depression, 2362–2363
- Fetal growth, perinatal depression, 2367–2368
- Fetal hydantoin syndrome (FHS), 685
- Fetishistic disorder, 1750–1752 *See also* Paraphilic disorders
- Fever of unknown origin (FUO), 1224
- ¹⁸F-fluoro-deoxy-glucose (FDG), 621
- FHS *See* Fetal hydantoin syndrome (FHS)
- Fire-setting behavior *See* Pyromania
- First-episode schizophrenia, 2102
- First-generation antidepressants
efficacy determination, 2058
mechanisms of actions, 2053
monoamine oxidase inhibitors, 2071, 2075
pharmacokinetic concerns, 2062
TCAs, 2075
tricyclic antidepressants, 2071
- First-generation antipsychotics (FGAs)
chemical structures of, 2088, 2089
groups of, 2094
- First-pass effect/bioavailability, 2028–2029
- Five-factor model (FFM), 123–124, 572, 573, 1710–1712
- Five-Minute Speech Sample Expressed Emotion Coding System, 1770
- Fixed neuromedical battery, 604
- Fixed psychiatric battery, 604
- FLAIR *See* Fluid-attenuated inversion recovery (FLAIR)
- Flexible battery approach, 603–604
- Flooding technique, 1850
- Florida Obsessive-Compulsive Inventory (FOCI), 1096, 1097
- Flow of consciousness, 16
- Fluctuation index, 2033
- Fluid-attenuated inversion recovery (FLAIR), 619
- Fluid restriction, enuresis management, 1255
- Flunitrazepam, 1553
- Fluorescence in situ hybridization (FISH) studies, 680
- Fluoxetine, 1360
alcohol use disorder, 1426
OCD, 1115–1116
- Fluranes, 1512
- Flurbiprofen, 2250
- Fluvoxamine, 1116
- FMR1, 387
- FMR1 protein (FMR1P), 682–683
- fMRI *See* Functional magnetic resonance imaging (fMRI)
- Focal conflict (French), 1820
- Focal psychotherapy (Michael Balint), 1820
- Focusing process, in MI, 1885, 1886
- FOD *See* Female orgasmic disorder (FOD)
- Follicle-stimulating hormone (FSH), 195
- Food and Drug Administration (FDA)
duloxetine, 2163
lithium, bipolar disorder, 2129
- Forensic issues
guardianship, 701
ID/IDD, 700
- Formal thought disorder, 536–537
- Forming/preaffiliation model, group development, 1931
- Fountain House model, 1988
- Four-Factor Romantic Relationship (FFRR) Scales, 1768

- FPE *See* Family psychoeducation (FPE)
- Fragile X syndrome (FXS), 682–683, 725
- FRAMES, 1883
- France, history of psychiatry, 2599–2600, 2602–2605
- FRAXA gene, 387
- Fregoli's syndrome, 544
- Freudian/classical psychoanalysis, 1799
- Freud's psychoanalytic theory, 1179
- Frontal intermittent rhythmic delta (FIRDA), 1650
- Frontal lobe syndrome, 1660
- Frontotemporal dementia (FTD)
 - anatomical profiles, 402–403
 - clinical features, 402–403
 - diagnosis, 403
 - genetics, 403–404
 - pathogenesis, 403
 - pathological features, 403
 - treatment, 403
- Frontotemporal lobar degeneration, 1663
 - assessment issues, 1678
 - associated features, 1678
 - comorbidity and course, 1678–1679
 - diagnostic features, 1677–1678
 - differential diagnosis, 1679
 - epidemiology, 1678
 - etiology and pathophysiology, 1679
 - treatment, 1679
- Frotteuristic disorder, 1750 *See also* Paraphilic disorders
- FSIAD *See* Female sexual interest/arousal disorder (FSIAD)
- FTD *See* Frontotemporal dementia (FTD)
- Function-ACT (FACT), 1967
- Functional circuitry, psychiatric disease, 247–248
- Functional disability, reduction of, 692
- Functional gastrointestinal disorders (FGIDs), 1912
- Functional hallucinations, 543
- Functional imaging modalities
 - bipolar disorder, 992–993
 - fMRI, 623
 - MRS, 623–624
 - PET, 620–623
 - psychiatric populations, 626–627
 - SPECT, 623
- Functional magnetic resonance imaging (fMRI), 313
 - ADHD, 753
 - cognitive neuroscience, 436
 - functional imaging modalities, 623
 - studies, 2022
- Functional medical complaints, 588
- Functional neuroimaging, of autism, 390–391
- Functional neurological symptom disorder *See* Conversion disorder; conversion disorder
- Fundamental attribution error, 454
- FUO *See* Fever of unknown origin (FUO)
- FXS *See* Fragile X syndrome (FXS)
- G72/G30 *See* D-amino-acid oxidase activator (*DAOA*)
- Gabapentin, cannabis dependence, 1466
- GAD *See* Generalized anxiety disorder (GAD)
- Gadolinium, 619
- Galantamine, 2244–2245, 2246
- Galphimia glauca* (*Galphimia*), 2270
- Gambling disorder
 - assessment issues, 1639
 - associated features, 1638–1639
 - clinical differences, 1640
 - comorbidity, 1639–1640
 - course, 1640
 - diagnostic features, 1638
 - differential diagnosis, 1640–1641
 - epidemiology, 1639
 - GAM-ANON, 1644
 - genetic factors, 1641
 - issues in clinician–patient relationship, 1645
 - neurobiological factors, 1641–1642
 - OCD *vs.*, 1106
 - psychiatric conditions in individuals with, 1640
 - social/environmental factors, 1642
 - treatment, 1642–1645
- Gamification, 2020
- Gamma-aminobutyric acid (GABA), 195, 311
 - anxiolytic drugs, 2159
 - cocaine use, 1589–1590
 - depression, 920
 - inhibition, insomnia, 2194
 - METH dependence, 1592
 - neurotransmission
 - alcohol consumption, 1406–1407
 - alcohol use disorder, 1406–1407
- Gamma band activity (GBA), 810
- Gastroenterology, 2414–2415
- Gastrointestinal disorders
 - autism, 385
 - hypnosis, 1912
- GC-3 *See* Cuban Glossary of Psychiatry, Third Edition (GC-3)
- GDC *See* Gender dysphoria in children (GDC)
- Gender, 13
 - acute stress disorder, 1158
 - adjustment disorder, 1160
 - agoraphobia, 1065
 - development, preschool children, 169–170
 - differences, posttraumatic stress disorder, 1147
 - disruptive mood dysregulation disorder, 998
 - DSM-5 classification, 666
 - dysphoria, 203, 1132
 - GAD, 1080–1081
 - identity, 203
 - major depressive disorder, 984
 - substance use disorders, 363, 364
- Gender dysphoria (GD) in adolescents and adults
 - assessment issues, 1344
 - associated features, 1344
 - case study, 1347–1348
 - clinician–patient relationship issues, 1347
 - combined treatments, 1347
 - comorbidity, 1344
 - course, 1344–1345
 - developmental/gender/cultural presentations, 1345
 - diagnosis, 1343–1345
 - differential diagnosis, 1345
 - epidemiology, 1344
 - etiology/pathophysiology, 1345
 - genetic factors, 1345
 - hormone therapy, 1346
 - identity-congruent gender role, 1347
 - mental health treatment, 1347
 - neurobiological factors, 1345
 - psychological factors, 1345
 - psychosocial treatments, 1347
 - reproductive health strategies, 1347
 - social/environmental factors, 1345
 - somatic treatments, 1346–1347
 - surgery, 1346–1347
 - treatment, 1346–1347
 - voice/communication therapy, 1347
- Gender dysphoria in children (GDC)
 - assessment issues, 1341
 - associated features, 1341
 - case study, 1343
 - clinician–patient relationship issues, 1343
 - combined treatments, 1342
 - comorbidity, 1341
 - course, 1341
 - developmental/gender/cultural presentations, 1341–1342
 - diagnosis, 1339–1342
 - differential diagnosis, 1342
 - epidemiology, 1341
 - etiology/pathophysiology, 1342
 - factors influencing treatment
 - genetic factors, 1342
 - neurobiological factors, 1342
 - psychological factors, 1342
 - psychosocial treatments, 1342
 - social/environmental factors, 1342
 - somatic treatments, 1342
 - treatment, 1342–1343
- Gene–environment interactions, 207–209, 327–330
- Gene expression, 306–307, 1148–1149
- General healthcare sector, 1787–1788
- Generalized anxiety disorder (GAD), 253, 262, 322, 1902
 - acceptance and mindfulness approaches, 1087
 - in adolescents, 2164

- agoraphobia, 1081
 anticonvulsant medication,
 2165–2166
 antipsychotic medication, 2166–2167
 assessment instruments in adults,
 1079
 associated features, 1078
 associated symptoms, 1077
 autonomic function, 1083
 benzodiazepine medications, 2165
 body dysmorphic disorder and, 1132
 buspirone, 2165
 cases, 1014–1016, 1088–1089
 in children, 2164
 clinician–patient relationship issues,
 1088
 combined treatments, 1087
 comorbidity, 1008–1009, 1080
 course, 1008–1009, 1080
 cultural presentations, 1080–1081
 developmental presentations,
 1080–1081
 diagnosis, 1008, 1076–1078
 diagnostic reliability, 1078
 differential diagnosis, 1081–1082
 discriminant validity, 1077
 duloxetine, 2163–2164
 dysthymic disorder and, 1081
 epidemiology, 1008, 1079–1080
 escitalopram, 2162, 2163
 etiology, 1009–1011
 gender presentations, 1080–1081
 genetic factors, 1082–1083
 ICD-10 criteria, 1079
 illness anxiety disorder, 1082
 MDD and, 1081
 MRI study, 1083
 neurobiological factors, 1083
 neuroimaging studies, 1083
 neurotransmitter abnormalities, 1083
 OCD, 1081–1082
 panic disorder, 1081
 paroxetine, 2162
 perceived lack of control, 1084
 persistent depression disorder and,
 1081
 PET study, 1083
 psychological factors, 1083–1084
 psychosocial treatments, 1085–1087
 refractory patients treatment, 1088
 selective serotonin reuptake
 inhibitors, 2162
 sertraline, 2162
 social/environmental factors, 1084
 somatic symptom disorder, 1082
 somatic treatments, 1084–1085
 special populations, 2163
 structured interviews, 1078
 trazodone, 2165
 treatment, 1011–1014, 1084, 1085,
 2167
 tricyclic antidepressant, 2164–2165
 venlafaxine XR, 2163
 worry criterion, 1076–1077
- Generalized Anxiety Disorder
 Questionnaire-IV (GAD-Q-IV),
 1078
 Genesis of social psychology, 453–454
 Genetic commonalities, 247
 Genetic counseling, 689
 Genetic epidemiology
 adoption studies, 260
 anxiety disorders, 262
 collaborative studies, 271
 cross-disorder studies, 263
 family studies, 259
 integration of molecular genetics,
 270–271
 migration studies, 260
 mood disorders, 261–262
 risk ratios and heritability estimates,
 260
 schizophrenia, 261
 substance use disorders, 262–263
 twin studies, 259–260
 Genetic factors
 ADHD, 752
 agoraphobia, 1068
 autism spectrum disorder, 729–730
 bipolar disorder, 992
 body dysmorphic disorder, 1133
 disruptive mood dysregulation
 disorder, 998
 dyslexia, 770
 excoriation disorder, 1138
 GAD, 1082–1083
 generalized anxiety disorder, 1009
 major depressive disorder, 984
 mathematics disorder, 773
 posttraumatic stress disorder,
 1148–1149
 severe mood dysregulation, 997
 trichotillomania, 1136
 weight-gain/fatness, 1237
 Genetic polymorphism
 catechol *O*-methyltransferase activity,
 2048–2049
 dopamine hypothesis, 2048
 DRD2 TaqI A RFLP, 2048
 of genes encoding drug-metabolizing
 enzymes, 2045, 2047
 monoamine oxidases, 2048
 serotonin system, 2048
 Genetics
 Alzheimer's disease, 401–402
 dementia with Lewy bodies, 404
 developmental neurobiology,
 306–307
 endophenotypic markers, 307–308
 frontotemporal dementia, 403–404
 personality development, 125–126
 personality style, 569–570
 schizophrenia
 adoption studies, 799
 association studies, 801
 copy number variants, 801
 epigenetics, 801–802
 family prevalence studies, 798–799
 linkage studies, 799–801
 twin studies, 799
 Genito-pelvic pain/penetration disorder
 (GPPPD), 1314
 assessment issues, 1326–1327
 associated features, 1326
 case study, 1328
 combined treatments, 1328
 comorbidity, 1327
 course, 1327
 cultural presentations, 1327
 developmental presentations, 1327
 diagnosis, 1326–1327
 differential diagnosis, 1327
 environmental factors, 1327–1328
 epidemiology, 1327
 etiology, 1327–1328
 genetic factors, 1327
 neurobiological factors, 1327
 pathophysiology, 1327–1328
 psychological factors, 1327
 psychosocial treatments, 1328
 social factors, 1327–1328
 somatic treatments, 1328
 treatment goals, 1328
 Genome-wide association method
 (GWAS), 258
 cocaine use disorder, 1564
 major depressive disorder, 917
 METH use disorder, 1565
 Genomic microarrays, prenatal causes,
 681
 The George Washington University
 Model, for organizing couple- or
 family-centered psychiatric
 treatment, 1945, 1946
 Geriatric psychiatry, 15
 Alzheimer's medications and
 behavioral disturbance, 2446
 approach to patient
 cognitive evaluation and
 management, 2441
 functional assessment,
 2440–2441
 guardianship and power of
 attorney, 2441
 physical evaluation, 2441–2442
 social setting, 2440
 dementia management
 antidepressants and, 2447
 antipsychotic medications in
 dementia, 2446–2447
 behavioral disturbance
 management, 2444–2445
 benzodiazepines and, 2447–2448
 caregivers, impact on, 2443
 cognitive assessment, 2442–2443
 delirium and, 2445
 driving and, 2443
 evaluation, 2442
 medical comorbidity and, 2444
 mood stabilizers in, 2447
 nonpharmacologic management,
 2445

- Geriatric psychiatry (*continued*)
 pharmacologic management, 2443–2444, 2446, 2448
 depression management
 clinical presentation, 2448
 and cognitive impairment, 2449
 electroconvulsive therapy, 2450
 and medical comorbidity, 2448–2449
 psychotherapy, 2449–2450
 suicide, 2449
 treatment, 2449
 multifactorial approach to, 2339
 Germany, history of psychiatry, 2599, 2601–2602
 Gerstmann–Straussler–Scheinker disease, 1695
 Gestational age and preterm birth, antidepressants, 2363–2367
Ginkgo biloba extract (GbE)
 cognitive enhancement, 2277–2278
 neuroprotective effects, 2252
 schizophrenia, 2275
 GLADP *See* Latin American Guide for Psychiatric Diagnosis (GLADP)
 Glasgow Coma Scale, 524
 Global Assessment of Relational Functioning Scale (GARF), 1768
 Global Burden of Disease Study (GBDS), 866
 Global hypoxic-ischemic disorders, 1655
 Glucocorticoid antagonists, 2249
 Glue sniffing, 1508
 Glutamate, 310–311
 cognitive enhancers, AD
 cholinesterase inhibitor and memantine, 2247
 memantine, 2246
 depression, 920
 neurotransmission
 alcohol consumption, 1407
 alcohol use disorder, 1407
 treatment-resistant depression, 2325
 Glycine, schizophrenia, 2274–2275
 Goldberg General Health Questionnaire (GHQ), 1866
 Gonadal hormone theory, 914
 Gonadal steroids, major depressive disorder, 921
 Gonadotropin-releasing hormone (GnRH), 195, 972–973, 1346
 Google Glass, 2019, 2022
 GPPPD *See* Genito-pelvic pain/penetration disorder (GPPPD)
 Grade 5 syndrome, 1898
 Graded task approach, 1848
 Greeks, history of psychiatry, 2595
 Grief, 224–225
 and bereavement, 2456–2459
 complicated variety, 2460–2461
 depression and anxiety, 2459–2460
 forms of, 2457
 interpersonal psychotherapy, 1861, 1862
 Grooved Pegboard test, 509
 Gross anatomical changes, 247
 Group-as-a-whole approach, 1926
 Group development
 five-stage model, 1931
 premature termination, 1932
 psychodynamic/interactional groups, 1932
 task of leader, 1932
 Group dynamics (Lewin), 1924
 Group matrix (Foulkes), 1924
 Group psychotherapy (Jacob Moreno), 1923, 1924
 Group therapy
 advantages of, 1923
 beginning and maintaining groups, 1928–1929
 cognitive behavioral therapy, 1928
 combined therapy, 1937
 conjoint therapy, 1937
 future directions, 1939–1940
 group-as-a-whole approach, 1926
 group process, 1932–1933
 history of, 1923–1924
 individual therapy, 1937
 interactional approach, 1926–1927
 interpersonal learning, 1927
 intrapsychic approach, 1926
 pregroup preparation, 1930–1931
 quality, 1925
 research, 1937, 1938, 1939
 self-help groups, 1928
 structure, 1925
 supportive therapy groups, 1927
 for SZPD, 1716–1717
 therapeutic factors, 1924–1926
 therapist interventions, 1933–1934
 attribution, 1935–1936
 caring, 1934–1935
 co-therapy, 1936–1937
 emotional activation, 1935
 executive function, 1934
 principles, 1936
 training, 1937, 1939
 Growth hormone-releasing hormone (GHRH), 2248
 Guardianship and power of attorney, geriatric psychiatry, 2441
 Gynecology, hypnosis, 1912
 Habilitation, ID/IDD, 689–692
 Habit reversal therapy (HRT), 783
Haemophilus influenzae (Hib) vaccine, 686
 Hair-pulling disorder *See* Trichotillomania (TTM)
 Half-life, of drug, 2033
 Hallucination, 542–543, 1214, 2603
 auditory, 543
 functional, 543
 Hallucinogen persisting perception disorder (HPPD)
 assessment, 1490
 comorbidity and course, 1490
 definition and diagnostic features, 1489
 epidemiology, 1490
 neurobiology, 1490–1492
 treatment
 goals, 1492
 issues in clinician–patient relationship, 1493
 psychosocial, 1493
 refractory patients, 1492–1493
 somatic, 1492
 Hallucinogens
 abuse
 assessment, 1487
 comorbidity and differential diagnosis, 1488
 diagnostic criteria, 1487
 epidemiology, 1487
 treatment, 1488
 ethnobotanical, 1480–1482
 human experimentation with, 1482
 intoxication
 assessment, 1484
 comorbidity patterns, 1484
 definition and diagnostic features, 1483–1484
 differential diagnosis, 1484
 epidemiology, 1484
 neurobiological factors, 1484–1485
 psychosocial factors, 1485
 treatment, 1485–1487
 LSD-related psychotic disorders, 1488–1489
 synthetic, 1482
 Haloperidol
 phencyclidine intoxication, 1477
 schizophrenia, 823
 Hamilton Anxiety Rating Scale (HARS), 1078, 2162
 Hamilton Rating Scale for Depression (HAM-D), 909, 2038
 Handicapped Children Act of 1975, 635
 Harm reduction, 1544–1545
 HARS *See* Hamilton Anxiety Rating Scale (HARS)
 Harvard Group Scale of Hypnotic Susceptibility, 1896
 Hashish, 1459
 HD *See* Hoarding disorder (HD)
 Headache
 caffeine withdrawal, 1441–1443
 major depressive disorder, 932
 Health belief model, 2042–2043
 Health Insurance Portability and Accountability Act (HIPAA), 78–79, 2017, 2018, 2019
 Health Maintenance Organization (HMO) Act, 1793
 Healthy Active Lives (HeAL) statement, 2004
 Healthy aging, 237
 Healthy narcissism, 468–469
 Hearing loss

- chromosomal disorders, 678
ID/IDD, 676
- Hedonic treadmill, 492
- Hemispheric Asymmetry Reduction in Older Adults (HAROLD), 234
- Hepatic encephalopathy, 1652
- Hepatic failure, major depressive disorder, 933
- Hepatic impairment, treatment of, 2074
- Hepatitis C virus antibody testing, 513
- Hepatosplenomegaly, 689
- Herbal medicines
anxiety disorders
Galphimia glauca (Galphimia), 2270
Matricaria recutita (Chamomile), 2270
Melissa officinalis, 2269
Passiflora incarnata (Passionflower), 2269
Piper methysticum (Kava), 2268–2269
Valeriana officinalis (Valerian), 2269
- attention-deficit/hyperactivity disorder, 2281
- cognitive enhancement
Ginkgo biloba (Ginkgo), 2277–2278
Melissa officinalis (Lemon Balm), 2278
Panax ginseng (Korean Ginseng, Asian Ginseng), 2278
Salvia lavandulaefolia (Spanish Sage), 2278
Salvia officinalis (Sage), 2278
- insomnia, 2276
- mood disorders
Crocus sativus (Saffron), 2264
Hypericum perforatum (St. John's wort, SJW), 2262–2263
Rhodiola rosea (Arctic root), 2263–2264
- preparations, 2044
- remedies, 2037–2038
- schizophrenia
Camellia sinensis (L-Theanine Derived from Tea), 2275
Ginkgo biloba (Ginkgo), 2275
Panax quinquefolium (American Ginseng), 2275
- Herb–drug interactions (HDIs), 2037, 2044
complementary and alternative medicine, 2282
- Heroin
epidemiology, 1535
routes of administration, 1533
withdrawal symptoms, 1536
- Herpes simplex type 2, 685
- Hierarchical multiple regression, 2587
- High-frequency inhalant users, 1510
- Highly active antiretroviral treatment (HAART), AIDS, 1693
- Hippocampus, 804
insufficiency of, 919
- Histamine
cognitive enhancers, AD, 2247–2248
side effects of, 2065, 2066
- Histamine H₁ antagonists, insomnia, 2198–2199
- Histone diacetylase (HDAC) activity, 375
- Histone H2A type 1 gene (*HIST1H2AG*), 801
- Histrionic personality disorder (HPD), 1727–1729
- Hoarding disorder (HD), 1096
distinct mental health problem, 1101
in DSM-5, 1099–1100
genetics in, 1108
neuroanatomical, 1109–1110
with pharmacotherapy, 1120–1121
rating scale, 1100
- Hoarding Rating Scale-Interview (HRS-I), 1100
- Holland, history of psychiatry, 2599
- Holoprosencephaly, 684
- Homelessness, 1976–1977
- Home-phobia, 2606
- Hopelessness, 482
major depressive disorder, 985
suicidal ideation, 2496
- Hospital Anxiety and Depression Scale
Anxiety subscale (HADS-A), 2164
- Hostile patient, 50
- Hostility, emotional expression, 564–565
- Housing, for SMI patients, 1976–1978
- HPPD *See* Hallucinogen persisting perception disorder (HPPD)
- HPRL *See* Hyperprolactinemia (HPRL)
- HRT *See* Habit reversal therapy (HRT)
- Human cytochrome P450 enzymes, 2046
- Human development
biological, 104–106
cognitive, 107–111
cultural considerations, 107
developmental stages, 101–103
emotional, 111–114
interlineal decalage, 120
models, 101, 104
moral, 115–118
psychopathology, 118–120
social, 114–115
- Human Genome Project (HGP), 104
- Human immunodeficiency virus (HIV)
infection *See also* Acquired immune deficiency syndrome (AIDS)
antibody testing, 513
dementia, 1664
maternal viral infections, 684
stimulant abuse, 1579
- Human psychopathology theory, 1179
- Human/technology interface, 2018, 2020–2021
- Huntington's disease, 1700–1702
- antipsychotic medication, 2098
dementia, 1664
- Hydrocephalus, 684
dementia, 1665
- Hydromorphone, 1533
- Hyperactive delirium, 1649
- Hyperactivity disorder,
neuropsychological assessment, 605
- Hyperbilirubinemia, 686
- Hypercalcemia, delirium, 1653
- Hyperglycemia, 831
delirium, 1653
- Hypericum perforatum* (St. John's wort, SJW)
mood disorders, 2262–2263
- Hyperlipidemia, 831
- Hypermagnesemia, delirium, 1653
- Hypernatremia, delirium, 1653
- Hyperprolactinemia (HPRL), 1330
- Hypersomnolence disorder
assessment issues, 1277–1278
associated features, 1277
case study, 1281–1282
clinician–patient relationship issues, 1281
combined treatments, 1281
comorbidity, 1278
course, 1278
developmental/gender/cultural presentations, 1278
differential diagnosis, 1278–1279
drugs for, 1280, 1281
epidemiology, 1278
etiology/pathophysiology, 1279
factors influencing treatment, 1281
genetic factors, 1279
neurobiological factors, 1279
psychological factors, 1279
psychosocial treatments, 1280–1281
social/environmental factors, 1279
somatic treatments, 1280
treatment, 1279–1281
treatment-refractory patients, 1281
- Hypertension
delirium, encephalopathy with, 1656
phencyclidine intoxication, 1474
- Hyperthyroidism, dementia, 1665
- Hypnosis, 516, 1895–1896, 2605
absorption factors, 1892, 1894
advantages of, 1906
applications of
considerations, 1899–1900
in forensic setting, 1913–1914
general medicine, 1910–1912
in habit control, 1912–1913
psychiatric disorders (*see* Psychiatric disorders)
definition of, 1892
DID, 1184–1185
dissociation factors, 1894
dissociative amnesia, 1188
history of, 1892, 1893
hypnotizability scales, 1896–1898

- Hypnosis (*continued*)
 neurophysiology of, 1914, 1915
 brain electrical activity, 1917
 neurotransmitters, 1917
 positron emission tomography, 1917, 1918
 ratings of perceived exertion, 1916
 regional cerebral blood flow, 1916
 somatosensory evoked potentials, 1916, 1917
 smoking, 1629
 suggestibility, 1894–1895
 Hypnotic Induction Profile, 1896–1898
 Hypnotic restructuring approach, 1901
 Hypnotic source amnesia, 1895
 Hypnotizability
 conversion phenomena, 1899
 enhancement, 1918
 eye-roll sign for, 1897, 1898
 scales, 1896–1898
 Hypoactive delirium, 1649
 Hypocalcemia, delirium, 1653
 Hypochondriasis
 case study, 1209
 course, 1208
 definition, 1207
 diagnostic features, 1207–1208
 epidemiology, 1208
 etiology/pathophysiology, 1208
 psychosocial treatments, 1208–1209
 somatic treatments, 1208–1209
 treatments, 1208–1209
 Hypoglycemia, delirium, 1653
 Hypomagnesemia, delirium, 1653
 Hypometabolism, 1187
 Hyponatremia, 1255
 delirium, 1653
 Hypotension, 2068
 Hypothalamic-pituitary-adrenal (HPA) axis, 920–921
 dysregulation, 1181
 Hypothalamic-pituitary-gonadal axis, 1233, 1234, 1241
 Hypothesis-testing approach, 603–604
 Hypothyroidism
 chromosomal disorders, 679
 dementia, 1665
 major depressive disorder, 912
 Hypoxia, 803
 perinatal causes, 685
 Hypoxic-ischemic encephalopathy (HIE), 685
 Hysteria, 2598 *See also* Somatization disorder
 Hysterical conversion, 2601
 Iatrogenic sedative-hypnotic dependence, 1552
 IATs *See* Implicit Association Tests (IATs)
 Ibn-Rhazes, 2595
 ICC *See* Intraclass correlation coefficient (ICC)
 ICDs *See* Impulse-control disorders (ICDs)
- Id, 464, 1799
 IDEA *See* Individual with Disabilities Education Act (IDEA)
 Idebenone, 2253
 Identity disorders, 543–545
 ID/IDD *See* Intellectual disability/intellectual developmental disorder (ID/IDD)
 Idiom of distress, 646
 IED *See* Intermittent explosive disorder (IED)
 IEP *See* Individualized education program (IEP)
 IGDA *See* International Guidelines for Diagnostic Assessment (IGDA)
 Illness anxiety disorder
 body dysmorphic disorder and, 1132
 case study, 1210
 definition, 1209
 diagnostic features, 1209–1210
 differential diagnosis, 1210
 generalized anxiety disorder, 1082
 vs. OCD, 1107
 Illness, stress-diathesis models of, 1945
 Illusions, 542–543
 Iloperidone, 2095
 schizophrenia, 825
 Imagery techniques, 1842–1843
 Imipramine, 2052
 panic disorder, 1057
 Immediate memory, 1658–1659
 Immunotherapy
 active, 2249–2250
 cocaine use disorder, 1590–1591
 passive, 2250
 IMPACT study, collaborative care, 2464
 Impaired affect regulation, 1873
 Impaired control, alcohol-seeking behavior, 1403
 Impaired reality testing, 1873
 Impairment/psychotherapy continuum, 1872
 Implicit Association Tests (IATs), 480
 Implicit memory, 441, 442, 527, 1182
 Implicit personality theories, 459
 Impulse-control disorders (ICDs), 360, 1367, 1370
 DSM-5 classification, 666
 symptomatic behavior in, 1368
 Impulsive behavior, 577–579
 Impulsivity, 1368, 1369
 suicidal ideation, 2496
 Inattention, Overactivity With Aggression (IOWA) Conners, 1353
 Inborn errors of metabolism, 682
 Incoherence, 1660
 Incredible Years program, 1772
 Individualized education program (IEP), 635–636
 Individual placement and support (IPS), 1969–1970
 Individual with Disabilities Education Act (IDEA), 635, 692
 Infant development
- 2- to 3-month transition
 biological-neurological development, 143–144
 cognitive development, 144
 communicative development, 144
 emotional development, 144
 social development, 144–145
 7- to 9-month transition
 biological-neurological development, 145
 cognitive development, 145–146
 communicative development, 146–147
 emotional development, 146
 social development, 147–148
 18- to 20-month transition
 biological-neurological development, 149
 cognitive development, 149
 communicative development, 150
 emotional development, 149–150
 social development, 150–151
 child maltreatment, 153
 conceptual framework, 138–141
 cultural context, 138
 first 2 months
 biological-neurological development, 138, 140–141
 cognitive development, 141–142
 communicative development, 142
 emotional development, 142
 social development, 142–143
 maternal substance abuse, 153–154
 poverty, 151–152
 premature stress and serious illness, 154
 risk and protective factors, 151
 theories, 134–137
 transactional model, 137–138
 Infantile spasms, 676
 Infectious diseases, psychological factors in, 2415
 Inferiority complex, 2608
 Infertility, psychological factors, 2416
 Inflammatory processes, cognitive enhancers in AD, 2252
 Information bias
 cognitive theory, 481–482
 psychiatric epidemiology, 416
 Information processing (IP), 199–200
 Inhalant-induced persistent neurocognitive disorder, 1690–1691
 Inhalant-related disorders
 CNS involvement, 1516–1517
 cranial nerve abnormalities, 1518
 encephalopathy, 1515–1516
 inhalant-induced disorder, 1513
 inhalant use disorder, 1512–1513
 issues in clinician–patient relationship, 1523
 myeloneuropathy, 1518
 neonatal inhalant-exposure syndrome, 1521–1522
 neurological sequelae, 1514–1515

- non-nervous system toxicity, 1519–1521
- ototoxicity, 1517
- prevalence, 1510–1511
- psychiatric disturbances, 1513–1514
- sociodemographic factors, 1511–1512
- substances inhaled, 1507–1510
- toxicology, 1514
- treatment, 1522–1523
- trigeminal neuropathy, 1518
- Inositol, mood disorders, 2266–2267
- Inpatient care in correctional setting, 2569
- Insanity defense, 2566
- Insight
- BDD, 1130, 1131
 - clinical evaluation, 532–533
- Insight-oriented therapy, 937
- Insomnia
- agents in development, 2201–2202
 - assessment issues, 1271–1272
 - associated features, 1270–1271
 - case study, 1276
 - clinician–patient relationship issues, 1275
 - cognitive behavioral approaches, 1274
 - cognitive-behavioral interventions for, 1276
 - combined treatments, 1274–1275
 - comorbidity, 1272
 - complementary and alternative medicine, 2201
 - melatonin, 2276–2277
 - mind–body techniques, 2277
 - Valeriana officinalis* (Valerian), 2276
 - course, 1272
 - definition, 2193
 - developmental/gender/cultural presentations, 1273
 - diagnosis, 1267–1270
 - differential diagnosis, 1273
 - drugs for, 1275
 - epidemiology, 1272
 - etiology/pathophysiology, 1273
 - factors influencing treatment, 1275
 - FDA-approved medications
 - benzodiazepine hypnotics, 2195–2196
 - GABAergic inhibition, 2194
 - histamine H₁ antagonists, 2198–2199
 - list of, 2195
 - nonbenzodiazepine hypnotics, 2195–2197
 - selective melatonin receptor agonists, 2197–2198
 - genetic factors, 1273
 - historical overview, 2194
 - hypnosis, 1911
 - major depressive disorder, 932
 - medical/psychiatric disorders and, 1270
 - medications/substances associated with, 1270
 - mood disorders, 587
 - neurobiological factors, 1273
 - OTC medications, 2201
 - prescription medication off-label use
 - anticonvulsants, 2200
 - antidepressants, sedating, 2199–2200
 - antihypertensives, 2200–2201
 - antipsychotics, sedating, 2200
 - chloral hydrate, 2200
 - γ -hydroxybutyrate, 2200
 - in psychiatric patients, 2202
 - psychological factors, 1273
 - psychosocial treatments, 1274
 - sleep-wake cycle regulation, 2194
 - social/environmental factors, 1273
 - somatic treatments, 1273–1274
 - treatment-refractory patients, 1275
 - treatments, 1273–1275
 - Valeriana officinalis* (Valerian), 2276
 - zolpidem, 1553–1554
- Integrated Behavioral Couple Therapy, 1772
- Integrated care, 2463–2464 *See also* Collaborative care (CC)
- Integrated psychological therapy (IPT), schizophrenia, 839
- Intellectual disability/intellectual developmental disorder (ID/IDD), 663, 1662, 2566
- assessment issues, 687
 - behavioral and mental disorders, 676
 - biomedical identified causes, 687
 - causes, 677, 687
 - cerebral palsy, 675–676
 - CNS problems, 675
 - concept of, 673–674
 - conceptualization of, 672
 - developmental history, 687, 690
 - diagnostic approach, 688, 689
 - differential diagnosis, 689–690
 - DSM-IV and DSM-IV-TR definition, 674
 - DSM-5 new definition, 674–675
 - early intervention and special education, 692
 - epidemiology, 675
 - etiologies of, 677, 678
 - external prenatal causes, 684–685
 - habilitation, 690–692
 - inborn errors of metabolism causing, 682
 - IQ score, 375
 - language, 676
 - least restrictive setting, 692
 - life expectancy, 690
 - mental disorders, 693–703
 - multifactorial and complex disorders, 686
 - perinatal causes, 685–686
 - physical examination, 688–689
 - postnatal causes, 686
 - prenatal causes, 677–684
 - prevention, 693
 - psychosocial considerations, 686–687
 - seizure, 676
 - sensory problems, 676–677
 - study of, 673
 - terminology of, 672–673
 - treatment goals, 692–693
 - and violence, 2510
- Intelligence, 529–531
- clinical evaluation, 531
 - Digit Span test, 532
 - explosion, 2021
 - global measures, 530
 - testing, 633
 - WAIS-IV, 530
- Intensive short-term dynamic psychotherapy (ISTDP), 294
- Interaction guidance therapy, 1173
- Interactive digital game (IDG), 2020
- Interactive video games and virtual worlds, 2020
- Intergenerational transmission of attachment, 470–471
- Intermittent explosive disorder (IED), 1367
- assessment issues, 1371–1372
 - case study, 1378
 - comorbidity, 1372–1373
 - course, 1373–1375
 - cultural presentations, 1375
 - definition, 1370
 - diagnostic features, 1370–1371
 - differential diagnosis, 1370, 1375
 - epidemiology, 1372
 - etiology/pathophysiology, 1375–1377
 - family/twin studies, 1376–1377
 - imaging and brain localization, 1377
 - laboratory findings, 1372
 - molecular genetic studies, 1377
 - physical examination, 1372
 - psychiatric examination and history, 1371–1372
 - psychosocial treatments, 1377–1378
 - SM-5 and ICD-10 diagnostic criteria, 1390
 - somatic treatments, 1377
 - treatment, 1377–1378
- Internal State Scale (ISS), 862
- International Classification of Diseases*, 10th Revision (ICD-10), 584
- Classification of Mental Disorders in, 348
 - DSM classification, 661
 - GAD, 1079
 - national and regional adaptations, 648
 - Panic attack, 1073
- International Classification of Diseases*, 11th Revision (ICD-11), 661
- International Classification of Mental Disorders, culture in, 639–640

- International Guidelines for Diagnostic Assessment (IGDA), 649
- International Suicide Prevention Trial (InterSePT), schizophrenia, 2101
- Internet environment
blogs, 2018
communities, 2017
computer malware, 2017
e-mail, 2016–2017
hacking, 2017
identity theft/impersonation, 2017
on-line medical forums, 2018
patient–physician relationship, 2018
physical theft of device, 2017
and social media, 80–82
- Interobserver agreement, 2583
- Interpersonal and Social Rhythm Therapy for Adolescents (IPSRT-A), 995
- Interpersonal counseling (IPC), 1866
- Interpersonal functioning, 574
- Interpersonal model, 924
- Interpersonal psychotherapy (IPT), 294, 872
case study, 1862–1863
vs. CBT, 1866–1867
cocaine use, 1584
definition of, 1859
for depression, 1774
for dysthymic and bipolar disorders, 1865
empirically based indications for, 1865, 1866
future outcome trials, 1868
grief, 1861, 1862
interpersonal deficits, 1861, 1862
long-term maintenance
antidepressant treatment, 1864–1865
for major depression, 1859
major depressive disorder, 937
for mood disorders, 1863–1865
for non-mood disorders, 1865–1866
patient guide, 1866
phases of, 1860, 1861
premises and goals of, 1859, 1860
role disputes and transition, 1861, 1862
telephone, 1866
time-limited structure of, 1860
training, 1867
- Interpersonal social rhythms therapy (IPSRT), 1865
- Intimate partner violence (IPV)
acute management, 2536–2538
at-risk populations, 2535
definitions, 2533–2534
long-term management
considerations
anxiety, 2543
depression, 2543
posttraumatic stress, 2544–2546
risk, 2542–2543
somatization, 2543–2544
substance abuse and dependence, 2543
long-term mental health sequelae, 2542
prevalence, 2534
relationship-specific characteristics, 2535
risk factors, 2534–2535
socioeconomic factors, 2535
- Intoxication
substance, 1394–1395
and withdrawal, 590
- Intracellular signal transduction pathways, 349–351
- Intracellular systems, 2053
- Intraclass correlation coefficient (ICC), 2583
- Intracranial disorders, delirium
global hypoxic-ischemic disorders, 1655
hypertensive encephalopathy, 1656
infectious and related disorders, 1655
microembolism syndrome, 1654–1655
radiation encephalopathy, 1655
stroke, 1654
subdural hematoma, 1655
thrombotic thrombocytopenic purpura, 1656
traumatic brain injury, 1655
- Intrauterine growth retardation (IUGR), 685
- Intravaginal ejaculation latency time (IELT), 1317, 1331
- Inventory for Depressive Symptomatology (IDS), 862, 908
- In vivo* neurochemical research, molecular imaging, 624
- Involuntary sleep loss, 1278
- Ion channels, autism, 388
- Ionic contrast, 618
- Iproniazid, 2052
- Ireland, history of psychiatry, 2605–2606
- IRIS Early Intervention in Psychosis Guidelines, 1999–2000
- Ironic process, 1945
- Irrational thinking patterns, in anxiety and depression, 1838
- Irregular sleep-wake type (ISWT), 1288, 1292
- Irritability, autism spectrum disorder, 733–735
- Ischemia, perinatal causes, 685
- ISWT *See* Irregular sleep-wake type (ISWT)
- Italy, history of psychiatry, 2601
- Jacobs v. Ramirez* (2005), 2570
- James–Lange theory, 547–548
- Johnson–Neyman technique, 1863
- Judgment, clinical evaluation, 532–533
- Justice, 73
- Juvenile-onset Huntington's disease, 1701
- Kauffman Brief Intelligence Test (K-BIT), 634
- K-BIT *See* Kauffman Brief Intelligence Test (K-BIT)
- Ketamine, bipolar disorder, 2144
- Kidney function tests, 512
- Kinetic-dynamic (KD) modeling, 2036
- Kleptomania, 1367
assessment issues, 1379
biological theories, 1381–1382
comorbidity, 1380
course, 1380–1381
definition, 1378–1379
diagnosis, 1378–1381
differential diagnosis, 1381
dopamine and reward deficiency, 1382
epidemiology, 1380
etiology/pathophysiology, 1381–1383
OCD vs., 1106
opioid system, cravings, and pleasure, 1382
psychiatrist–patient relationship, 1383
psychodynamic models, 1382–1383
psychosocial treatments, 1384–1385
somatic treatments, 1383–1384
treatment, 1383–1385
considerations, 1385
goals, 1383
refractoriness to initial, 1385
- Klismaphilia, 1751
- Korsakoff syndrome, 527, 1409, 1670, 1689
- The Kosovar Family Professional Educational Collaborative (KFPEC), 1956
- La belle indifférence*, 592, 1216
- Laboratory tests, psychiatric patient, 513
anorexia nervosa, 1235
blood cultures, 513
blood glucose, 511–512
brain imaging, 514–515
cerebrospinal fluid evaluation, 514
complete blood count, 511
electrocardiogram, 514
electroencephalography, 514
electrolytes, 513
HCV antibody testing, 513
HIV antibody testing, 513
kidney function tests, 512
liver function tests, 513
pregnancy testing, 513–514
psychiatric evaluation, 636–637
syphilis screening, 513
thyroid function tests, 513
toxicology, 511
urine testing, 514
- Lacunar dementia, 1664, 1683–1684
- Lamotrigine
acute bipolar depression, 2142–2143
maintenance therapy, acute bipolar depression, 2146–2147

- pregnancy, psychiatric symptoms risk, 2430
- Language acquisition device (LAD), 165
- Language development, preschool children, 164–166
- Language disorder
 - academic comorbidity, 712–713
 - assessment issues, 708–709
 - associated features, 708
 - clinician–patient relationship, 712
 - comorbidity, 709
 - course, 709
 - cultural issues in treatment, 713
 - definition and diagnostic features, 707–708
 - developmental, gender, and cultural presentation, 710
 - developmental language, 708
 - differential diagnosis, 709–710
 - epidemiology, 709
 - genetic factors, 710–711
 - ID/IDD, 676
 - neurobiological factors, 711
 - psychological factors, 711
 - psychosocial factors, 712
 - social/environmental factors, 711
 - somatic treatments, 712
 - treatment goals, 711–712
 - treatment-refractory patients, 712
- Language functions, neuropsychological assessment, 602
- Laser therapy, smoking, 1630
- Late life
 - adaptation, 230–231
 - coping mechanism, 230–231
 - defense mechanism, 230–231
 - diet, 237
 - exercise, 237–238
 - hearing, 236
 - intelligence, 233–234
 - lifespan theory, 230
 - memory, 232–233
 - physiological changes, 239
 - plasticity, 234–235
 - processing and learning, 232
 - remiscence, 231
 - sexuality, 238–239
 - smell and taste, 236
 - touch, 236–237
 - vision, 235
- Late-onset cases, Huntington's disease, 1701
- Latin American Guide for Psychiatric Diagnosis (GLADP), 648–649
- Latin American Psychiatric Association (APAL), 648
- Lead poisoning, postnatal causes, 686
- Learned helplessness, 454
- Learning disorders
 - academic skills, 765, 766
 - approximate number sense, 765
 - automatic basic skills, 765
 - complex nonacademic skills, 765
 - DSM-5 criteria, 766–768
 - DSM-IV, 766–768
- fluid intelligence, 766
- generalized anxiety disorder, 1009
- poor comprehender, 766
- resource allocation hypothesis, 766
- transcription, 766
- Learning theory, OCD, 1112
- Legal issues
 - ID/IDD, 700
 - suicidal ideation, 2500–2501
- Legal rights, psychiatric patients, 2489
- Legislation, psychological evaluation, 635–636
- Leigh syndrome, 683
- Leisure, 575–576
- Leiter International Performance Scale-Revised, 633
- Lesbian, gay, and bisexual (LGB), 1345
- Lesbian, gay, bisexual, and transgendered individuals (LGBTs), 203
- Lesch–Nyhan syndromes, 676
- Leteprenim, cognitive enhancers in AD, 2248
- Lewy body disease, 1663
 - assessment issues, 1681
 - associated features, 1681
 - comorbidity and course, 1681
 - diagnostic features, 1680–1681
 - differential diagnosis, 1681–1682
 - epidemiology, 1681
 - etiology and pathophysiology, 1682
 - treatment, 1682
- Life-span theory, 230
- Light therapy, pregnant psychiatric treatment, 2431
- Limbic encephalitis, 1656
- Limbic system, 804–805
- Line scan diffusion imaging (LSDI), 803
- Linkage studies, schizophrenia, 799–801
- Listening
 - children, 14
 - chronically mentally ill patients, 15–16
 - common blocks, 6–8
 - crucial attitudes, 8–10
 - empathy, 17
 - flow of consciousness, 16
 - geriatric patients, 15
 - hearing, 6
 - human condition, 18
 - language, 4–5
 - personal therapy, 12
 - physically ill patients, 16
 - psychological product, 12–14
 - relisting, 14
 - self-awareness, 12
 - self-education, 17
 - skill, 3–4
 - theoretical perspectives, 10–11
 - transference and counter transference, 11
 - words, 5–6
- Lithium
 - acute bipolar depression, 2143
 - adverse effects, 2132
- aggression treatment, 2515
- augmentation, 2080
- clinical application, 2131–2132
- Cockcroft–Gault equation, 2132
- cognitive enhancers, AD, 2252
- cyclic adenosine
 - monophosphate-generating system, 2131
- FDA approval, bipolar disorder, 2129
- inhibitory effects, 2131
- interactions, 2131
- levels and/or toxicity, 2132
- major depressive disorder, 938
- mechanism of action, 2131
- pharmacokinetics, 2131
- phosphomonoester concentrations, 2131
- pregnancy, psychiatric symptoms risk, 2429–2430
- psychotic excitement, 2130
- short-term efficacy, 2130
- side effects, 2132
- suicidal ideation treatment, 2498
- treatment-resistant depression, 2323
- triple threat properties, 2129
 - and valproate combination, acute bipolar depression, 2148
- Liver effects, idiopathic effects, 2069
- Liver function tests, 513
- Living In Families (LIFE) coding system, 1769–1770
- LOD scores (logarithm of the odds score), 799
- Lofexidine, opioid use disorder, 1538
- Long-acting injectable (LAI) APDs, 2107
- Longitudinal cognitive change, 606
- Longitudinal factors
 - need for intervention, 2061
 - particular agent selection, 2062
- Long-term memory, 527, 528, 529, 1659
- Lorazepam
 - agitation management, 2485
 - cocaine use disorder, 1571
 - delirium, 1657
- Low-frequency inhalant users, 1510
- Lurasidone, 2095
 - acute bipolar depression, 2141
 - schizophrenia, 825
- Lysergic acid diethylamide (LSD)-related psychotic disorders
 - assessment, 1489
 - comorbidity and course, 1489
 - definition and diagnostic features, 1488
 - differential diagnosis, 1489
 - epidemiology, 1489
 - psychiatric effects of, 1485
 - psychological factors, 1489
 - treatment, 1489
- MAD *See* Mandibular advancement devices (MAD)
- Magnetic resonance angiography (MRA), 619

- Magnetic resonance imaging (MRI)
 advantages and limitations, 619–620
 in autism, 388–389
 brain tumor, 620
 cognitive neuroscience, 436
 CT vs., 620, 621
 generalized anxiety disorder, 1083
 in psychiatric populations, 624–625
 relative indications for, 626
 structural imaging modalities, 618–620
- Magnetic resonance spectroscopy (MRS)
 bipolar disorder, 993
 functional imaging modalities, 623–624
- Magnetic seizure therapy (MST), 2301–2302
- Magnetization transfer imaging (MTI), 627
- Magnetoencephalography (MEG), 624
- Maintenance period, of treatment, 2078–2079
- Maintenance therapy, mood stabilizers
 for acute bipolar disorder
 anticonvulsants/AEDs, 2146–2148
 atypical antipsychotics, 2148–2151
 lithium, 2145–2146
 need for, 2144
 prevention of, 2145
- Major depressive disorder (MDD), 1859
 acute antidepressant treatment, 1863
 agoraphobia and, 1063
 amitriptyline, 1863
 antidepressant agents, 927
 assessment issues, 907–909, 983
 associated features, 905–907, 982–983
 body dysmorphic disorder and, 1132
 case, 988
 clinical features, 984
 combined treatments, 987
 comorbidity, 909–913, 983
 course, 913–914, 983
 cultural and ethnic differences, 915
 cultural presentations, 984
 developmental presentations, 984
 diagnostic features, 904–905, 982
 differential diagnosis, 915–917, 984
 DSM-5 diagnostic criteria, 982
 epidemiology, 909, 983
 gender presentations, 984
 gender-related differences, 914–915
 generalized anxiety disorder and, 1081
 genetic factors, 917–918, 984
 imipramine, 1863, 1864
 issues in clinician–patient relationship, 943
 neurobiological factors, 918–922, 984
 OCD, 1102
 pharmacotherapy, 986
 posttraumatic stress disorder and, 1145, 1146
 psychological factors, 922–924, 984–985
 psychosocial treatments, 987
 with psychotic features, antipsychotic medication, 2097
 research vs. clinical diagnosis, 903–904
 social/environmental factors, 924–925, 985–986
 somatic treatments, 986–987
 special factors influencing treatment, 988
 symptoms, 906
 treatment goals, 986
 treatment-refractory patients, 987–988
- Major neurocognitive disorders
 amnesic disorders (*see* Amnesia)
 dementia, 1658–1667
- Maladaptive schemas, 1838, 1839
- Male hypoactive sexual desire disorder (MHSDD), 1320
 assessment issues, 1329
 case study, 1331
 combined treatments, 1330–1331
 comorbidity, 1329
 course, 1329
 developmental/cultural presentations, 1329
 diagnosis, 1329
 differential diagnosis, 1329
 epidemiology, 1329
 etiology/pathophysiology, 1329–1330
 genetic factors, 1329
 neurobiological factors, 1329–1330
 psychosocial factors, 1330
 psychosocial treatments, 1330
 social/environmental factors, 1330
 somatic treatments, 1330
 treatment, 1330–1331
- Malformation syndromes
 associated with ID/IDD, 680
 of CNS, 683–684
 due to micro-deletions, 680–681
 of unknown cause, 683
 of unknown origin, 684
- Malingering
 neuropsychological assessment, 600–601
 symptom, 603
- Malnutrition, psychological effects, 1237
- Managed care, 30
- Mandibular advancement devices (MAD), 1284
- Mania
 bipolar disorder, 990–991, 994
 mood stabilizers
 anticonvulsants/AEDs, 2136–2138
 antipsychotics, 2133–2136
 drug list, 2130
 lithium, 2130–2132
 two-by-two type, 2130
 precipitation of, 2069–2070
- Manic depressive disorder
 acute depression agents, 876
 acute mania, 875
 age, gender, and cultural issues, 867
 antidepressant treatment, 878
 bipolar I disorder (*see* Bipolar I disorder)
 cell degeneration and neuroprotective effects, 871
 childhood and adolescence, 886
 chronic care models, 885
 clinical outcome, 865–866
 clinician–patient relationship, 885
 comorbid disorders, 862–865, 885–886
 definition and diagnostic features, 858
 differential diagnosis, 867
 drug–drug interactions, 877
 economic outcome, 866–867
 electrolyte abnormalities, 870–871
 epidemiology, 862–863
 etiology and pathophysiology, 867–873
 functional outcome, 866
 health-related quality of life, 866
 historical background, 857–858
 lithium and anticonvulsants, 880
 medical assessment, 860–861
 molecular genetic studies, 869
 neuroanatomic hypotheses, 871
 neurocognitive factors, 872–873
 neuroendocrine hypotheses, 870
 neurotransmitter hypotheses, 869–870
 older adults, 887
 postconceptual congenital factors, 869
 pregnancy, 886
 psychological hypotheses, 872
 psychosocial interventions, 882–884
 psychotherapies, 879, 881
 second-messenger system hypotheses, 870
 side effects, 876–877
 social/environmental factors, 873
 somatic treatments, 873–874
 symptoms, 861–862
 treatment algorithm, 874–875
 treatment-refractory patients, 885
- Manicula, 2606
- Mann's four central themes, 1821
- MANOVA *See* Multivariate analysis of variance (MANOVA)
- Manualized matrix model, stimulant abuse, 1585
- MAO *See* Monoamine oxidase (MAO)
- MAOIs *See* Monoamine oxidase inhibitors (MAOIs)
- Marijuana, 1458 *See also* cannabis and cannabinoids, 2353–2354
 with cocaine, 1594
 substance use disorders, 361
- Marijuana treatment project (MTP), 1464
- The Marital Attitudes Survey, 1769

- Marital communication, associated features of, 1768
- Marital Satisfaction Inventory, 1770
- Mastery-pleasure exercises, 1848
- Maternal substance abuse, 153–154
- Maternal viral infections, external prenatal causes, 684
- Mathematics disorder (MD), 767
comorbidity, 772
diagnostic features, 772
differential diagnosis, 772–773
epidemiology, 772
genetic factors, 773
neurobiological factors, 773–774
psychological factors, 774–775
treatment, 775–776
- Matricaria recutita* (Chamomile), 2270
- MATRICES *See* Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) program
- MATRICES Consensus Cognitive Battery (MCCB), 608–609
- Maturation, 2579
- Maudsley method, 1240
- MCCB *See* MATRICS Consensus Cognitive Battery (MCCB)
- McFarlane's multifamily group treatment, 1945
- McLean-Harvard First Episode Study, 415
- MD *See* Mathematics disorder (MD)
- MDD *See* Major depressive disorder (MDD)
- MDMA *See* 3,4-Methylenedioxy-methamphetamine (MDMA)
- Mean, research design, 2584
- Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) program, 608–609, 816–817, 835
- Mechanistic models, antidepressants development, 2059
- MECP2 *See* Methyl-CpG binding protein 2 (MECP2)
- Medical blogs, 2018
- Medical care, 629
- Medical disorders
with anxiety-like symptoms, 589
with depression-like symptoms, 589
- Medical Expenditure Panel Survey (MEPS), 1795
- Medical professionalism, 71–72
- Medical withdrawal process, opioid use disorder, 1537
- Medicare Payment Advisory Committee (MEDPAC) report, 1789
- Medication-induced delirium, 1651–1652
- Medication management, correctional setting, 2569
- Medieval times, history of psychiatry, 2595–2596
- Meditation
anxiety disorders, 2270–2271
attention-deficit/hyperactivity disorder, 2281
meditative movement, 2271–2274
mood disorders, 2267
- MEG *See* Magnetoencephalography (MEG)
- Melancholia, 903, 924, 2061
- Melatonin, schizophrenia, 2275
- Melissa officinalis* (Lemon Balm)
anxiety disorders, 2269
cognitive enhancement, 2278
- Membrane-stabilizing activity, side effects of, 2069
- Memory, 526–529
abnormalities, 442–443
clinical evaluation, 531–532
declarative vs. non-declarative, 527
in dissociative amnesia, 1178, 1187
executive control, 439–440
explicit, 441–442
implicit, 442, 1187–1188
long-term, 527, 528, 529
misattribution, 443
and representation, 440–443
short-term, 527–529
stages, 528
- Memory disorders, flexible battery in, 604
- Memory systems, DD and, 1182
- Meningomyelocele, 684
- Menninger Foundation research project, 1878
- The Menninger Psychotherapy Research Project, 1814
- Menstrual cycles, eating disorder effects, 1233, 1241
- Mental compulsions, 1099
- Mental disorders, 584, 1279
adverse responses, 698
behavioral measures, 698
behavioral phenotypes, 695, 696
behavior, functional analysis, 698
biomedical factors, 694–695
CAM, 696–697
challenging behaviors, 695
Chinese classification of, 648
clinical data evaluation, 698
clinical manifestation of, 694
cognitive and adaptive impairments, 694
competency to stand trial, 700
competency to testify, 700
diagnosis, 695
dual diagnosis, 694
environmental-social factors, 694
family history, 697
insanity defense, 700
medical history, 697
medications, 696
mood disorders, 698–699
patient's interview, 697–698
phenotypes, 695
psychiatric assessment, 695–701
psychiatric history, 697
psychiatrist–patient relationship issues, 702–703
psychological factors, 694
psychosocial interventions, 702
reason for referral, 695–696
service history, 697
somatic treatments, 702
treatment goals, 701
- Mental experience, models of, 1180
- Mental Health America (MHA), 1983–1985
- Mental healthcare
assessment and evaluation, 2568
community treatment of offenders, 2570
inpatient care, 2569
medication management, 2569
minimum standards for, 2568
outpatient care, 2568–2569
psychotherapy, 2569
release planning, 2569–2570
screening, 2568
special housing, 2569
treatment and management, 2568
- Mental health collaborative interventions, 2566–2567
- Mental Health Integration Program, 1794, 2470
- Mental health law, 85
- Mental health service, definition of, 1999
- Mental health treatment
accountable care organizations, 1794, 1795
emergency departments, of hospitals, 1792
expenditures
distribution of, 1788, 1789
shares of, 1788, 1789
on substance abuse services, 1788–1789
by type of service, 1790
financing mechanisms, 1792–1794
National Nursing Home survey, 1791–1792
private practice, 1794–1796
sources of funding, 1789, 1790
utilization of, 1790–1791
inpatient beds, 1791
mental health manpower, 1792
service utilization by setting, 1791–1792
- Mental illness
in correctional psychiatry, 2564–2566
flat rate, 2566
housing placement, 2565
individuals with, 2565
intellectual disability, 2566
in less developed countries, 2565
prevalence of, 2565, 2566
rates of, 2565
- Mentalization-based therapy (MBT), 1726, 1812

- Mentally healthy elders, 230
- Mental phenomena
dynamic point of view, 1799
economic point of view, 1800
genetic point of view, 1800
structural point of view, 1799
- Mental retardation, 1662
- Mental rituals, 1099
- Mental status examination (MSE), 41–42
abstraction, 819
additional testing, 820
affect and mood, 818
appearance, 817
attention and concentration, 819
attitude, 817
behavior, 817–818
components, 504–506
consciousness and orientation, 819
eye contact, 818
fund of knowledge, 819
judgment and insight, 819–820
memory, 819
perceptions, 819
physical examination, 820
psychiatric interview, 504–506
speech, 818
thought content, 818–819
thought process, 818
- Mental symptoms, secondary, 588–589
- Meperidine, phencyclidine intoxication, 1477
- Mesocorticolimbic dopamine system, 370
- Metabolic delirium, 1652–1653
- Metabolic enhancement, cognitive enhancers in AD, 2249
- Metabolic syndrome (MS), 237
antipsychotic drugs, 2115
definition of, 2115
- Metacognition, 200–201
- Metal chelators, AD cognitive enhancers, 2251
- Metapsychology, 291
- Methadone
laboratory findings, 1534
medical withdrawal, 1537–1538
opioid agonist, 1538–1540
in women, 1544
- Methamphetamine (METH), 1280
description, 1561–1562
and HIV, 1569
prevalence, 1563
use disorder
antidepressants and serotonergic agents, 1592
cardiovascular disease, 1577
course and natural history, 1572
dopaminergic agents and agonist therapy, 1591
epidemiology, 1562–1563
GABAergic agents and anticonvulsants, 1592
genetic vulnerability, 1565
naltrexone, 1592
neurobiological mechanisms, 1567–1569
psychosocial treatment, 1584
- Methodological approach, to mental phenomena, 2594–2595
- Methyl-CpG binding protein 2 (MECP2), 723
- 3,4-Methylenedioxymethamphetamine (MDMA)
acute adverse psychological effects, 1497–1498
acute positive psychological effects, 1497
assessment, 1493–1494
comorbidity, 1494
course, 1495
definition, 1482–1483
differential diagnosis, 1495
epidemiology, 1494
genetic factors, 1497
metabolism and pharmacokinetics, 1496–1497
neurobiological factors, 1495–1496
pharmacology, 1497
physical consequences of, 1498
treatment, 1498–1499
- Methyl n-butyl ketone (MBK), 1518–1519
- Methylphenidate (MPH), 1572
ADHD, stimulants in children, 2205
somatic treatments, 755
stimulant abuse, 1587–1588
- Met tyrosine kinase, autism, 387
- MFE *See* Multifactorial evaluation (MFE)
- MHSDD *See* Male hypoactive sexual desire disorder (MHSDD)
- MI *See* Motivational interviewing (MI)
- Michaelis–Menten constant, 2032
- Microcephaly, 684
- Microdeletions, malformation syndromes, 680–681
- Microembolism syndrome, delirium, 1654–1655
- Microencephalopathy, 1515–1516
- Midazolam, HPPD, 1491, 1493
- Middle childhood, 179
- Middle years, history of psychiatry, 2610–2613
- Midtown Manhattan Study, 417
- Migraine, major depressive disorder, 912
- Mild neurocognitive disorder
assessment issues, 1672
associated features, 1672
comorbidity, 1672
course, 1673
diagnostic features, 1671–1672
differential diagnosis, 1673
epidemiology, 1672
etiology and pathophysiology, 1673
treatment, 1673
- Miller–Dieker syndrome, 684
- Milnacipran, major depressive disorder, 933
- Mind and brain, psychiatric disease, 246
- Mind–body techniques
anxiety disorders
acupuncture, 2270
meditation, 2270–2271
meditative movement, 2271–2274
attention-deficit/hyperactivity disorder
meditation, 2281
neurotherapy, 2281–2282
mood disorders
acupuncture, 2267
meditation, 2267
Qigong, 2267
yoga, 2267
schizophrenia, 2275–2276
- Mind-computer analogy, 436
- Mindfulness-based cognitive therapy (MBCT), 1846
- Mindfulness-based models, posttraumatic stress disorder, 1151
- Minimal effective concentration (MEC), 2033
- Mini-Mental State Examination (MMSE), 640
- Minnesota Multiphasic Personality Inventory (MMPI) test, 509, 1224
- Mirtazapine, 2076
panic disorder, 2173
social anxiety disorder, 2169
treatment-resistant depression, 2321, 2325
- Mismatch negativity (MMN), 809–810
- Mistrust, in correctional setting, 2570–2571
- Mitochondria DNA (mtDNA), mutations to, 683
- Mitochondrial disorders, prenatal causes, 683
- Mixed serotonin antagonist/reuptake inhibitors, 2055
- MMSE *See* Mini-Mental State Examination (MMSE)
- Mobile phone revolution
artificial intelligence, 2016
continuum of platforms, 2015, 2016
Siri and Google, 2016
smart phones, 2016
- Modafinil, 1280
ADHD, 758
bipolar disorder, 2143–2144
depression in adults, stimulants, 2228–2229
- Modern medicine, 21–22
- Molecular genetics
bipolar disorder, 263–264
schizophrenia, 264–270
- Molecular imaging, *in vivo* neurochemical research, 624
- Monitoring the Future (MTF) study, 1510–1511

- Monoamine hypothesis of depression, 2052–2053
- Monoamine neurotransmitter, life cycle of, 2055–2056
- Monoamine oxidase (MAO), 2067–2068
- Monoamine oxidase A (MAO-A) enzyme, 208
- Monoamine oxidase inhibitors (MAOIs), 1481, 2052, 2054, 2071, 2159
- anxiolytic drugs, 2159
 - obsessive-compulsive disorder, 2182
 - panic disorder, 2172–2173
 - posttraumatic stress disorder, 1153, 2176
 - social anxiety disorder, 2168
 - treatment-resistant depression, 2322
- Monoaminergic arousal systems, 1279
- Monoaminergic stimulants, 1280
- Montgomery-Asberg Depression Rating Scale (MADRS), 909
- Mood
- assessment, 505, 551–553
 - disturbances of affect incongruent with, 565
 - spectrum, 561
 - states, 553
- Mood-congruent memory bias, 442
- Mood disorders, 249, 261–262, 1774
- anxiety and, 1077–1078
 - behavioral genetics, 342–343
 - cocaine use disorder, 1595
 - complementary and alternative medicine
 - herbal medicines, 2262–2264
 - mind–body techniques, 2267–2268
 - nutritional medicines, 2264–2267
 - cross-cultural research, 642–643
 - cyclic AMP-CREB cascade, 350–351
 - epigenetics, 347
 - gene–environment interactions, 346
 - herbal medicines
 - Crocus sativus* (Saffron), 2264
 - Hypericum perforatum* (St. John's wort, SJW), 2262–2263
 - Rhodiola rosea* (Arctic root), 2263–2264
- ID/IDD, 698–699
- mind–body techniques
- acupuncture, 2267
 - meditation, 2267
 - Qigong, 2267
 - yoga, 2267
- neuroendocrine systems, 349
- neurogenesis, 353–354
- neurotrophic factors, 351–353
- nomenclature, 341–342
- nutritional medicines
- 5-hydroxytryptophan (5-HTP), 2266
 - acetyl-L-carnitine (ALCAR), 2267
 - B vitamins, 2266
 - inositol, 2266–2267
 - omega-3 fatty acids, 2265
 - S-adenosyl-L-methionine (SAME), 2264–2265
 - zinc, 2266
- OCD, 1102
- physical manifestations, 587–588
 - suicidal ideation, 2494–2495
 - susceptibility gene discovery, 343–346
 - transmitter systems, 347–349
 - violence, 2509
- Mood disorders, IPT for, 1863–1865
- Mood Disorders Questionnaire (MDQ), 860
- Mood stabilizers, 1360–1361
- class A type, 2130
 - class B type, 2130
 - dementia in geriatrics, 2447
 - manic depressive disorder, 873–874
 - two-by-two type, 2130
- Moral development
- human, 115–118
 - preschool children, 170–172
 - school-age children, 185–187
- Moral disengagement, 454
- Moral insanity, 2605
- Morality, 186
- Morphine, 1532
- Mortality rates
- anorexia nervosa, 1236
 - threat to, 2579
- Motivational enhancement therapy (MET), 1584, 1883–1884
- Motivational interviewing (MI)
- alcohol problems, interventions for, 1883
 - applications of, 1889
 - CAT, 1886
 - clinical supervision, 1889–1890
 - cognitive behavioral therapy, 1883, 1884
 - DARN, 1886
 - definition of, 1882
 - discord, 1888–1889
 - vs. disease model, 1884
 - dissemination of, 1890
 - empirical support, 1889
 - engagement process, 1885–1886
 - evoking process, 1885–1888
 - focusing process, 1885, 1886
 - future research, 1890
 - learning, 1889–1890
 - OARS, 1885
 - overlapping process of practitioners, 1882
 - patient-centered counseling skills, 1883, 1884
 - piolt study, 1584
 - planning process, 1885, 1888
 - practices of, 1885
 - stages of change model, 1883
 - sustain talk, 1888–1889
 - training, 1889–1890
- Motor development, preschool children, 162
- Motor disorders, 779–780
- developmental coordination disorder, 780–781
 - stereotypic movement disorder, 782–783
 - TIC disorders, 783–788
- Motor skills, ID/IDD, 675–676
- Mowrer's two-stage model, 1034–1035
- MSE *See* Mental status examination (MSE)
- MTI *See* Magnetization transfer imaging (MTI)
- Multifactorial evaluation (MFE), 635–636
- Multifamily group therapy, 1944–1945
- Multi-infarct dementia, 1664, 1683
- Multiple correlation/regression, 2587–2588
- Multiple personality disorder *See* Dissociative identity disorder (DID)
- Multiple sclerosis, major depressive disorder, 911
- Multivariate analysis of variance (MANOVA), 2589
- Multivariate approaches, research design, 2586–2587
- analysis and power, 2591
 - design, 2590
 - factor analysis, 2588–2589
 - measures, 2591
 - multiple correlation/regression, 2587–2588
 - multivariate analysis of variance, 2589
 - reading published research, 2590
 - sample, 2591
 - structural equation modeling, 2589–2590
- Munchausen's syndrome, 1223
- case study, 1227
 - diagnosis, 1225
 - treatment, 1226
- Muscarinic acetylcholine receptors, side effects of, 2065
- Muscarinic agonists and antagonists, cognitive enhancers in AD, 2241
- Mutilation Questionnaire, 1022–1023
- Myeloneuropathy, inhalant abuse, 1518
- Myocardial infarction, cocaine use, 1576
- Myoclonic seizures, ID/IDD, 676
- N24SWD *See* Non-24-Hour Sleep-Wake Disorder (N24SWD)
- N170, 808–809
- N400 ERP, 808
- N-acetyl aspartate (NAA), 624
- N-acetylcysteine (NAC)
- anxiety disorders, 2270
 - cannabis dependence, 1466
 - schizophrenia, 2274
- Nalmefene, 1425
- Naloxone, 1540
- Naltrexone
- alcohol use disorder, 1425

- Naltrexone (*continued*)
 cocaine use, 1588–1589
 METH dependence, 1592
 opioid use disorder, 1536, 1540–1542
- Naphthalene inhalation, 1509
- Narcissism, healthy, 468–469
- Narcissistic personality disorder (NPD), 1729–1731
- Narcolepsy
 assessment issues, 1277–1278
 associated features, 1277
 case study, 1282
 clinician–patient relationship issues, 1281
 combined treatments, 1281
 comorbidity, 1278
 course, 1278
 developmental/gender/cultural presentations, 1278
 diagnostic features, 1277
 differential diagnosis, 1278–1279
 drugs for, 1280, 1281
 epidemiology, 1278
 etiology/pathophysiology, 1279
 factors influencing treatment, 1281
 genetic factors, 1279
 neurobiological factors, 1279
 psychological factors, 1279
 psychosocial treatments, 1280–1281
 social/environmental factors, 1279
 somatic treatments, 1280
 treatment, 1279–1281
 treatment-refractory patients, 1281
- Narrative approach, to postmodern family therapies, 1954–1955
- NaSSAs *See* Noradrenergic and specific serotonergic antidepressants (NaSSAs)
- National Alliance for Research on Schizophrenia and Affective Disorders (NARSAD), 1984
- National Alliance on Mental Illness (NAMI), 1983–1986
- National Ambulatory Medical Care Survey (NAMCS), 1795
- National Association for Persons with Developmental Disabilities and Mental Health Needs (NADD), 673
- National Comorbidity Survey (NCS), 245, 418, 429
 comorbidity, 419
 design, 419
 mental health services use, 419
 prevalence, 419
 risk factors and correlation of, 419
- National Comorbidity Survey Replication (NCS-R), 419, 429, 1023, 1079, 1354
 design, 420
 DSM-IV-TR disorders, 422, 425, 427
 failure and delays in initial help-seeking, 422–424
 lifetime mental disorders, 420–422
 prevalence rates, 420
 survey, 1024
- National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), 360, 1023, 1639
- National Household Survey of Drug Use and Health (NSDUH), 1402
- National Institute of Mental Health (NIMH), 1984, 2209
- National Registry of Evidenced Based Programs and Practices (NREPP), 2489–2490
- National Survey on Drug Use and Health (NSDUH), 1510–1511
- National Vietnam Veterans Readjustment Study, 417
- NDRIs *See* Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
- Necrophilia, 1751
- Nefazodone, 2055, 2063, 2076
 GAD treatment, 2165
 posttraumatic stress disorder, 2176
- Negative cognitive triad, 1837
- Negative reinforcement, 479
- Negative valence systems domain, 669
- Neodissociation theory, 1179
- Neonatal and post-neonatal demise, perinatal depression, 2375
- Neonatal behavioral syndrome, perinatal depression, 2375–2378
- Neonatal inhalant-exposure syndrome, 1521–1522
- Neoplasia and major depressive disorder, 913
- Nerve growth factor (NGF), 311, 2248
- Neural circuits, 312–313
 and executive functioning, 201–202
- Neural tube defects, 684
- Neurasthenia, 2607
- Neuregulin 1, 799
- Neuroaffective phenotype, 277
- Neurobehavioral effects, pregnancy, 2429
- Neurobiological factors, 203
 ADHD, 752–754
 agoraphobia, 1066–1068
 autism spectrum disorder, 730–731
 bipolar disorder, 992–993
 body dysmorphic disorder, 1133
 childhood-onset fluency disorder, 716
 disruptive mood dysregulation disorder, 998
 dyslexia, 770
 excoriation disorder, 1138
 generalized anxiety disorder, 1009, 1083
 language disorder, 711
 major depressive disorder, 984
 mathematics disorder, 773–774
 posttraumatic stress disorder, 1149–1150
 severe mood dysregulation, 997
 social anxiety disorder, 1032–1034
 specific phobia, 1032–1034
 stuttering, 716
 trichotillomania, 1136
- Neurochemical commonalities, 247
- Neurocognitive disorder
 alcohol-induced, 1409, 1689–1690
 Alzheimer's disease, 1674–1677
 Binswanger's disease, 1684
 culture and, 640
 delirium, 1647–1658
 DSM-5 classification, 666
 frontotemporal lobar degeneration, 1677–1680
 inhalant-induced persistent, 1690–1691
 lacunar dementia, 1683–1684
 Lewy body disease, 1680–1682
 major (*see* Amnesia; Dementia)
 mild, 1671–1674
 multi-infarct dementia, 1683
 OCD, 1110
 substance-induced, 1688–1689
 traumatic brain injury, 1685–1688
 vascular disease, 1682–1683
- Neurocognitive impairment, 610
- Neurodegenerative diseases
 Alzheimer's disease, 400–402
 dementia with Lewy bodies, 404
 frontotemporal dementia, 402–403
- Neurodevelopmental disorders, DSM-5 classification, 663–664
- Neuroendocrine systems, 349
- Neurogenesis, 353–354
- Neurogranin (*NRGN*), 801
- Neurokinin receptors, 920
- Neuroleptic malignant syndrome (NMS), 830, 1652, 2113
- Neuroleptics
 major depressive disorder, 938–939
 sensitivity, 1680
- Neurologins, autism, 387
- Neurologic immune reconstitution inflammatory syndrome (NeuroIRIS), 1693
- Neurology, 2598
 psychological factors in, 2413–2414
- Neuropathological/pharmacological phenotypes
 conflict behavior, 282–283
 schizophrenia, 283–285
- Neuropathology, 314
 AD, 2237
 autism, 388–390
- Neurophysiology, of hypnosis, 1914, 1915
 brain electrical activity, 1917
 neurotransmitters, 1917
 positron emission tomography, 1917, 1918
 ratings of perceived exertion, 1916
 regional cerebral blood flow, 1916
 somatosensory evoked potentials, 1916, 1917
- Neuropsychiatric Screening Adjunct, 416–417

- Neuropsychological assessment
 ADHD, 750
 clinical interpretive methods, 605–607
 clinical research contributions, 608–609
 clinical utility, 598
 decision-making capacity, 601
 domains of, 602
 foundations and conceptual principles, 597–598
 guardianship evaluation, 601
 malingering, 600–601
 procedures and methods, 602–605
 process-oriented approach, 607
 purpose and uses, 598–601
 quantifiable/qualitatively samples, 598 reports, 608
 therapeutic feedback, 607–608
- Neuropsychological effects, cannabis, 1460
- Neuropsychological testing, 509–510
- Neurosurgery, OCD, 1122
- Neurotherapy,
 attention-deficit/hyperactivity disorder, 2281–2282
- Neurotransmitter abnormalities,
 generalized anxiety disorder, 1083
- Neurotransmitter-based approaches,
 AD, 2238–2240
- Neurotrophic factors
 cognitive enhancers, AD
 cerebrolysin, 2248
 estrogens, 2249
 glucocorticoid antagonists, 2249
 leteprinin, 2248
 nerve growth factor (NGF), 2248
 paliroden, 2249
 xaliproden, 2248
 in depression and antidepressant actions
 antidepressant treatment,
 expression of, 352
 BDNF and synaptogenesis role, 352
 functional consequences, 352
 neurotrophic factor signaling cascades, 351–352
 neurotrophic factor systems, 351
- Neutrality, 1802
- New-generation antipsychotics (NGAs)
 amisulpride, 2094–2095
 aripiprazole, 2095
 asenapine, 2095
 blonanserin, 2095
 chemical structures of, 2088, 2090
 clozapine, 2095
 features and properties of, 2103, 2104
 iloperidone, 2095
 lurasidone, 2095
 olanzapine, 2096
 paliperidone, 2096
 perospirone, 2096
 quetiapine, 2096
 risperidone, 2096
 sertindole, 2096
 ziprasidone, 2096
 zotepine, 2097
- Newscaster framing, 2015
- New-variant Creutzfeldt–Jakob disease, 1695
- New York Teacher Rating Scale, 1353
- Next-generation sequencing (NGS), 269–270
- Nicotine dependence, 1620
 antidepressant medications, 2348–2349
 combined treatments, 2349
 co-occurring psychiatric disorders and nicotine dependence, 2349–2350
 effects, 370
 features, 2347
 nicotine replacement therapy, 2347–2348
 substance use disorders, 361
 varenicline, 2349
- Nicotine replacement therapies (NRTs),
 tobacco use disorder, 1618, 1624
- Nicotinic agonists, cognitive enhancers in AD, 2241
- Night alarms, enuresis, 1254, 1255
- Nightmare, 932
- Nightmare disorders
 associated features, 1296
 case study, 1298
 combined treatments, 1298
 comorbidity, 1296
 course, 1297
 developmental/gender/cultural presentations, 1297
 diagnostic features, 1295–1296
 differential diagnosis, 1297
 epidemiology, 1296
 etiology/pathophysiology, 1297
 genetic factors, 1297
 neurobiological factors, 1297
 psychological factors, 1297
 psychosocial treatments, 1298
 social/environmental factors, 1297
 somatic treatments, 1297
 treatment, 1296, 1297–1298
- NIMH-sponsored Research Domain Criteria (RDoC) project, 668–669
- N*-methyl-D-aspartate receptor (NMDA-R) hypofunction hypothesis of schizophrenia, 2093
- N*-methyl-D,L-aspartate (NMDA) antagonists, 352–353
 receptors, 195
- Nocturnal enuresis, 1250, 1252, 1253
- Non-24-Hour Sleep-Wake Disorder (N24SWD), 1288, 1292
- Non-benzodiazepine hypnotics, insomnia, 2195–2197
- Non-criminal forensic issues
 guardianship, 701
- Non-declarative memory, 527 *See also*
 Implicit memory
- Non-disordered gambling, 1640
- Non-experimental studies, psychiatric epidemiology, 414–415
- Non-insulin dependent diabetic (NIDD), 1301
- Non-ionic contrast, 618
- Nonmaleficence, 73
- Non-medical use of prescription stimulants (NMUPS), 1562, 1572–1573
- Non-mood disorders, for IPT
 anxiety disorders, 1866
 applications, 1866
 eating disorders, 1865–1866
 substance abuse, 1866
- Non-psychotic disorders in children,
 antipsychotic medication, 2099
- Non-psychotropic drugs, 1334
- Non-REM (NREM) sleep arousal disorders, 1265, 1266
 assessment issues, 1294
 associated features, 1293
 case study, 1295
 combined treatments, 1295
 comorbidity, 1294
 course, 1294
 diagnosis, 1293–1294
 differential diagnosis, 1294
 epidemiology, 1294
 etiology/pathophysiology, 1294
 genetic factors, 1294
 neurobiological factors, 1294
 psychological factors, 1294
 psychosocial treatments, 1295
 social/environmental factors, 1294
 somatic treatments, 1295
 treatment, 1294
- Non-restorative sleep, 1267
- Non-sexual boundary transgressions
 acceptance of gifts, 78
 self-disclosure, 77
- Non-specific parent–adolescent conflicts, 1772
- Non-steroidal anti-inflammatory drugs (NSAIDs), 2250
- Non-strategic gambling, 1640
- Non-trauma-focused therapies, 1155
- Non-verbal communication, 44, 163
- Nootropics, metabolic enhancement, 2249
- Noradrenergic and specific serotonergic antidepressants (NaSSAs), 2055
- Norepinephrine
 depression, 920
 side effects of, 2065, 2066
- Norepinephrine-dopamine reuptake inhibitors (NDRIs), 2054
- Norepinephrine reuptake inhibitors (NRIs), 2054
- Normalization principle, 692–693
- Norming/intimacy model, group development, 1931

- Nosologies, 646–647
 NRIs *See* Norepinephrine reuptake inhibitors (NRIs)
 Number needed to inconvenience (NNI) concept, 2003
 Number needed to treat (NNT) concept, 2003
 Number needed to worry (NNW) concept, 2003
 Nutritional medicines
 anxiety disorders, 2270
 attention-deficit/hyperactivity disorder
 dietary elimination strategies, 2280–2281
 omega-3 fatty acids, 2280
 phosphatidylserine, 2280
 cognitive enhancement
 omega-3 fatty acids, 2278–2279
 phosphatidylserine, 2279
 vitamins, 2278
 mood disorders
 5-hydroxytryptophan (5-HTP), 2266
 acetyl-L-carnitine (ALCAR), 2267
 B vitamins, 2266
 inositol, 2266–2267
 omega-3 fatty acids, 2265
 S-adenosyl-L-methionine (SAME), 2264–2265
 zinc, 2266
 schizophrenia
 glycine, 2274–2275
 melatonin, 2275
 N-acetylcysteine (NAC), 2274
 omega-3 fatty acids, 2274
 vitamin E, 2275
- Obesity, eating disorder relationship, 1231
 Object permanence, 163
 Object relations impairment, 1873
 Object relations theory
 basics of model, 466–467
 borderline personality disorder, 467
 empirical study, 467
 formulation and treatment, 467–468
 healthy narcissism, 468–469
 historical context, 466
 transference focused psychotherapy, 467
 Observation bias, psychiatric epidemiology, 416
 Obsessive-compulsive disorder (OCD), 188, 250, 262, 320, 322–323, 725, 1375
 adult, 1104
 age of onset, 1104–1105
 animal models, 1111–1112
 anorexia nervosa relationship, 1236, 1237
 anticonvulsant medication, 2183
 antipsychotic medication, 2183–2184
 anxiety disorders, 1103
 assessing treatment resistance, 1118
 augmentation strategies, 1118–1119
 behavioral therapy, 1119–1120
 benzodiazepine medication, 2182
 beta-blocker medication, 2182–2183
 body dysmorphic disorder, 1107, 1129–1134
 bupropion, 2182
 buspirone, 2182
 citalopram, 1117
 clomipramine, 1116–1117
 contamination, 1098
 deep brain stimulation, 1122
 definition and diagnostic features, 1095–1098
 and DSM-5, 1093, 1095
 DSM-5 classification, 664–665
 epidemiology, 1100–1101
 excoriation disorder, 1137–1139
 factors for initial treatment failure, 1106
 fluoxetine, 1115–1116
 fluvoxamine, 1116
 vs. gambling disorder, 1106
 gender distribution, 1101
 generalized anxiety disorder and, 1081–1082
 genetic factors, 1107–1108
 genome-wide association studies, 1108
 hoarding disorder (*see* Hoarding disorder (HD))
 vs. illness anxiety disorder, 1107
 insight, 1100
 vs. kleptomania, 1106
 learning theory, 1112
 linkage and association studies, 1108
 marital status, 1101–1102
 mental compulsions/rituals, 1099
 mood disorders, 1102
 need for symmetry, 1098
 neural circuitry, 1109
 neuroanatomical, 1108–1109
 neurobiological factors, 1108–1110
 neurochemical aspects, 1110–1111
 neurocognition, 1110
 neurosurgery, 1122
 vs. obsessive-compulsive personality disorder, 1107
 paroxetine, 1116
 pathological doubt, 1099
 personality disorders, 1104
 physician–patient relationship, 1112–1114
 psychoanalytic theory, 1112
 psychotherapy, 1121–1122
 psychotic disorders, 1103, 1106
 selective serotonin reuptake inhibitors, 2180–2182
 serotonin, 2182
 sertraline, 1116
 sexual and aggressive obsessions, 1098–1099
 somatic treatments, 1114
- SRI, 1114–1115
 substance use disorders, 1103–1104
 tic disorders, 1102
 Tourette's syndrome, 1102, 1106
 treatment, 1113, 1114, 1122–1123, 2184–2185
 trichotillomania, 1106, 1135–1137
 tricyclic antidepressant medication, 2182
 twin and family studies, 1107–1108
 typical course of illness, 1105
 Obsessive-compulsive personality disorder (OCPD)
 comorbidity, 1737
 course, 1737
 diagnostic and associated features, 1736
 differential diagnosis, 1736–1737
 epidemiology, 1737
 etiology and pathophysiology, 1737–1738
 OCD and, 1098, 1107
 treatment, 1738
 Obstetrics
 hypnosis, 1912
 psychological factors in, 2416
 Obstructive sleep apnea, 1279
 delirium, 1652–1653
 Obstructive sleep apnea hypopnea (OSAH)
 assessment issues, 1283
 associated features, 1283
 case study, 1285
 clinician–patient relationship issues, 1285
 combined treatments, 1285
 comorbidities/consequences associated with, 1283
 comorbidity, 1283–1284
 course, 1284
 developmental/gender/cultural presentations, 1284
 diagnosis, 1282–1283
 differential diagnosis, 1284
 epidemiology, 1283
 etiology/pathophysiology, 1284
 factors influencing treatment, 1285
 genetic factors, 1284
 neurobiological factors, 1284
 psychological factors, 1284
 psychological treatments, 1285
 social/environmental factors, 1284
 somatic treatments, 1284–1285
 treatment, 1284–1285
 treatment-refractory patients, 1285
 Occupational functioning, 575
 OCD *See* Obsessive-compulsive disorder (OCD)
 Oculomotor dysfunction, 1517
 ODD *See* Oppositional defiant disorder (ODD)
 Oedipal conflict, 465
 Offenders, community treatment of, 2570

- Olanzapine, 833, 2096
 acute bipolar depression, 2139–2140
 aggression treatment, 2514
 maintenance therapy, 2148–2149
 schizophrenia, 824
- Olanzapine-fluoxetine combination (OFC), 2139–2140
- Omega-3 fatty acids
 attention-deficit/hyperactivity disorder, 2280
 cognitive enhancement, 2278–2279
 mood disorders, 2265
 schizophrenia, 2274
- Oncology, psychological factors in, 2408–2410
- One-group post-test-only design, 2578
- One-group pretest-post-test, 2578
- One Mind for Research, 1984
- On-line medical forums, 2018
- Operant conditioning, 479
- Opiates
 detoxification, 2337–2341
 maintenance treatments, 2341–2347
- Opioid, 1394
 description, 1532, 1533
 intoxication, 1535, 1536
 reward, 370
 routes of administration, 1533
 substance use disorders, 360
 use disorders
 Affordable Care Act, 1545–1546
 antagonist therapy, 1540–1541
 clinical presentation, 1533–1534
 comorbidity, 1542–1544
 course and natural history, 1535
 differential diagnosis, 1534–1535
 epidemiology, 1535
 etiology and pathophysiology, 1535
 harm reduction, 1544–1545
 issues in clinician–patient relationship, 1546
 laboratory findings, 1534
 medical withdrawal, 1537–1538
 opioid agonist pharmacotherapy, 1538–1540
 psychosocial/behavioral treatments, 1541–1542
 withdrawal, 1535–1536
- Opioidergic hypothesis of alcoholism, 1406
- Opioidergic neurotransmission, alcohol use disorder, 1406, 1424–1425
- Oppositional defiant disorder (ODD)
 assessment issues, 1351, 1353–1354
 associated features, 1351
 bipolar disorder and, 991
 case study, 1362
 clinical assessment, 1351
 clinician–patient relationship issues, 1362
 combined treatments, 1361–1362
 comorbidity, 1354
 course, 1354–1355
 developmental/gender/cultural presentations, 1355–1356
 diagnostic features, 1350
 diagnostic interviews, 1353
 differential diagnosis, 1356
 discrimination of, 1356
 epidemiology, 1354
 etiology/pathophysiology, 1356–1359
 factors influencing treatment, 1362
 genetic factors, 1356–1357
 laboratory measures, 1354
 neurobiological factors, 1357–1358
 neuropsychological assessment, 1353
 psychological factors, 1358
 psychosocial treatments, 1361
 rating scales, 1351–1353
 risk for, 1351
 social/environmental factors, 1358–1359
 somatic treatments, 1359–1361
 treatment, 1359–1363
 algorithms/practice guidelines, 1362
 goals, 1360
 refractory patients, 1362
- Oral contraceptives, premenstrual dysphoric disorder, 972
- Organisation for Economic Co-operation and Development (OECD), 495
- Organ system, anxiety by, 586
- OROS-MPH, stimulants in children, 2209
- OSAH *See* Obstructive sleep apnea hypopnea (OSAH)
- Outcome assessment, antidepressants treatment, 2079
- Outpatient care in correctional setting, 2568–2569
- Overt Aggression Scale, 1353
- Over-the-counter (OTC) analgesic agents, 590
- Oxycodone, 1533
- Oxytocin receptors (OXTR)
 autism, 387
- P50, 809
- P100, 808
- P300 ERP, 808
- Package inserts (PI), for oral medications, 2036
- Pain
 management, hypnosis, 1910–1911
 physical signs and symptoms, 592–593
- Pain disorder
 case study, 1212–1213
 course, 1211
 definition, 1210
 diagnostic features, 1210
 epidemiology, 1210–1211
 etiology/pathophysiology, 1211
 psychosocial treatments, 1211–1212
 somatic treatments, 1211–1212
 treatments, 1211–1212
- Paliperidone, 2096
 maintenance therapy, 2150–2151
- Paliperidone/9-hydroxy risperidone, 825
- Palipoden, 2249
- Panax ginseng* (Korean Ginseng, Asian Ginseng), 2278
- Panax quinquefolium* (American Ginseng), 2275
- Panic and Agoraphobia Scale, 1061
- Panic attacks, 556, 1058
 completed record, 1062
 expected vs. unexpected, 556
 ICD-10 Diagnostic Criteria for Research, 1073
 patients assessment presenting with, 1060
 types, 559
 unexpected and expected, 1058
- Panic disorder (PD), 262, 322, 477
 anticonvulsant medication, 2174
 antipsychotic medication, 2174
 behavioral theory, 485–486
 benzodiazepine medication, 2173–2174
 bupropion, 2173
 buspirone, 2174
 cognitive theory, 486
 comorbidity data, 1063
 diagnosis of, 1057, 1058
 diagnostic features, 1058–1059
 DSM-5 definition, 1058–1059
 generalized anxiety disorder, 1081
 mirtazapine, 2173
 origin, 1057
 physical signs and symptoms, 585
 psychoanalytic psychotherapy treatment, 1811
 reboxetine, 2171–2172
 selective serotonin reuptake inhibitors, 2170–2171
 treatment, 2174–2175
 tricyclic antidepressant medication, 2172–2173
 venlafaxine, 2171–2172
- PANSS, 826
- Parahallucinations, 1491
- Parallax or gaze angle, 2015
- Paraneoplastic syndrome and major depressive disorder, 913
- Paranoia, cocaine-induced, 1564–1565
- Paranoid personality disorder (PPD)
 comorbidity, 1714–1715
 course, 1715
 diagnostic and associated features, 1714
 differential diagnosis, 1714
 epidemiology, 1714
 etiology and pathophysiology, 1715
 treatment, 1715–1716
- Paraphasias, 1660
- Paraphilic disorders, 1749, 1750
 assessment issues, 1751–1752
 associated features, 1751

- Paraphilic disorders (*continued*)
 comorbidity and course, 1753
 diagnostic features, 1749–1751
 differential diagnosis, 1753
 DSM-5 classification, 667
 epidemiology, 1752–1753
 gender differences in, 1753
 genetic factors, 1753
 issues in clinician–patient relationship, 1755
 neurobiological factors, 1754
 psychological factors, 1754
 social/environmental factors, 1754
 treatment, 1754–1755
- Parasomnias, 1293, 1295
- Parental care
 psychiatric evaluation, 630
 referring sources, 637
- Parental competency in child protection cases, 701
- Parental relationship distress, negative effects on child, 1760
- Parent behavior training (PBT), 759
- Parent–child attachment bonds, 172
- Parent–child communication, associated features of, 1768
- Parent–Child Conflict Tactics Scale, 1353
- Parent–child interaction therapy (PCIT), 1772
- Parenting Stress Index (PSI), 632
- Parkinson's disease, 1664
 antipsychotic medication, 2098
 assessment issues, 1698
 associated features, 1697–1698
 comorbidity and course, 1698
 diagnostic features, 1697
 differential diagnosis, 1698
 epidemiology, 1698
 etiology and pathophysiology, 1698
 major depressive disorder, 911
 treatment, 1699
- Parkinson's disease dementia (PDD), 404
- Paroxetine
 generalized anxiety disorder, 2162
 OCD, 1116
- PARS *See* Pediatric Anxiety Rating Scale (PARS)
- Passiflora incarnata* (Passionflower), 2269
- Past psychiatric history, psychiatric interview, 503
- Pathogenic cascade hypothesis, 2238
- Pathoplasty model, depression, 560
- Patient Centered Medical Homes (PCMHs)
- Patient portal, 2021
- Patient Protection and Affordable Care Act (PPACA), 1787, 1789, 1793, 1794
- Patient's physical/emotional distress, 42
- Patient's rights
 competency and treatment refusal, 87–88
 hospitalization decisions, 86–87
 involuntary hospitalization, 86
- PBT *See* Parent behavior training (PBT)
- PD *See* Panic disorder (PD)
- PDDs *See* Pervasive developmental disorders (PDDs)
- PE *See* Premature (early) ejaculation (PE)
- Pediatric Anxiety Rating Scale (PARS), 1010
- Pediatric brain imaging studies, 306
- Pedophilic disorder, 1750, 1754 *See also* Paraphilic disorders
- Peer/family support models, 1986–1987
- Penn State Worry Questionnaire (PSWQ), 1078
- Perception, mental status examination, 505–506
- Perceptual disturbances, 542–543
- Perimenopause, psychiatric symptoms
 approach, 2434
 hormonal changes, 2433–2434
 treatment considerations, 2434–2435
- Perinatal depression
 antidepressants
 congenital malformations, 2368–2375
 epidemiology, 2361–2362
 fetal death, 2362–2363
 fetal growth, 2367–2368
 gestational age and preterm birth, 2363–2367
 neonatal and post-neonatal demise, 2375
 neonatal behavioral syndrome, 2375–2378
 neurodevelopmental effects, 2378–2379
 persistent pulmonary hypertension, 2378
 spontaneous abortion, 2362
- causes
 hypoxia and ischemia, 685
 infections, 685
 retrolental fibroplasia, 686
- Periodic limb movements (PLMs), 1299
- Periventricular heterotopias, 684
- Periventricular leukomalacia (PVL), 685
- Perospirone, 2096
- Peroxisome proliferator-activated receptor-g agonists, 2251–2252
- Persistent depressive disorder
 assessment issues, 947
 associated features, 946–947
 comorbidity and course, 947
 diagnostic features, 945–946
 differential diagnosis, 947–948
 epidemiology, 947
 etiology and pathophysiology, 948
 generalized anxiety disorder and, 1081
 symptoms, 906
- treatment, 948–949
- Persistent pulmonary hypertension, 2378
- Personality development
 attachment, 126–128
 character, 128–129
 genetics, 125–126
 life experiences, 128
 personality disorders, 129–131
 personality traits, 123–126
 temperament, 122–123
- Personality disorder (PD), 129–131, 911, 1373
 agoraphobia and, 1064
 antisocial, 1720–1724
 assessment, 1707–1708
 avoidant, 1732–1734
 borderline, 1724–1727
 comorbidity, 1709–1713
 course, 1713
 culture, 1708
 culture and, 646
 definition, 1706–1707
 dependent, 1734–1736
 differential diagnosis, 1708
 DSM-5 classification, 666–667
 due to medical condition, 1739–1741
 emotional expression, 553–554
 epidemiology, 1708–1709
 etiology and pathophysiology, 1713
 histrionic, 1727–1729
 hypnosis, 1899
 narcissistic, 1729–1731
 obsessive-compulsive, 1736–1739
 OCD, 1104
 paranoid, 1714–1716
 Schizoid, 1716–1717
 Schizotypal, 1717–1720
 supportive psychotherapy, 1878–1879
 treatment, 1714
 treatment-resistant depression, 2315–2317
 violence and, 2510
- Personality style, 569–574
 Alternative Model, 571–572
 anorexia nervosa, 1237–1238
 biogenic spectrum model, 573–574
 categorical model, 571–572
 Cloninger's seven-factor model, 572–573
 dimensional model, 571–574
 five-factor model, 572, 573
 genetic factors, 569–570
- Personality traits, 123–126
- Person-centered integrative diagnosis (PID), 649–650
- Pervasive anxiety state, 1873
- Pervasive developmental disorder-not otherwise specified (PDD-NOS), 383, 723
- Pervasive developmental disorders (PDDs), 722
 antipsychotic medication, 2098–2099
- PET *See* Positron emission tomography (PET)

- PFAOMC *See* Psychological factors affecting other medical conditions (PFAOMC)
- PFC *See* Prefrontal cortex (PFC)
- Phallometry, 1752
- Pharmacodynamics (PD)
- concentration-effect relationships, 2034
 - drug interactions, 2034–2035
 - drug-receptor concept, 2033–2034
 - genetic variability, 2035–2036
 - kinetic-dynamic modeling, 2036
 - safety and efficacy
 - adverse drug reactions, 2036–2037
 - drugs of abuse, 2037
 - evidence-based medicine, 2038
 - herbal remedies, 2037–2038
 - package inserts, for oral medications, 2036
 - social drugs, 2037
 - schematic illustration, 2046
 - variability in, 2033
- Pharmacogenomics, 918
- Pharmacokinetics (PK)
- aspects of, 2027, 2028
 - CYP1A2 isoenzymes, 2029
 - CYP2C9 isoenzymes, 2029, 2030
 - CYP2C19 isoenzymes, 2029, 2030
 - CYP2D6 alleles, 2031, 2032
 - CYP2D6 isoenzymes, 2029, 2031
 - CYP3A4,-5,-7 isoenzymes, 2029, 2032
 - cytochrome P450 system, 2029–2032
 - description of, 2027
 - drug absorption/formulation, 2027–2028
 - drug distribution, 2029
 - first-pass effect/bioavailability, 2028–2029
 - herb–drug interactions, 2044
 - intramuscular antipsychotics, 2028
 - oral drug administration, 2028
 - passive transport, 2028
 - phase I drug metabolism, 2029
 - phase II drug metabolism, 2029
 - phencyclidine, 1473
 - population, 2033
 - schematic illustration, 2046
 - steady states, 2033
- Pharmacotherapy
- cannabis dependence, 1465–1466
 - future of, 2081
 - hoarding treatment with, 1120–1121
 - major depressive disorder, 986
 - OCD, 1117
 - posttraumatic stress disorder, 1152–1154
 - for tics, 786–787
- Phencyclidine
- single-dose effects of intravenous, 1472
 - street names for, 1471
 - tolerance and dependence, 1473
- Phencyclidine use disorder
- assessment, 1476–1477
 - differential diagnosis, 1476
 - dose range effect of, 1473
 - epidemiology, 1470–1471
 - intoxication, 1470
 - medical comorbidity, 1477
 - model of NMDA receptor function, 1472
 - nonpsychiatric presentation, 1474–1475
 - pharmacokinetics, 1473
 - physician–patient relationship in psychiatric management, 1476
 - psychiatric comorbidity, 1477
 - psychiatric presentation, 1474
 - psychotomimetic effects, 1472
 - somatic treatment, 1476–1477
- Phenobarbital, 1557–1558
- Phenothiazines, 2094
- schizophrenia, 823
- Phenylketonuria (PKU), 681–682
- Phenylalanine hydroxylase, 388
- Phenylisopropylamine, 1485, 1486
- Phenytoin, 2516
- Pheochromocytoma, removal of, 589
- Phillies blint, 1459
- Phobia
- specific (*see* Specific phobia)
 - weight-gain/fatness, anorexia nervosa, 1237
- Phobic Stimuli Response Scales, 1022
- Phonemic paraphasia, 1660
- Phonological awareness, 165
- Phosphatidylserine
- attention-deficit/hyperactivity disorder, 2280
 - cognitive enhancement, 2279
- Phosphorous MR spectra, 623
- Physical disorders, secondary mental symptoms, 588–589
- Physician–patient relationship
- adolescents, 31
 - assessment and evaluation, 23
 - attachment theory, 22–23
 - children, 31
 - cross-cultural and ethnic issues, 30
 - defense mechanisms, 25
 - families, 31
 - health and illness, 30
 - important persons, 31
 - inpatient and outpatient treatment, 29
 - managed care, 30
 - mental status of patient, 26–27
 - modern medicine, 21–22
 - OCD, 1112–1114
 - physicians, 31
 - placebo effect, 20–21
 - rapport, 23
 - relatives, 31
 - research, 27–28
 - roles and motivations, 21
 - terminally ill patients, 31
 - therapeutic/working alliance, 23–24
 - transference and counter transference, 24–25
 - treatment phase, 28–29
 - treatment settings, 29
- Physician, sharing information, 637
- Physiognomy, 2597
- Physiological dependence, 1551
- Piaget’s experiment, 163–164
- PICA, 1247
- PID *See* Person-centered integrative diagnosis (PID)
- Pindolol
- major depressive disorder, 939–940
 - treatment-resistant depression, 2324
- Piperazine class, of phenothiazines, 2094
- Piperazine phenothiazines, schizophrenia, 823
- Piperidine class, of phenothiazines, 2094
- Piperidine phenothiazines, schizophrenia, 823
- Piper methysticum* (Kava), 2268–2269
- PK *See* Pharmacokinetics (PK)
- PKU *See* Phenylketonuria (PKU)
- Placebo effect, 20–21
- psychiatric epidemiology, 413
 - social psychology, 455
- Placental insufficiency, toxemia of, 685
- Play, 163
- PLMs *See* Periodic limb movements (PLMs)
- PMR *See* Progressive muscle relaxation (PMR)
- Policy implementation guidelines (PiGs), for early intervention, 1999
- Polysomnography (PSG), 1267
- Polysubstance dependence, 1394
- Poor impulse control, 1873
- Poor neonatal adaptation syndrome (PNAS), 2429
- Population pharmacokinetics, 2033
- Positive education, 493–494
- Positive illusions, 455–456
- Positive psychology
- application, 495
 - appreciative inquiry, 494
 - character strengths classification, 492–493
 - engaged life, 490
 - flourishing individuals, 489
 - full life, 491
 - hedonic treadmill, 492
 - languishing individuals, 489
 - meaningful life, 490–491
 - new areas of investigation, 494–495
 - OECD, 495
 - overview, 489–490
 - pleasant life, 490
 - positive education, 493–494
 - posttraumatic growth, 494
 - salient developments, 491–494
 - theoretical foundations, 490–491
- Positive psychotherapy (PPT), 495
- Positive reinforcement, 479
- Positive valence systems domain, 669
- Positron-electron annihilation event, 621

- Positron emission tomography (PET)
 advantages and limitations, 623
 cognitive neuroscience, 436
 co-registration, 622
 functional imaging modalities, 620–623
 generalized anxiety disorder, 1083
 right parietal glioblastoma, 622
 vs. SPECT, 623
- Possession trance, 1192
- Posterior-anterior shift in aging (PASA), 234
- Posterior cortical atrophy (PCA), 400
- Postmodern family therapies, 1953–1955
- Postpartum depression (PPD), 587
 antidepressants, 2433
 breastfeeding, 2433
 DSM-IV-TR classification, 2432
 evaluation, 2432
 pathophysiologic basis, 2431
 treatment considerations, 2432–2433
- Post-Roman times, history of psychiatry, 2595–2596
- Post-stroke depression, treatment of, 2074
- Post-test-only with nonequivalent groups, 2578
- Posttraumatic amnesia (PTA), 527
- Posttraumatic growth (PTG), 494
- Posttraumatic stress disorder (PTSD), 253, 323, 564, 1027, 1178, 1227, 1398–1399
 acute and, 1903–1904
 anticonvulsant medication, 2177–2178
 antipsychotic medication, 2178–2179
 ASD and, 1146
 assessment, 1143–1144
 behavioral theory, 486
 beta-blocker medication, 2177
 cognitive theory, 486
 comorbidity, 1144–1145
 conceptual models, 2554–2555
 course, 1145–1146
 cultural differences, 1147
 definition, 1142–1143
 demographic factors, 1156
 developmental and age differences, 1146–1147
 diagnostic features, 1142–1143
 differential diagnosis, 1146
 with dissociative symptoms, 1194–1195
 doctor–patient relationship issues, 1157
 DSM-IV-TR, 1143
 epidemiology, 1144
 gender differences, 1147
 general medical comorbidity, 1156
 genetic factors, 1148–1149
 hypnosis, 1898
 ID/IDD, 700
 issues, 2554
 and major depressive disorder, 1145, 1146
 nefazodone, 2176
 neurobiological factors, 1149–1150
 nonresponse to treatment and resistance, 1156–1157
 pharmacotherapy, 1152–1154
 phenomenology, 544
 psychiatric comorbidity, 1155–1156
 psychological factors, 1150–1151
 psychosocial treatments, 1154–1155
 selective serotonin reuptake inhibitors, 2175–2176
 serotonin, 2176
 sexual violence, management of
 assessment, 2544–2545
 choice of treatment, 2545
 cognitive-behavior therapy, 2545–2546
 eye movement desensitization and reprocessing, 2546
 nonresponse to treatment, 2546
 pharmacotherapy, 2546
 prolonged exposure, 2546
 psychotherapy, 2545
 social/environmental factors, 1151
 symptomatology and comorbidity, 2553–2554
 treatment goals, 1152
 treatments, 2179–2180
 tricyclic antidepressant medication, 2176
- Poverty, 151–152, 205
- PPD *See* Postpartum depression (PPD)
- PPT *See* Positive psychotherapy (PPT)
- Prader–Willi syndrome (PWS), 680
- Pragmatic communication disorder
 assessment issues, 718
 associated features, 718
 course, 718
 definition and diagnostic features, 717–718
 developmental, gender, and cultural presentation, 718
 differential diagnosis, 718
 genetic factors, 718
 nonverbal elements, 708
 treatment, 718
- Pragmatics, 2389–2390
- Pramipexole, 939
- Preemptive psychiatry, 1994
- Prefrontal cortex (PFC), 250–252, 1181, 1357
 schizophrenia, 805–806
- Pregnancy, psychiatric symptoms
 antipsychotic drugs, 2109–2110
 evaluation, 2427–2428
 insufficiency, toxemia of, 685
 postpartum psychiatric illness
 antidepressants, 2433
 breastfeeding, 2433
 DSM-IV-TR classification, 2432
 evaluation, 2432
 pathophysiologic basis, 2431
 treatment considerations, 2432–2433
- risks, medications
 antidepressant exposure, 2429
 antipsychotics, 2430
 benzodiazepine, 2430–2431
 carbamazepine, 2430
 congenital malformations, 2428–2429
 lamotrigine, 2430
 lithium, 2429–2430
 long-term neurobehavioral effects, 2429
 valproic acid, 2430
- testing, 513–514
- treatment
 drug discontinuation, 2428
 electroconvulsive therapy, 2431
 light therapy, 2431
 psychotherapy, 2431
 repetitive transcranial magnetic stimulation, 2431
- Preliminary information, psychiatric evaluation, 629–630
- Premature (early) ejaculation (PE)
 assessment issues, 1331
 associated features, 1331
 case study, 1333
 combined treatments, 1333
 comorbidity, 1331
 course, 1331
 developmental/cultural presentations, 1331
 diagnosis, 1331–1332
 differential diagnosis, 1332
 epidemiology, 1331
 etiology/pathophysiology, 1332
 genetic factors, 1332
 neurobiological factors, 1332
 psychosocial factors, 1332
 psychosocial treatments, 1332–1333
 social/environmental factors, 1332
 somatic treatments, 1332
 treatment, 1332–1333
- Premature stress and serious illness, 154
- Premenstrual dysphoric disorder (PMDD)
 antidepressant treatment, 970–972
 assessment issues, 967
 associated features, 966–967
 clinical case, 975
 clinical course, 967–968
 combined treatments, 974–975
 comorbidity, 967
 developmental and cultural presentations, 968
 diagnostic features, 966
 dietary supplements, 973–974
 differential diagnosis, 968–969
 DSM-5, 966
 genetic factors, 969
 herbal and complementary treatments, 974
 neurobiological factors, 969–970

- oral contraceptives, 972
 ovulation suppression treatments, 972–973
 prevalence of, 967
 progesterone, 973
 psychological factors, 970
 psychosocial treatments, 974
 social/environmental factors, 970
 treatment, 970–975
- Premorbid ability, neuropsychological assessment, 602
- Prenatal causes
 chromosomal anomalies, 679–680
 chromosomal disorders, 677–679
 malformation syndromes, 680–681, 683–684
 mitochondrial disorders, 683
 single gene defects, 681–683
 submicroscopic rearrangements, 681
- Prenatal diagnosis, ID/IDD, 689
- Preoccupation/anticipation stage,
 addiction, 371–372
 conditioning circuitry, 374
 impaired inhibitory control, 374–375
 perception of internal states, 374
- Prepulse inhibition (PPI), 809
- Presbycusis, 236
- Presbyopia, 235
- Preschool development
 biological, 161–162
 cognitive, 163–165
 emotional, 166–167
 gender, 169–170
 language, 164–166
 moral, 170–172
 motor, 162
 overview, 159–160
 social competence, 167–168
 social development theories, 168–170
 sociocultural influences, 172–174
- Prion diseases, 404, 1693–1696
 anatomical profiles, 405
 clinical features, 405
 diagnosis, 405
 pathogenesis, 405
 pathological features, 405
 treatment, 405
- Private psychiatric practice, 1794–1796
- PRL *See* Prolactin (PRL)
- Problem gambling severity index (PGSI), 1639
- Problem-solving communication training (PSCT), 1767
- Procedural learning and memory, 603
- Procedural memory, 1182
- Processing speed, neuropsychological assessment, 602
- Procrastination, 1847
- Prodetoxon, 1536
- Professional ethics and boundaries
 autonomy, 73
 beneficence, 73
 confidentiality, 78–79
 conflicts of interest, 78
 distributive justice, 73
 doctor–patient relationship, 75–76, 79–80
 ethical violation prevention, 82–83
 historical development, 73–75
 Internet and social media, 80–82
 justice, 73
 medical professionalism, 71–72
 nonmaleficence, 73
 non-sexual boundary transgressions, 77–78
 professional issues, 76
 sexual boundary violations, 76–77
 teaching, 82
- Progesterone, 973
- Progressive muscle relaxation (PMR), 1087
- Progressive supranuclear palsy (PSP), 402
- Project for a Scientific Psychology*, 465
- Projective identification, 1952–1953
- Prolactin (PRL), 1330
- Propentofylline, 2253
- Prosopagnosia, 1659
- Prostate-specific antigen (PSA), 1330
- Protean psychiatric disorder, 245
- Protected patient information (PPI), 2019
- Protracted withdrawal syndrome, 1689
- Provoked confabulations, 1668–1669
- Provoked vestibulodynia (PVD), 1327
- PSA *See* Prostate-specific antigen (PSA)
- Pseudodementia, 905
- Pseudoneurotic schizophrenia, 2612
- PSI *See* Parenting Stress Index (PSI)
- PSWQ *See* Penn State Worry Questionnaire (PSWQ)
- Psychiatric classification
 categorical vs. dimensional, 658–659
 DSM-I and DSM-II, 659
 DSM-III, 659
 DSM-III-R, 660
 DSM-IV, 660
 DSM-IV-TR, 661
 DSM-5, 661–662
 DSM-5.x, 667–668
 etiological vs. descriptive, 657–658
 goals of, 657
 ICD-10/ICD-11, 661
 syndrome vs. symptom, 658
- Psychiatric disability assessments, 1960
- Psychiatric disorders
 adherence to medication
 direct measures, 2385
 indirect measures, 2385–2386
 intervention strategies, 2393–2395
 medication compliance
 measurement, 2384–2385
 patterns, medication
 noncompliance, 2384
 prevalence, poor adherence to medication, 2384
 risk factors, noncompliance, 2386–2391
 shared decision-making, 2382–2383
 specific patient populations, 2391–2393
 theoretical models, health behavior, 2383–2384
- hypnosis
 anxiety disorders, 1901–1903
 authoritarian approach, 1901
 borderline personality disorder, 1899
 case study, 1900
 condensed hypnotic approach, 1905–1906
 conversion disorder, 1906–1908
 depersonalization/derealization disorder, 1898
 dissociative amnesia, 1898
 dissociative disorders, 1904–1905
 dissociative identity disorder, 1898
 eating disorders, 1899, 1908
 ego-strengthening technique, 1901
 Grade 5 syndrome, 1898
 hypnotherapeutic techniques, 1900
 personality disorders, 1899
 psychotic patients, 1899
 PTSD, 1898, 1903–1904
 self-mothering techniques, 1901
 therapeutic precautions, 1906
- physical examination, 585
 stigma, 584, 586
 suicidal ideation, 2494
- Psychiatric emergency services (PESs)
 future endeavors, 2477
 goals for care, 2476–2477
 history of, 2475–2476
 models of care, 2476
- Psychiatric epidemiology
 attributable risk, 412
 case-control studies, 414
 characteristics, 409
 clinical, 410
 cohort studies, 414
 complex sampling procedures, 409
 Composite International Diagnostic Interview, 412–413
 confounding bias, 416
 cross-sectional designs, 414
 cumulative incidence, 411
 definition, 409
 Diagnostic Interview Schedule, 412
 discipline, 409
 double-blind study, 413
 ECA study, 417–418
 experimental studies, 413
 first-generation studies, 416
 goal, 410
 incidence, 411
 information/observation bias, 416
 instruments to identify cases, 412
 longitudinal studies, 415, 429–430
 major findings from surveys, 429
 measures of association, 412
 methods, 411–413

- Psychiatric epidemiology (*continued*)
- National Comorbidity Survey
 - Replication, 419–425, 427
 - NCS, 418–419
 - nonexperimental studies, 414–415
 - placebo control groups, 413
 - prevalence, 411
 - prospective cohort studies, 415
 - psychometric properties of
 - instruments, 412–413
 - quasi-experimental studies, 413–414
 - randomization, 413
 - relative risk, 412
 - reliability, 412
 - retrospective cohort studies, 414
 - risk factor identification, 413
 - scope of inquiry, 410–411
 - second-generation studies, 416–417
 - selection bias, 415–416
 - socioenvironmental factors, 413
 - structured diagnostic interviews, 410
 - third-generation studies, 417–419
 - traditional, 410
 - triple-blind study, 413
 - validity, 412
 - WMH Survey Initiative, 425–426, 428, 429
- Psychiatric evaluation
- collateral and preliminary
 - information, 629–630
 - laboratory assessment, 636–637
 - meeting the child, 630–631
 - mental status examination outline, 632
 - National Comorbidity Survey, 629
 - outcome of, 637–638
 - parents, 630
 - standardized assessment instruments, 632
 - telepsychiatry, 631–632
- Psychiatric GWAS consortium-bipolar disorder (PGC-BD), 345
- Psychiatric interview
- attitude and behavior, 45
 - biological factors, 37–38
 - biological theory of illness, 34
 - chief complaint, 40, 502–503
 - cognitive capacities, 43
 - confused patient, 51
 - cultural disparity, 52
 - data identification, 39–40
 - deceitful patient, 52–53
 - delusional patient, 48–49
 - depressed patient, 50–51
 - diagnosis, 35–37
 - directiveness, 46–47
 - emotionally based biases, 43
 - environmental factors, 37
 - fact vs. feeling orientation, 48, 50
 - family history, 40, 504
 - feedback, 48, 51
 - hostile patient, 50
 - ideal setting, 43
 - identifying information, 502
 - illness severity, 35
 - issues, 35
 - listening and observation, 44–45
 - medical history, 504
 - mental organization, 34
 - mental status examination, 41–42, 504–506
 - nonverbal communication, 44
 - overview, 501–502
 - past medical history, 40
 - past psychiatric history, 40, 503
 - patient's baseline level, 35, 37–38
 - patient's motivation, 39
 - patient's physical/emotional distress, 42
 - personal history, 40–41, 503–504
 - phases, 46
 - present illness history, 40, 503
 - psychological factors, 38
 - racial, ethnic, and cultural factors, 43
 - seductive patient, 52
 - situational factors, 43
 - structure, 45–46
 - substance use history, 504
 - supportiveness, 47–49
 - telepsychiatry, 53
 - verbal communication, 43–44
 - violent, agitated patient, 49–50
- Psychiatric patients, insomnia, 2202
- Psychiatric populations
- functional imaging, 626–627
 - structural neuroimaging, 624–626
- Psychiatrists
- and patients relationship, 702–703
 - roles of, 701
- Psychic energy, nature of, 1800
- Psychic numbing, 1903
- Psychoanalysis
- characteristics of, 1802
 - indications for, 1804, 1806
- Psychoanalytic psychotherapy
- abstinence, 1802
 - analyst's listening process, 1803
 - characteristics of, 1802
 - common factors, 1798
 - concepts of, 1799–1800
 - contraindications to, 1809
 - cost-offset studies, 1811
 - counterresistance, 1801
 - countertransference, 1800, 1801
 - dream interpretation, 1803
 - drives, concept of, 1804
 - effectiveness of
 - in breast cancer patients, 1811
 - cognitive behavioral therapy, 1812
 - dialectical behavior therapy, 1812
 - dynamic deconstructive
 - psychotherapy, 1812
 - mentalization-based therapy, 1812
 - in panic disorder treatment, 1811
 - short-term dynamic
 - psychotherapy, 1812
 - short-term psychodynamic
 - psychotherapy, 1812–1814
 - transference-focused
 - psychotherapy, 1812
 - empathic listening, 1803
 - essential operations of, 1798
 - expressive-supportive continuum, 1798–1799
 - indications for, 1808–1809
 - interpersonal and object
 - relationships, 1804–1806
 - managed care, 1797
 - metapsychological viewpoints, 1799
 - neutrality, 1802
 - phases of, 1808
 - vs. psychoanalysis, 1806
 - psychotherapist, tasks of, 1806–1808
 - research challenges for, 1814
 - resistance, 1800, 1801
 - rule of free association, 1802–1803
 - supportive, 1809–1810
 - task of, 1798
 - therapeutic alliance, 1803–1804
 - transference, 1800
 - working through process, 1803
- Psychoanalytic theory, 185, 202–203
- human development
 - adolescence/genital stage, 113–114
 - anal stage, 113
 - ego integrity vs. despair, 114
 - generativity vs. stagnation, 114
 - intimacy vs. isolation, 114
 - latency stage, 113
 - oral stage, 113
 - phallic-oedipal/genital stage, 113
 - OCD, 1112
- Psychodynamic model
- major depressive disorder, 924
 - of mind
 - attachment theory, 470–472
 - change, 463
 - description, 463–464
 - development, 463
 - dreams and fantasies, 463
 - ego psychology, 464–466
 - object relations theory, 466–468
 - psychic determinism, 463
 - relational theory, 472–474
 - self psychology, 468–470
 - therapist/analyst role, 463
 - unconscious, 463
 - panic disorder, 1066
- Psychodynamic therapy
- anorexia nervosa, 1240
 - posttraumatic stress disorder, 1155
- Psychoeducation
- cognitive and behavioral therapies, 1841–1842
 - generalized anxiety disorder, 1086
 - for relational problems, 1771
- Psychogenic amnesia, 525, 532
- Psychological distress, 225
- Psychological evaluation
- child questionnaires, 634
 - cognitive assessment, 633–634
 - drawings, 634

- educational assessment, 635
 educational evaluation, 636
 educational evaluation, indications, 635
 educational plan, 636
 electronic and social media, 635
 family interaction, 634–635
 legislation and rights, 635–636
 parent and teacher questionnaires, 632–633
 play observations, 634
- Psychological factors
 ADHD, 754
 agoraphobia, 1065–1066
 anorexia nervosa, 1237–1238
 autism spectrum disorder, 731
 bipolar disorder, 993
 childhood-onset fluency disorder, 716
 disruptive mood dysregulation disorder, 998
 dyslexia, 770
 GAD, 1083–1084
 language disorder, 711
 major depressive disorder, 984–985
 mathematics disorder, 774–775
 mental disorders, 694
 posttraumatic stress disorder, 1150–1151
 stuttering, 716
- Psychological factors affecting other medical conditions (PFAOMC)
 assessment and diagnosis, 2405–2406
 course, 2406
 definition, 2404–2405
 differential diagnosis, 2406
 epidemiology and comorbidity, 2406
 etiology and pathophysiology, 2406–2407
 treatment, 2407–2408
- Psychological first aid (PFA) core actions, 2528
- Psychological testing, 509–510
 Psychological tolerance, drinking, 1404
 Psychology, 2597
- Psychopathology
 cultural considerations, 640–646
 wellness continuum, 1872, 1873
- Psychopharmacoevidence, 410
 Psychopharmacological treatments, 393
 Psychopharmacotherapy
 clinicians' attitudes, 2042
 cultural context of, 2042
 expectation/placebo effects, 2043–2044
 factors affecting drug response, 2041, 2042
 herbal preparations, 2044
 medication adherence, 2042–2043
- Psychosis, 2601
 in Alzheimer's disease, 400
 early intervention
 antipsychosis agents, 1992
 clinical high risk criteria, 1991
 clinical staging, 1994–1995
 cost-effectiveness of, 1992–1993
 critical period, 1992
 dose reduction/discontinuation study, 1992
 evidence-based
 bio-psycho-socio-cultural interventions, 1991
 headspace programs, 1997
 occurrences of, 1991
 preventive interventions, 1994
 “start low, go slow” prescribing approach, 1992
 sub-threshold syndromes, 1994
 symptomatic remission, 1992
 ultra-high risk criteria, 1991
 worldwide dissemination, 1993–1994
- Psychosocial approach, positive impacts of, 1962, 1963
 Psychosocial environment, 62–63
 Psychosocial factors
 attachment, 126–128
 character, 128–129
 hallucinogen intoxication, 1485
 life experiences, 128
 personality disorder, 129–131
- Psychosocial treatments
 agoraphobia, 1069–1071
 cannabis, 1460, 1461
 GAD, 1085–1087
 paraphilic disorders, 1754–1755
 persistent depressive disorder, 949
 planning, 520
- Psychosomatic condition, 911
 Psychosomatic disorders, 292
 Psychosomatic medicine (PM)
 clinical practice, 2403–2404
 definition, 2401
 history, 2401–2402
 international developments, 2402
- PFAOMC
 assessment and diagnosis, 2405–2406
 course, 2406
 definition, 2404–2405
 differential diagnosis, 2406
 epidemiology and comorbidity, 2406
 etiology and pathophysiology, 2406–2407
 treatment, 2407–2408
- psychiatric diagnosis, medically ill patients, 2404
- psychological factors in specific medical disorders
 in cardiology, 2410–2411
 in dermatology, 2415
 in endocrinology, 2411–2412
 in end-stage renal disease, 2414
 in gastroenterology, 2414–2415
 infectious diseases, 2415
 in infertility, 2416
 in neurology, 2413–2414
 in obstetrics, 2416
 in oncology, 2408–2410
 in pulmonary disease, 2412–2413
 in rheumatoid arthritis, 2413
 scholarly discipline, 2402–2403
- Psychostimulants, 1359
 ADHD, 755–757
 treatment-resistant depression, 2324
- Psychotherapy, 2080
 biological and neuroimaging studies, 297–298
 borderline personality disorder, 294
 brief vs. long-term, 1814–1815
 cognitive behavioral therapy, 293–294
 components of, 1798
 in correctional setting, 2569
 depression in geriatrics, 2449–2450
 dialectical behavior therapy, 294
 ethnocultural issues in, 1810–1811
 human behavior model, 293
 interpersonal therapy, 294
 long-term, 296
 manualization, 293
 mechanisms, 295
 neurobiology of, 1815–1816
 practice and research, 1815
 pregnancy, psychiatric treatment, 2431
 psychoanalysis, 290–293
 randomized clinical trials, 293
 scientific basis, 290
 sedative-hypnotic use disorder, 1558–1559
 therapist factors, 295–296
- Psychotic depression, 2079
 Psychotic disorders
 alcohol-induced, 1408–1409
 cannabis-induced, 1462
 LSD-related, 1488–1489
 OCD and, 1103, 1106
- Psychotomimetics, 1482
 Psychotropic drugs, 1334
 Psychotropic medications, 2027
 adverse effects of, 2043
 nonadherence to, 2042
- Psychotropic treatment, 2027
 PTEN, 387
 PTG *See* Posttraumatic growth (PTG)
 PTSD *See* Posttraumatic stress disorder (PTSD)
 Puberty, 194–198
 Pulmonary disease, 2412–2413
 Pulmonary edema, stimulant abuse, 1579
 Pulmonary problems, inhalant use, 1520
 Punishment, 170
 Pure dysthymic syndrome, 947
 Purging, eating disorders, 1233
 PVD *See* Provoked vestibulodynia (PVD)
 PVL *See* Periventricular leukomalacia (PVL)
 Pyromania, 1367
 assessment issues, 1386
 biological theories

- Pyromania (*continued*)
 case study, 1389–1390
 comorbidity, 1387
 course, 1387–1388
 definition, 1386
 diagnosis, 1386–1388
 differential diagnosis, 1388
 dopamine and reward deficiency
 epidemiology, 1386–1387
 etiology/pathophysiology, 1388
 opioid system, cravings, and pleasure
 psychiatric interview, 1386
 psychiatrist–patient relationship,
 1389
 psychodynamic models, 1388
 psychosocial treatments, 1389
 somatic treatments, 1389
 treatment, 1389
- qEEG *See* Quantitative EEG (qEEG)
 Qigong, mood disorders, 2267
 Quantitative EEG (qEEG), 611–612
 Quantitative inferences, 606
 Quetiapine, 2096
 acute bipolar depression, 2140–2141
 adjunctive to lithium/divalproex,
 2149–2150
 schizophrenia, 824
 Quick Inventory of Depressive
 Symptomatology (QIDS), 862, 908
- Race, 58
 schizophrenia, 797
 substance use disorders, 363, 365, 366
 Rachman's pathways to fear
 development, 1035–1036
 RAD *See* Reactive attachment disorder
 (RAD)
 Radiation encephalopathy, 1655
 Radiopaque contrast material, 618
 Rage, emotional expression, 564–565
 Ramelteon, 1550
 Random-digit-dial telephone survey,
 caffeine users, 1438
 Randomized controlled trials (RCTs),
 2580
 Rapid cycling bipolar disorder,
 2151–2153
 Rapid eye movement (REM) sleep, 523,
 1265, 1266, 2620
 Raskin Depression Scale, 2163
 Rating scales, 749, 1351–1353
 RBD *See* REM sleep behavior disorder
 (RBD)
 RCTs *See* Randomized controlled trials
 (RCTs)
 RD *See* Reading disorder (RD)
 RDoC project *See* Research Domain
 Criteria (RDoC) project
 Reactive attachment disorder (RAD),
 1170
 assessment issues, 1171
 associated features, 1171
 case study, 1173
 clinician–patient relationship issues,
 1173
 combined treatment, 1173
 comorbidity, 1171
 course, 1171–1172
 developmental/gender/cultural
 presentations, 1172
 diagnosis, 1170–1172
 differential diagnosis, 1172
 epidemiology, 1171
 etiology/pathophysiology, 1172
 genetic factors, 1172
 neurobiological factors, 1172
 psychological factors, 1172
 psychosocial treatment, 1173
 social/environmental factors, 1172
 somatic treatment, 1173
 treatment, 1173
 treatment-refractory patients, 1173
 Reading disorder (RD), 767
 comorbidity, 769
 course, 769–770
 diagnostic features, 768–769
 epidemiology, 769
 genetic factors, 770
 neurobiological factors, 770
 psychological factors, 770
 psychosocial treatments, 770–772
 Reasoning and problem solving, 817
 Reboxetine
 major depressive disorder, 933
 panic disorder, 2171–2172
 Recent memory, 1659
 Recent trends, history of psychiatry,
 2614–2619
 Receptor antagonism, side effects of,
 2066, 2067, 2068, 2069
 Receptor blockade, side effects of,
 2065–2067
 Receptors, 2053
 Reckitt Benckiser Pharmaceuticals
 (RBP), 1540
 Reelin, 805
 Reflective function (RF), 1812
 Rehabilitation case management model,
 1965
 Reinforcement schedules, 111
 Relapse prevention therapy (RPT), 2060
 cocaine use, 1589
 Relational problems
 assessment of, 1768–1770
 case example, 1775–1776
 cause-and-effect relations, 1759
 child upbringing away from parents,
 1760
 clinical attention, 1759
 couples
 expression of affect, 1764–1765
 problem solving, 1766
 structure, 1761–1762
 verbal communication,
 1762–1763
 definition of, 1759–1760
 diagnosis of, 1767–1768
 divorce/separation, family disruption
 by, 1760
 empirically derived family relational
 constructs, 1760, 1761
 epidemiology of, 1770–1771
 families
 expression of affect, 1765–1766
 problem solving, 1766–1767
 structure, 1762
 verbal communication, 1763–1764
 high expressed emotion level, 1760
 in marital dyad, 1759
 parental relationship distress, negative
 effects on child, 1760
 parent–child relational problems,
 1760
 in primary support group, 1767–1768
 sibling relational problems, 1760
 spouse/intimate partner, relationship
 distress with, 1760
 treatment
 cognitive behavioral techniques,
 1771
 efficacy of, 1771
 family/marital treatment,
 investigations of, 1771–1774
 format, 1771
 goals of, 1771
 medical comorbidity, 1774–1775
 psychoeducational approaches,
 1771
 strategic-systemic approach, 1771
 structural approach, 1771
 uncomplicated bereavement, 1760
 Relational theory
 basics of model, 472–473
 definition, 472
 formulation and treatment, 473–474
 historical context, 472
 infant research, 473
 mirror neurons discovery, 473
 one-person models, 472
 two-person models, 472
 The Relationship Attribution Measure,
 1769
 Relaxation training
 cognitive and behavioral therapies,
 1849
 generalized anxiety disorder, 1087
 Reliability
 psychiatric epidemiology, 412
 research designs, 2581–2582
 Remote/long-term memory, 233
 REM sleep behavior disorder (RBD)
 assessment issues, 1296
 associated features, 1296
 case study, 1298
 combined treatments, 1298
 comorbidity, 1296–1297
 course, 1297
 developmental/gender/cultural
 presentations, 1297
 diagnosis, 1295–1297
 differential diagnosis, 1297
 epidemiology, 1296

- etiology/pathophysiology, 1297
 genetic factors, 1297
 neurobiological factors, 1297
 psychological factors, 1297
 psychosocial treatments, 1298
 social/environmental factors, 1297
 somatic treatments, 1297
 treatment, 1297–1298
- Renal failure, stimulant abuse, 1578
- Renal impairment, treatment of, 2074
- R-enantiomer, amyloid-based interventions, 2250
- Repetitive transcranial magnetic stimulation (rTMS), 2621
 pregnancy, psychiatric treatment, 2431
- Research Domain Criteria (RDoC) project, 253
 NIMH, 668–669
- Research methodology and statistics change, 2583–2584
 contrast group, 2579
 control group, 2579
 design issues, 2577–2578
 designs validation, 2578–2580
 interobserver agreement, 2583
 measurement issues, 2581–2584
 multivariate approaches, 2586–2590
 power and statistical inference, 2580–2581
 quasi-experimental design, 2579–2580
 reliability, 2581–2582
 standard statistical techniques, 2584
 statistical parameters, 2584–2585
 threats, validation, 2578–2580
 univariate approaches, 2585–2586
 validity, 2582
- Resilient individuals, 218
- Resistance, 1799, 1800, 1801
- RESPECT-MIL program, 2470
- Respiratory conditions, hypnosis, 1912
- Response/acute treatment period, of treatment, 2077
- Response styles theory (RST), 985
- Restless legs syndrome (RLS)
 assessment issues, 1299
 associated features, 1299
 case study, 1301
 clinician–patient relationship issues, 1301
 combined treatments, 1301
 comorbidity, 1299
 course, 1299
 developmental/gender/cultural presentations, 1299
 diagnosis, 1298–1299
 differential diagnosis, 1299
 epidemiology, 1299
 etiology/pathophysiology, 1299–1300
 factors influencing treatment, 1301
 genetic factors, 1299
 neurobiological factors, 1299–1300
 psychological factors, 1300
 psychosocial treatments, 1300–1301
 social/environmental factors, 1300
 somatic treatments, 1300
 treatment, 1300–1301
 treatment-refractory patients, 1301
- Restraint and seclusion (R/S)
 controversies, 2487
 definition, 2487
 legal rights, psychiatric patients, 2489
 National and State Reduction Efforts, 2489–2490
 state of education, 2489–2490
 state of research, 2487–2489
- Restraint, in correctional setting, 2571
- Retrograde amnesia, 526–527, 1668
- Retrolental fibroplasia (ROP), 686
- Rett syndrome, 384, 683, 723
 methyl-CpG-binding protein 2, 388
- Reverse symptom identification technique, 1908
- Revised Version of the Latin American Guide (GLADP-VR), 649
- Rey–Osterrieth Complex Figure (ROCF), 611
- Rhabdomyolysis
 METH use, 1578
 phencyclidine use disorder, 1474
- Rheumatoid arthritis, psychological factors in, 2413
- Rhodiola rosea* (Arctic root), mood disorders, 2263–2264
- Richardson syndrome, 1665, 1681
- Right to free and appropriate public education (FAPE), 692
- Rimonabant, 1465
- Risperidone, 1492, 2096
 aggression treatment, 2514
 maintenance therapy, 2150
 schizophrenia, 824
- Rivastigmine, 2243–2244
- RLS *See* Restless legs syndrome (RLS)
- ROCF *See* Rey–Osterrieth Complex Figure (ROCF)
- Roman, history of psychiatry, 2595
- Romanticism, 2601
- ROP *See* Retrolental fibroplasia (ROP)
- Rorschach Test, 509
- Rubinstein–Taybi syndrome, 680
- Ruiz v. Estelle*, 2567
- Rule of free association, 1802–1803
- Ruminations, 540–541, 985, 1247
- S-adenosyl-L-methionine (SAME), 2264–2265
- SADS *See* Schedule for Affective Disorders and Schizophrenia (SADS)
- Safety concerns, bipolar disorder, 994–995
- Saliency, alcohol-seeking behavior, 1402–1403
- Salvia lavandulaefolia* (Spanish Sage), 2278
- Salvia officinalis* (Sage), 2278
- Salvinorin A, 1481
- SASSI *See* Substance Abuse Subtle Screening Inventory (SASSI)
- Scaffolding Theory of Aging and Cognition (STAC), 235
- Schedule for Affective Disorders and Schizophrenia (SADS), 412
- Schemas, 459–460
 description of, 1845
 emotions, 547
 implicit personality theories, 459
 levels of cognitive processing, 480
 maladaptive, 1838, 1839
 modification of
 cognitive response prevention, 1846
 computerized learning programs, 1846
 downward arrow technique, 1845, 1847
 listing advantages and disadvantages procedure, 1846
 psychoeducational interventions, 1845
 Socratic questioning, 1845
 third wave CBT therapies, 1846
 in panic disorder, 1838
 psychological well-being, 1838
- Schizoaffective disorder
 clinical signs and symptoms, 842
 course and prognosis, 842–843
 diagnosis, 841–842
 differential diagnosis, 843
 DSM-5 criteria, 820
 epidemiology, 842
 etiology, 843
 treatment, 843–844
- Schizoid personality disorder (SZPD), 1716–1717
- Schizophrenia, 216, 249, 251, 435, 600, 1398, 1773–1774
 acetylcholine, 311
 acute phase treatment, 825–827, 2102–2105
 adherence to medication, psychiatric disorders, 2392
 affective symptoms, 2101
 age, 796
 antipsychotic medications, 823–825
 behavioral theory, 486
 birth complications, 802–803
 brain imaging studies, 305–307
Camellia sinensis (L-Theanine Derived from Tea), 2275
 clinical cases, 840–841
 cognitive dysfunction, 308
 cognitive flexibility, 281
 cognitive impairments, 816–817, 2100–2101
 cognitive theory, 486–487
 common genetic variation, 265–266
 compound models, 270
 conditions that resemble, 820–821

- Schizophrenia (*continued*)
- cortical-subcortical dopamine imbalance, 283–284
 - course of illness, 821–822
 - CPM with antipsychotics, 833–835
 - cross-cultural presentation, 641–642, 794–795
 - De Novo copy-number variants, 267
 - depression and, 827–832
 - diagnosis, 792–798
 - disorganization, 816
 - dopamine, 308–309
 - dopamine-glutamate theory, 813
 - DSM-5 definition, 793–794
 - eating problems, 1236–1237
 - environmental exposures, 286
 - epidemiology, 795–798
 - family psychoeducation for, 1944
 - features of, 1962
 - Feighner criteria, 792
 - first-episode, 822, 2102
 - functional brain imaging, 313
 - GABA, 311
 - gender differences, 303
 - genetics, 798–802
 - and developmental neurobiology, 306–307
 - and endophenotypic markers, 307–308
 - epidemiology, 261
 - glutamate, 310–311
 - glutamatergic and GABAergic neurotransmission, 284–285
 - herbal medicines, 2275
 - historical overview, 791–792
 - ICD-10 and DSM-5 definitions, 852–853
 - immigration, 797
 - immune dysfunction, 802
 - incidence, 795–796
 - industrialization, 797
 - infection hypotheses, 802
 - linkage studies, 264
 - maintenance treatment, 827
 - adherence, 2106–2107
 - goals of, 2105
 - long-acting formulations, 2107
 - oral FGAs, 2106
 - oral NGAs, 2106
 - marital status and fertility, 797
 - medical differential diagnosis, 817
 - medical illnesses, 798
 - mental status examination, 817–820
 - mind–body techniques, 2275–2276
 - modern concept of, 791–792
 - morbidity and mortality, 798
 - motivation, 445–446
 - motor abnormalities, 304–305
 - negative symptoms, 815–816, 2099–2100
 - neural circuits, 312–313
 - neuroanatomical theories, 803–810
 - neurochemical theories, 810–813
 - neurodevelopmental pathogenic pathways, 285
 - neuropathology, 314
 - neuroprotection, 814–815
 - next-generation sequencing, 269–270
 - NMDA-R hypofunction hypothesis of, 2093
 - nonpharmacological treatment, 836–840
 - nutritional medicines, 2274–2275
 - glycine, 2274–2275
 - melatonin, 2275
 - N*-acetylcysteine (NAC), 2274
 - omega-3 fatty acids, 2274
 - vitamin E, 2275
 - pathophysiology, 803
 - perceptual and preattentive deficits, 280
 - plasma membrane pathology, 311–312
 - positive symptoms, 815–816, 2099
 - pre- and perinatal risk, 304
 - premorbid stage of, 305, 821
 - prodromal stage of, 821, 2101–2102
 - progressive stage of, 822
 - psychopathological domains, 303, 305
 - psychopharmacological treatment, 822–823
 - quality of life, 2101
 - race and ethnicity, 797
 - rare copy-number variants, 267–269
 - rare genetic variation, 265, 267
 - resistance for treatment, 832–833
 - season of birth, 797–798
 - sensorimotor gating and latent inhibition, 280–281
 - serotonin, 310
 - sex, 796
 - social and cognitive development, 305
 - social skill deficits, 1963–1964
 - sociocultural factors, 641
 - socioeconomic status, 797
 - structural and functional abnormalities, 303
 - structural brain changes, 314
 - structured diagnosis, 792–793
 - suicidal behavior, 2101, 2495
 - supportive psychotherapy, 1878
 - treatment, 822–840
 - violence and, 2508–2509
 - Schizophrenia spectrum, DSM-5 classification, 664
 - Schizophreniform disorder
 - clinical cases, 847–848
 - clinical signs and symptoms, 846
 - course and prognosis, 847
 - diagnosis, 846
 - differential diagnosis, 847
 - epidemiology, 846–847
 - etiology, 847
 - treatment, 847
 - Schizotypal personality disorder (STPD)
 - assessment issues, 1718
 - comorbidity and course, 1718–1719
 - diagnostic and associated features, 1718
 - differential diagnosis, 1718
 - epidemiology, 1718
 - etiology and pathophysiology, 1719
 - treatment, 1719–1720
 - School-age development, 207
 - biological, 181–182
 - cognitive, 181–183
 - conceptual framework, 180–181
 - developmental psychopathology, 188–189
 - emotional, 183–184
 - latency, 179
 - middle childhood, 179
 - moral, 185–187
 - puberty, 179
 - risk and protective factors, 186–188
 - sharing information, 637
 - sociocultural, 184–185
 - SCIT *See* Social cognition and interaction training (SCIT)
 - Scotland, history of psychiatry, 2600–2601, 2605–2606
 - SeAD *See* Separation anxiety disorder (SeAD)
 - Seclusion, in correctional setting, 2571
 - Second-generation antidepressants, 2075–2076
 - efficacy determination, 2058
 - mechanisms of actions, 2054
 - pharmacokinetic concerns, 2062–2063
 - selective serotonin reuptake inhibitors, 2071, 2075
 - serotonin syndrome, 2071–2072
 - Second-generation antipsychotics (SGAs), 2088
 - Secretase inhibitors, 2250
 - Sedation, major depressive disorder, 932
 - Sedative/anxiolytic, schizophrenia, 833–834
 - Sedative-hypnotics
 - dependence, 1552–1553
 - drug medications, 1550–1551
 - heroin-dependent addicts, 1553
 - intoxication
 - diagnosis, 1554
 - issues in physician–patient relationship, 1555
 - treatment, 1554–1555
 - as street drugs, 1551–1552
 - use disorder
 - considerations for patient recovery, 1556–1557
 - diagnosis, 1555
 - laboratory tests, 1557
 - presentation in patients, 1556
 - psychiatric comorbidity, 1555
 - risk factors, 1556
 - treatment, 1557–1559
 - withdrawal syndromes, 1555–1556
 - Seductive patient, 52

- Seizures
autism, 385
disorder
 ID/IDD, 676
 idiopathic effects, 2069
 major depressive, 932
 neuropsychiatric populations, 627
 types, 385
Selection bias, 415–416
Selective impairment, 607
Selective melatonin receptor agonists, 2197–2198
Selective serotonin reuptake inhibitor (SSRI), 1208, 1360, 2054, 2071
 agoraphobia and, 1068, 1071
 antidepressants, perinatal depression, 2363, 2367, 2368
 anxiolytic drugs, 2159
 comparative trials, 2058–2059
 DSMIV-TR, anxiety disorders, 2159
 generalized anxiety disorder, 2162
 obsessive-compulsive disorder, 2180–2182
 panic disorder, 2170–2171
 posttraumatic stress disorder, 1152–1154, 2175–2176
 social anxiety disorder, 2167–2168
 suicidality with, 986
 treatment-refractory patients, 987
Self-esteem, 209
 concept, 458–459
Self-evaluation maintenance theory, 458
Self-help groups, 1928
Self-help services, for mental illness, 1983, 1986, 1987
Self-injurious behavior (SIB), 725
Self-medication, development of addiction, 362
Self-monitoring, generalized anxiety disorder, 1086
Self-mothering techniques, 1901
Self-neglect, 518–519
Self-psychology
 basics of model, 468–469
 formulation and treatment, 469–470
 historical context, 468
Self-regulation, development of addiction, 362
Self-Report Manic Inventory, 862
Self-selection bias, 415
Self-verification theory, 458
Semantic dementia, 1660
Semantic memory, 527
Semantic paraphasia, 1660
Sensorimotor gating, 809
Sensorineural hearing loss, 1517
Sensory impairments, 676–677
Sensory-motor functions, 602
Sentence Completion Test for Children, 634
Separation anxiety disorder (SeAD)
 associated features, 1008
 diagnostic features, 1007–1008
 treatment, 1011–1014
Sequential Treatment Alternatives to Relieve Depression (STAR*D) trial, 2261, 2312
Sequential treatments, agoraphobia, 1071
Serious mental illness (SMI), 419, 422
Serological evaluations, psychiatric patient, 510
 blood cultures, 513
 blood glucose, 511–512
 complete blood count, 511
 electrolytes, 513
 HCV antibody testing, 513
 HIV antibody testing, 513
 kidney function tests, 512
 liver function tests, 513
 pregnancy testing, 513–514
 syphilis screening, 513
 thyroid function tests, 513
 toxicology, 511
Serotonergic antidepressants, 1360
Serotonin (5-HT), 310, 2052
 ADHD, stimulants in children, 2209
 alcohol use disorder, 1406
 bipolar disorder, 870
 depression, 919
 obsessive-compulsive disorder, 2182
 posttraumatic stress disorder, 2176
 receptor modulation, antipsychotic drugs, 2091, 2093
 in schizophrenia, 811–812
 side effects of, 2066, 2068
 transporter, autism, 387
Serotonin-norepinephrine reuptake inhibitors (SNRIs), 1068, 1118, 2055
Serotonin-reuptake inhibitors (SRIs), 1360
 body dysmorphic disorder and, 1133
 excoriation disorder, 1139
 treatment, 1098, 1114–1115
 trichotillomania, 1136
Serotonin syndrome, 1652, 2071–2072
Sertindole, 2096
Sertraline
 for children, 2163
 generalized anxiety disorder, 2162
 OCD, 1116
Severe mental illness (SMI), 1959, 1960
 See also Community living needs
 education for people with, 1970–1971
 employment for people with, 1968–1970
 features of, 1962
 FPE efficacy and benefits, 1972–1973
 need for family involvement, 1971–1972
Severe mood dysregulation (SMD), 996
 associated features, 997
 epidemiology, 997
 genetic factors, 997
 neurobiological factors, 997
 treatments, 999
Severe psychological distress, 1792
Sex Offender Need Assessment Rating (SONAR), 1752
Sexsomnia, 1293
Sexting, 2019
Sexual boundary violations, 76–77
Sexual disorders, culture and, 645
Sexual dysfunctions
 alcohol-induced, 1409
 biomedical conditions, 1314
 clinician–patient relationship, 1316–1317
 dedichotomizing treatments, 1316
 diagnostic commonalities across, 1313–1314
 differential diagnoses, 1314
 DSM-5 classification, 666
 etiological commonalities across, 1314
 factors in treatment, 1316–1317
 idiopathic effects, 2070
 major depressive disorder, 932
 overview, 1313
 psychosocial assessment across, 1314–1315
 psychosocial treatment components, 1315–1316
 treatment modalities, 1316
 treatment-refractory patients, 1316
Sexuality, 203, 238–239
Sexually transmitted infections (STI), 2540
Sexual masochism disorder, 1750, 1752
 See also Paraphilic disorders
Sexual obsessions, 1098–1099
Sexual sadism disorder, 1750, 1752 *See also* Paraphilic disorders
Sexual violence (SV)
 acute management, 2538–2541
 forensic referral, 2540
 HIV exposure, 2540–2541
 laboratory investigation, 2540
 physical examination, 2539–2540
 pregnancy test, 2540
 STI prophylaxis, 2540
 definitions, 2535
 long-term management
 considerations
 anxiety, 2543
 depression, 2543
 posttraumatic stress, 2544–2546
 risk, 2542–2543
 somatization, 2543–2544
 substance abuse and dependence, 2543
 long-term mental health sequelae, 2542
 prevalence, 2535
 psychological treatment, 2541
 risk factors, 2535–2536
SHANK3, autism, 387
Shared decision-making, 2382–2383
Shared psychotic disorder
 clinical cases, 852
 clinical signs and symptoms, 851
 course and prognosis, 852

- Shared psychotic disorder (*continued*)
 diagnosis, 851
 differential diagnosis, 852
 epidemiology, 851–852
 treatment, 852
- Shedler-Westen Assessment
 Procedure-200 (SWAP-200), 1707
- Sheehan Disability Scale (SDS), 2164
- Shift work disorder (SWD), 1288–1289
- Short-term anxiety-provoking
 psychotherapy, 1821
- Short-term dynamic psychotherapy
 (STDP), 1812
- Short-term memory, 527–529
- Short-term psychoanalytic
 psychotherapy, 987
- Short-term psychodynamic
 psychotherapy, 1812–1814
- Short-term visual memory, 233
- Shprinzen syndrome *See*
 Velocardiofacial syndrome (VCFS)
- Shy–Drager syndrome, 1296
- SIB *See* Self-injurious behavior (SIB)
- Sibling relational problems, 1760
- Signal latency, 2015
- Single gene defects, 681
- Single nucleotide polymorphism (SNP),
 258, 681, 2061
- Single photon emission computed
 tomography (SPECT), 623
 PET *vs.*, 623
- Situational depression, 941
- Skin-picking disorder (SPD) *See*
 Excoriation disorder
- Skin-popping, 1533
- Sleep, 1264
 assessment tools for, 1266–1267
 clinical assessment, 1267
 definitions and neurobiology,
 1265–1266
 deprivation, 1278
 disturbance, autism spectrum
 disorder, 736
 inertia, 1277
 paralysis, 1280
- Sleep apnea, obstructive, 1279
- Sleep disorder, 1266–1267
 alcohol-induced, 1409
 caffeine-induced, 1451–1453
- Sleep-related breathing disorders
 (SRBD), 984
- Sleep-related eating disorder, 1293
- Sleep-related hallucinations, 1280
- Sleep-related hypoventilation (SRH)
 assessment issues, 1287
 associated features, 1287
 course, 1287
 diagnostic features, 1287
 differential diagnosis, 1287
 etiology/pathophysiology, 1287–1288
 genetic factors, 1287
 neurobiological factors, 1288
 psychological factors, 1288
 treatment, 1288
 treatment-refractory patients, 1288
- Sleep-related sexual behavior, 1293
- Sleep terrors, 1293
- Sleep-wake cycle regulation, 2194
- Sleep-wake disorders, 665–666
- Sleepwalking, 1293
- SLO gene *See* Smith–Lemli–Opitz
 (SLO) gene
- SMD *See* Severe mood dysregulation
 (SMD)
- SMI *See* Serious mental illness (SMI)
- SMISD *See*
 Substance/medication-induced
 sexual dysfunction (SMISD)
- Smith–Lemli–Opitz (SLO) gene, 388
- Smith–Lemli–Opitz syndromes, 676
- SNP *See* Single nucleotide
 polymorphism (SNP)
- SNRIs *See* Serotonin–Norepinephrine
 Reuptake Inhibitors (SNRIs)
- Social Adjustment Scale
 leisure, 576
 occupational functioning, 575
 social and interpersonal functioning,
 574
- Social anxiety disorder (SAD)
 for adolescents, 2168
 anticonvulsant medication, 2169
 assessment, 1022
 benzodiazepine medication, 2169
 beta-blocker medication, 2169
 body dysmorphic disorder and, 1132
 bupropion, 2168
 buspirone, 2169
 clinical case, 1047–1048
 for children, 2168
 cognitive variables, 1037
 comorbidity patterns, 1025
 course, 1025–1026
 cross-racial/ethnic studies, 1030
 cultural differences, 1030–1031
 definition and diagnostic features,
 1020
 developmental differences, 1027–1028
 diagnosis, 1008
 diagnostic decision tree, 1028
 differential diagnosis, 1026–1027
 DSM-5/ICD-10 diagnostic criteria
 comparison, 1048
 epidemiology, 1023–1024
 exposure hierarchy, 1042
 gender differences, 1028–1030
 genetic factors, 1031–1032
 individuals with phobias, percentage,
 1036
 learning and conditioning
 perspectives, 1034
 lifetime prevalence, 1023
 mean age of onset, 1026
 measures for, 1023
 mirtazapine, 2169
 Mowrer's two-stage model,
 1034–1035
 neurobiological factors, 1032–1034
 personality variables, 1036–1037
 phenomenology and subtypes, 1021
 psychoanalytic perspectives, 1034
 psychological treatments and
 medication, 1043–1044
 psychosocial treatments, 1040–1043
 Rachman's pathways to fear
 development, 1035–1036
 relapse and return of fear, 1047
 selective serotonin reuptake
 inhibitors, 2167–2168
 self-report measures, 1022–1023
 somatic treatments, 1037–1039
 structured and semistructured
 interviews, 1022
taijin kyōfu, 1030–1031
 treatments, 1011–1014, 1038, 2169
 decision tree, 1045
 goals, 1037
 outcome predictors, 1046–1047
 refractory patients, 1045–1046
 tricyclic antidepressant medication,
 2168
 venlafaxine, 2168
 virtual reality exposure, 1042
- Social class, 58
- Social cognition, 443–447, 817, 1660,
 1672, 1975–1976
 anxiety disorders, 446
 autism spectrum disorder, 445–446
 brain regions in, 444
 depression, 446
 difficulties, 445–447
 emotional empathy in psychopathy,
 445
 implications for therapeutic
 intervention, 446–447
 interaction processes, 444–445
 neuroimaging studies, 443, 444
 neuropsychological assessment, 603
 schizophrenia, 445–446
- Social cognition and interaction training
 (SCIT), 1976
- Social communication disorder (SCD),
 690
 assessment issues, 718
 associated features, 718
 course, 718
 definition and diagnostic features,
 717–718
 developmental, gender, and cultural
 presentation, 718
 differential diagnosis, 718
 genetic factors, 718
 treatment, 718
- Social competence, 167–168
 preschool children, 167–168
- Social detoxification, alcohol
 withdrawal, 1421
- Social development
 adolescent development, 204–207
 human, 114–115
 infant, 142–143, 144–145, 147–148,
 150–151

- Social development theories, 168–170
 preschool children, 168–170
- Social domain theory, 171
- Social factors
 ADHD, 754–755
 agoraphobia, 1068–1069
 anorexia nervosa, 1238
 autism spectrum disorder, 731–732
 bipolar disorder, 993–994
 childhood-onset fluency disorder, 716
 disruptive mood dysregulation disorder, 998
 GAD, 1084
 generalized anxiety disorder, 1009–1010
 language disorder, 711
 major depressive disorder, 985–986
 mental disorders, 694
 posttraumatic stress disorder, 1151
 stuttering, 716
- Social firms, for SMI, 1968
- Social functioning, 574
- Socialization-internalization theory, 171
- Social media, 2018–2019
 psychological evaluation, 635
- Social phobia, 1011
 diagnostic nomenclature, 1020
- Social psychology
 attribution theory, 454–460
 authoritarian personality, 453
 bystander effect, 454
 cognitive dissonance, 459
 cognitive vulnerability models, 454–455
 diffusion of responsibility, 454
 explanatory style, 455
 fundamental attribution error, 454
 genesis, 453–454
 learned helplessness, 454
 moral disengagement, 454
 placebo effect, 455
 positive illusions, 455–456
 retrospective recall, 456–457
 schemas, 459–460
 self-esteem, 458–459
 self-evaluation maintenance theory, 458
 self-report rating scales, 457–460
 self-verification theory, 458
 theory, 453
- Social rhythm model, major depressive disorder, 924
- Social skills, 168
- Social skills training (SST), 1964
 cognitive and behavioral therapies, 1850
- Socio-cognitive processes, 1358
- Sociocultural context, 173
- Sociocultural development, school-age children, 184–185
- Sociocultural factors
 schizophrenia, 641
 substance-related disorders, 640–641
- Sociocultural influences, 172–174
 preschool children, 172–174
- Sociodemographic factors
 inhalant abuse, 1511–1512
- Socioeconomic factors, 205
- Socioeconomic status (SES), 1355
- Socratic questioning, 1842, 1845
- Sodium ion channels, autism, 388
- Somatic symptom disorder (SSD), 1063, 1200, 1222
 definition, 1201–1202
 diagnostic features, 1202
 differential diagnosis, 1202–1203
 DSM-5 classification, 665
 epidemiology/natural history of, 1201
 generalized anxiety disorder, 1082
 physical signs and symptoms, 591, 592, 594
 treatment, 1202
- Somatic treatment
 anorexia nervosa, 1240
 autism spectrum disorder, 732–733
 body dysmorphic disorder, 1133
 breathing-related sleep disorders, 1284–1285
 bulimia nervosa, 1244–1245
 childhood-onset fluency disorder, 716–717
 CRSWD, 1291–1292
 disruptive mood dysregulation disorder, 999
 erectile disorder, 1321
 gambling disorder, 1643
 hallucinogenic drug, 1492
 major depressive disorder
 antidepressant pharmacotherapy, 929–930
 antidepressant side effects, 931
 discontinuation syndrome, 931
 efficacy, 930
 overdose potential, 930
 serum levels, 931
 suicide, 930–931
- MDMA, 1499
- mental disorders, 702
- paraphilic disorders, 1754–1755
- persistent depressive disorder, 949
- phencyclidine use disorder, 1476–1477
- tobacco use disorder, 1624–1627
- Somatization disorder, 584, 591
 case study, 1206–1207
 course, 1204
 definition, 1203
 diagnostic features, 1203
 epidemiology, 1204
 etiology/pathophysiology, 1204–1205
 intimate partner violence, 2543–2544
 treatment, 1205–1206
- Somatiform disorders, 1199
 culture and, 643–644
 diagnostic changes for, 1200
 epidemiology, 1200–1201
 treatment, 1201, 1202
 undifferentiated, 1207
- Somatostatin, cognitive enhancers in AD, 2248
- South Oaks Gambling Screen (SOGS), 1639
- Special housing in correctional setting, 2569
- Specialized mental health services, 1787
- Specific phobia
 assessment, 1022
 clinical case, 1048
 cognitive variables, 1037
 comorbidity patterns, 1024–1025
 course, 1025–1026
 cross-racial/ethnic studies, 1030
 cultural differences, 1030–1031
 definition and diagnostic features, 1020
 developmental differences, 1027–1028
 diagnostic decision tree, 1029
 differential diagnosis, 1026–1027
 DSM-5/ICD-10 diagnostic criteria comparison, 1048
 epidemiology, 1023–1024
 gender differences, 1028–1030
 genetic factors, 1031–1032
 individuals with phobias, percentage, 1036
 learning and conditioning perspectives, 1034
 lifetime prevalence, 1023
 mean age of onset, 1026
 measures for, 1023
 Mowrer's two-stage model, 1034–1035
 neurobiological factors, 1032–1034
 personality variables, 1036–1037
 phenomenology and subtypes, 1020–1021
 psychoanalytic perspectives, 1034
 psychological treatments and medication, 1043–1044
 psychosocial treatments, 1040–1041
 Rachman's pathways to fear development, 1035–1036
 relapse and return of fear, 1047–1048
 self-report measures, 1022–1023
 somatic treatments, 1037–1039
 structured and semistructured interviews, 1022
taijin kyōfu, 1030–1031
 treatment decision tree, 1046
 treatment goals, 1037
 treatment outcome predictors, 1046–1047
 treatment-refractory patients, 1045–1046
 treatments for, 1039
 virtual reality exposure, 1042
- SPECT *See* Single photon emission computed tomography (SPECT)
- Spectrum model, depression, 559–560
- Speech
 delays, 166
 mental status examination, 504–505

- Speech disorders, 536–539
 digression, 537
 poverty of speech, 538
 Speech-language pathologist indications, 712
 language disorder, 709
 Speech-language pathology assessment instruments, 710
 Speech sound disorder (SSD)
 associated features, 713–714
 comorbidity, 714
 course, 714
 definition and diagnostic features, 713
 developmental, gender, and cultural presentation, 714
 differential diagnosis, 714
 epidemiology, 714
 etiology and pathophysiology, 714
 special factors, 714–715
 Spironolactone, premenstrual dysphoric disorder, 973
 SPM *See* Statistical parametric mapping (SPM)
 Spontaneous abortion, antidepressants, 2362
 Spontaneous confabulations, 1669
 Spouse/intimate partner, relationship distress with, 1760
 SQUIDS *See* Super-cooled superconducting quantum interference devices (SQUIDS)
 SRBD *See* Sleep-related breathing disorders (SRBD)
 SRH *See* Sleep-related hypoventilation (SRH)
 SRIs *See* Serotonin-reuptake inhibitors (SRIs)
 SSRI *See* Selective serotonin reuptake inhibitor (SSRI)
 Stages of Change model, 1883
 Standard deviation, research design, 2584–2585
 Standardized assessment instruments, 632
 Standards for early intervention, 1999
 Stanford–Binet Intelligence Scale-Fifth Edition, 633
 Stanford Hypnotic Susceptibility Scale, 1896
 Starvation, 1235
 State Mental Health Agencies, funding of, 1790
 Statins, amyloid-based interventions, 2251
 Statistical clustering technique, 1405
 Statistical parameters, research design
 contingency tables, 2585
 correlation, 2585
 mean, 2584
 standard deviation and variance, 2584–2585
 Statistical parametric mapping (SPM), 622
 Statistical power, 2580
 Statistical regression, 2579
 Stereotypic movement disorder, 779
 assessment issues, 782
 comorbidity, 782
 course, 782
 diagnostic criteria, 782
 differences in development, gender, and cultural presentations, 782
 differential diagnoses, 782–783
 epidemiology, 782
 etiology and pathophysiology, 783
 treatment, 783
 Stereotypy, 384
 Stigma, of mental illness, 584, 586
 Stimulants, 370, 1256, 2080
 cardiovascular risks of, 756
 depression, adults
 abuse potential, 2228
 acceleration of response, 2227
 acute effects, 2226
 augmentation in depression, 2227
 chronic effects, 2226
 dextroamphetamine *vs.* methylphenidate, 2227–2228
 in late-life depression, 2227
 medically ill and geriatric patients, 2226–2227
 modafinil for depression, 2228–2229
 side effects and safety, 2228
 disorders of
 course and natural history, 1570–1573
 diagnosis, 1573–1575
 epidemiology, 1562–1563
 gender differences in, 1596–1597
 genetic vulnerability to, 1563–1565
 medical complications, 1575–1579
 neurobiological mechanisms, 1565–1569
 psychotherapies, 1582–1585
 transcriptional and epigenetic regulation, 1569–1570
 treatment, 1579–1592
 disruptive behavior disorders, children
 clinical use, 2221–2226
 indications, 2210
 medications, 2205–2208
 pharmacology, 2208–2210
 review of efficacy data, 2210–2218
 side effects, 2218–2221
 Stimulus control strategy, tobacco use disorder, 1629
 Stirling County Study, 417
 Storming/power and control model, 1931
 STPP *See* Short-term psychoanalytic psychotherapy (STPP)
 Strange situation test, 1173
 Strategic-systemic approach, for relational problems, 1771
 Strategic therapies (Erickson and Haley), 1822
 Strengths model, 1965
 Stress-diathesis explanation, 915
 Stress-diathesis models, of illness, 1945
 Stressor-related disorders, 665
 Striatal-enriched protein tyrosine phosphatase (STEP), 232
 Striatum, schizophrenia, 806–807
 Stroke
 amnesia, 1670
 delirium, 1654
 stimulant abuse, 1578
 Structural Analysis of Social Behavior (SASB), 575
 Structural approach, for relational problems, 1771
 Structural-developmental theory, 115
 Structural equation modeling, 2589–2590
 Structural imaging modalities
 CT, 617–618
 guidelines for, 625–626
 MRI, 618–620
 psychiatric populations, 624–626
 Structural-strategic family therapy, 1950–1951
 Structured Clinical Interview for DSM-IV-TR (SCID-IV), 412, 420, 1078
 Stupor, 1650
 Stuttering
 associated features, 715
 comorbidity, 715
 course, 715–716
 definition and diagnostic features, 715
 developmental, gender, and cultural presentation, 716
 differential diagnosis, 716
 epidemiology, 715
 genetic factors, 716
 neurobiological factors, 716
 outcome, 717
 psychological factors, 716
 social/environmental factors, 716
 somatic treatments, 716–717
 treatment goals, 716
 Subcortical heterotopias, 684
 Subdural hematoma, delirium, 1655
 Submicroscopic rearrangements, prenatal causes, 681
 Substance abuse
 IPT, 1866
 treatment-resistant depression, 2315
 Substance Abuse and Mental Health Service Administration (SAMHSA), 1458, 1960
 Substance abuse disorders
 adherence to medication, psychiatric disorders, 2392
 agonist replacement, 2332
 alcohol
 alcohol use disorder treatment, 2335–2337
 medically supervised withdrawal, 2334–2335
 antagonist treatment, 2332

- antipsychotic drugs, 2098
cocaine and amphetamines, 2350–2353
co-occurring psychiatric disorders, 2333
culture and, 640–641
DSM-5 classification, 666
high-affinity partial agonists, 2332
indirect modulatory strategies, 2332–2333
marijuana and cannabinoids, 2353–2354
nicotine dependence
 antidepressant medications, 2348–2349
 combined treatments, 2349
 co-occurring psychiatric disorders and nicotine dependence, 2349–2350
 features, 2347
 nicotine replacement therapy, 2347–2348
 varenicline, 2349
opiates
 detoxification, 2337–2341
 maintenance treatments, 2341–2347
Substance Abuse Subtle Screening Inventory (SASSI), 634
Substance dependence, 1394 *See also* Addiction
Substance-induced neurocognitive disorders, 1688–1689
Substance-induced violence
 alcohol, 2510
 illegal drug use, 2511
Substance intoxication, 1394–1395, 1398
Substance/medication-induced sexual dysfunction (SMISD), 1313
 assessment issues, 1333
 associated features, 1333
 comorbidity, 1334
 course, 1334
 developmental/cultural presentations, 1334
 diagnosis, 1333–1334
 differential diagnosis, 1334
 epidemiology, 1334
 psychotropic/nonpsychotropic drugs, 1334
 somatic treatments, 1334
 treatment, 1334
Substance/medication-induced sleep disorder
 assessment issues, 1302
 associated features, 1301–1302
 case study, 1304
 clinician–patient relationship issues, 1303–1304
 combined treatments, 1303
 comorbidity, 1302
 course, 1302
 developmental/gender/cultural presentations, 1302
 diagnosis, 1301–1302
 differential diagnosis, 1302
 epidemiology, 1302
 etiology/pathophysiology, 1302–1303
 factors influencing treatment, 1303
 psychological treatments, 1303
 social/environmental factors, 1303
 somatic treatments, 1303
 treatment, 1303–1304
 treatment-refractory patients, 1303
Substance P, in depression, 920
Substance use disorders (SUD), 262–263, 1373
 age differences, 363, 365
 agoraphobia and, 1063–1064
 alcohol, 360–361
 bipolar disorder, 991
 definition, 359
 environmental factors, 369
 gender patterns, 363, 364
 genetic factors, 369
 manic depressive disorders with, 863–864
 marijuana, 361
 medical consequences, 365, 367
 nicotine, 361
 OCD, 1103–1104
 opioids, 360
 prevalence, 362–363
 psychiatric comorbidity, 367–368
 race/ethnic differences, 363, 365, 366
 suicidal ideation, 2495
 supportive psychotherapy, 1873
 vulnerability, 368–369
Substance withdrawal, 1395
 developmental/gender/cultural presentations, 1397–1398
 differential diagnosis, 1398
 laboratory findings, 1397
 pharmacotherapy, 1399–1400
 phenomenology and variations, 1395–1396
 physical examination, 1397
 psychiatric examination issues, 1396
 psychiatrist–patient relationship, 1399
 psychosocial treatments, 1400
 treatment, 1399–1400
Subthreshold depressive disorder, 916
Suicidal ideation, 1396
 and behavior, 2492
 clinical risk and protective factors
 alcohol and substance use disorders, 2495
 anxiety disorders, 2495
 biological factors, 2496
 borderline personality disorder, 2496
 childhood history of abuse and neglect, 2496
 history of suicidal ideation, 2494
 hopelessness, 2496
 impulsivity and aggression, 2496
 mood disorders, 2494–2495
 psychiatric disorder, 2494
 schizophrenia, 2495
demographic risk and protective factors
 age, 2493
 employment, 2494
 familial association, 2494
 family and social factors, 2494
 gender, 2493
 religiosity, 2493–2494
and depression, 913–914
in geriatrics with depression, 2449
legal and ethical issues, 2500–2501
management
 assessment, 2496–2497
 engaging the patient, 2496
mortality and morbidity, 2492–2493
risk and protective factors, 2493
treatment
 antidepressants, 2498–2499
 antipsychotics, 2499
 approaches, 2497
 brief interventions, 2500
 cognitive behavioral therapy (CBT), 2499–2500
 dialectical behavior therapy, 2500
 electroconvulsive therapy, 2500
 with empirical support, 2498
 family treatments, 2500
 lithium, 2498
 no harm contracts, 2500
 for patients, 2074–2075
Suicide
 rates, 205
 risk, 517, 518
Summer Treatment Program (STP), 1361
Sundowning, 1650
Super-cooled superconducting quantum interference devices (SQUIDs), 624
Superego, 1799
Superior temporal gyrus (STG), 805
Supported education (SEd), for SMI patients, 1970–1971
Supported employment, for SMI, 1969
Supported housing model, 1977
Supportive-expressive (SE) psychotherapy (Luborsky), 1821
Supportive-expressive therapy, 1584
Supportive psychoanalytic psychotherapy, 1809–1810
Supportive psychotherapy
 acute-care or episode-of-care model, 1873
 alliance ruptures, 1877–1878
 assessment, 1875
 case formulation, 1875
 clarification, 1876
 clinician's advice, 1876
 cognitive behavioral therapy, 1871
 confrontation, 1876
 contraindications for, 1874

- Supportive psychotherapy (*continued*)
 conversational style, of
 communication, 1875
 dysfunction, 1872
 efficacy of, 1878–1879
 encouragement, 1875–1876
 evolution of, 1871
 goals of, 1875
 indications for, 1872–1874
 interpretation, 1876
 learning theory, 1871, 1872
 learning theory techniques,
 1876–1877
 patient's defenses, 1874
 praise and reassurance, 1875
 principle strategies in, 1874
 psychodynamic theory, 1871
 real and transference relationships,
 1871
 reframing and rationalizing, 1876
 rehearsal and anticipatory guidance,
 1876
 self-disclosure, 1874
 self-esteem, 1874
 therapeutic alliance, 1877
 therapeutic relationship, 1874
 therapist–patient relationship,
 1871
 transference–counter transference
 relationship, 1877
- Supportive therapy groups, 1927
- Susceptibility genes
 affective disorders
 angiotensin converting enzyme,
 344
 BDNF, 344
 cytogenetics, 343
 d-amino acid oxidase activator,
 344
 depression, 345
 gamma amino butyric acid, 343
 genetic risk factors, 346
 genome-wide association studies,
 343
 glutamic acid decarboxylase, 344
 P2RX7 gene, 344
 phosphodiesterase, 343
 single-nucleotide polymorphisms,
 343
 transgenic mouse model, 345
 functional significance, 285–286
- Sustain talk, in MI session, 1882,
 1888–1889
- SWD *See* Shift work disorder (SWD)
- Switzerland, history of psychiatry,
 2599
- Symbolism, 1216
- Sympathomimetic stimulants,
 1256
- Symptom rebound, 1556
- Symptom-system fit, 1945
- Syndrome of inappropriate secretion of
 antidiuretic hormone (SIADH),
 933
- Synthetic antidiuretic hormone (ADH),
 1255
- Synthetic cannabinoids (SCs),
 1462–1463
- Synthetic hallucinogens, 1482
- Syphilis screening, 513
- Systematic desensitization, cognitive
 and behavioral therapies, 1849
- Systems for social processes domain, 669
- T-ACE screening test, 1415
- Tacrine, cognitive enhancers in AD,
 2242, 2245
- Tangentiality, 537
- Tanner stage sex maturity ratings,
 194–196
- Tapering, 2078
- TaqI A restriction fragment length
 polymorphism, of dopamine D₂
 receptor (DRD2), 2048
- Tardive dyskinesia (TD), 830,
 2112–2113
- TAT *See* Thematic Apperception Test
 (TAT)
- Tau-based therapies, cognitive
 enhancers in AD, 2252
- TBI *See* Traumatic brain injury (TBI)
- TCAs *See* Tricyclic antidepressants
 (TCAs)
- TCF4*, 801
- Team-based approach, ACT, 1966
- Teens and sexual behavior, 205–206
- Telegraphic style, 1660
- Telemedicine, 2012, 2016
- Telephone interpersonal psychotherapy,
 1866
- Telephone scatologia, 1751
- Telepsychiatry, 53, 631–632
 administrative issues for, 2014
 protocol and procedures manual,
 2014–2015
 safety, 2015
 strengths and limitations of, 2012,
 2013
 technical, and clinical issues for, 2014
 technological and physical
 infrastructure, 2014
- Telescoping phenomenon, 1640
- Temperament, 122–123, 560–561
- Temporal lobe and schizophrenia, 805
- Temporal lobe epilepsy (TLE), 1376
- Temporary suicidal behavior, 1396
- Terminally ill patients
 physician–patient relationship, 31
 work with
 advance directives, 2454–2455
 management, 2455–2456
- Testosterone replacement therapy
 (TRT), 1330
- Tetracyclic antidepressants, 2054
- Thalamus and schizophrenia, 807
- Thematic Apperception Test (TAT),
 509, 611
- The Onion*, 2453–2454
- Theory of mind, 167
- Therapeutic communities (TCs), 1542
- Therapeutic component of
 neuropsychological assessment,
 607–608
- Therapeutic drug monitoring (TDM),
 2034, 2076
 of APDs, 2108
- Therapeutic intervention,
 neuropsychological assessment, 610
- Thioxanthenes, 823
- Third-generation antidepressants,
 2054–2055, 2058, 2072
 doses, 2076
 pharmacokinetic concerns, 2063
- Third wave cognitive behavioral
 therapies, 1846
- Thought
 disorders, 539–542
 mental status examination, 505
 recording, 1843
- Thought change record (TCR), 1843,
 1844
- Thrombotic thrombocytopenic purpura
 (TTP)
 delirium, 1656
- Thyroid function tests, 513
- Thyroid hormone, 2080
 dysregulation, major depressive
 disorder, 921
 treatment-resistant depression, 2323
- Tiagabine, cocaine use, 1589
- Tianeptine, major depressive disorder,
 933
- Tic disorders, 779
 assessment issues, 784
 in children, 783
 comorbidity, 784
 course, 784
 development, gender, and cultural
 presentations, 784
 diagnostic criteria, 784
 differential diagnoses, 784–785
 epidemiology, 784
 etiology and pathophysiology, 785
 muscle twitches, 784
 OCD, 1102
 treatment, 785–788
- Time-limited psychotherapy (Mann's),
 1821
- Timeline, history of psychiatry,
 2622–2624
- TLE *See* Temporal lobe epilepsy (TLE)
- TMS *See* Transcranial magnetic
 stimulation (TMS)
- Tobacco use disorders
 assessment, 1617–1618
 comorbidity patterns, 1619–1620
 course, 1620
 definition, 1616
 diagnosis, 1615–1616
 diagnostic features, 1616–1617
 differential diagnosis, 1620
 epidemiology, 1618–1619

- gender differences in, 1620–1621
genetic factors, 1621
issues in clinician–patient relationship, 1632
neurobiological factors, 1621–1622
outcomes, 1623
problems in management, 1630–1632
psychological factors, 1622
social/environmental factors, 1622
treatment
 benefits, 1623–1624
 combination medication, 1627–1628
 goals, 1623
 pharmacological, 1626
 phases, 1623
 psychiatric medication management issues, 1624
 psychosocial, 1627–1628
 somatic, 1624–1627
- Tolerance**
 alcohol-seeking behavior, 1403–1404
 caffeine intoxication, 1439–1440
 diagnostic criteria, 360
- Toluene**, 1509
- Topiramate**
 acute bipolar depression, 2143
 cocaine use, 1589–1590
- Topographagnosia**, 1672
- Torture**
 culture influence and sociopolitical context, 2559–2560
 definition, 2549–2550
 diagnostic considerations, 2552–2553
 educational issues, 2560–2561
 ethical issues, 2561
 gender issues, 2560
 methods, 2550–2551
 outcome evaluation, 2559
 physical effects, 2551
 prevalence, 2550
 psychological effects, 2551–2552
 rehabilitation models, 2559
 survivor issues, 2560
 therapeutic considerations
 approaches to treatment, 2555–2556
 cognitive behavioral therapy, 2557
 communication with patients, 2556
 psychodynamically oriented therapy, 2557
 psychopharmacological treatment, 2557–2558
 therapist–patient relationship, 2556
 treatment models, 2558
 torture syndrome, 2553
- Tourette's syndrome (TS)**, 188, 780, 784
 antipsychotic medication, 2097
 OCD and, 1102, 1106
- Toxic delirium**, 1651
- Toxic stress**, 1777
- Toxic substances**
 external prenatal causes, 684–685
 postnatal causes, 686
- Trait-state conception**, of anxiety, 555
- Trance experiences**, phenomenon of, 1892
- Trance logic phenomenon**, 1894
- Trance syndrome**
 dissociative, 1191–1192
 possession, 1192
- Tranquilliser Recover and Awareness Place**, 1555
- Transactional model**, 214–215
- Transcranial direct current polarization (tDCS)**, 2302–2303
- Transcranial magnetic stimulation (TMS)**, 934–935, 2298–2301, 2621
- Transference-focused psychotherapy (TFP)**, 467, 1812
- Transference reactions**, 24–25
- Transitional employment**, 1968
- Transitions and developmental crises**, in adult, 225
- Transmissible infectious diseases**, 1397
- Transmitter systems**, 347–349
- Transvestic disorder**, 1750–1753 *See also* Paraphilic disorders
- Trauma**
 in childhood, 592
 DD and, 1180–1181
- Trauma-related disorders**, 1178
 DSM-5 classification, 665
- Traumatic brain injury (TBI)**
 amnesia, 1670–1671
 assessment issues, 1686
 associated features, 1686
 comorbidity and course, 1687
 delirium, 1655
 dementia, 1664
 diagnostic features, 1685–1686
 differential diagnosis, 1687
 epidemiology, 1686–1687
 etiology and pathophysiology, 1687
 neuropsychiatric populations, 627
 and posttraumatic stress disorder, 1146
 treatment, 1687–1688
- Trazodone**
 GAD treatment, 2164–2165
 generalized anxiety disorder, 2165
- The Treatment Advocacy Center (TAC)**, 1984, 1985
- Treatment-refractory depressed patients**, therapeutic options for, 2080
- Treatment-resistant depression (TRD)**, 941, 942
 augmentation, 2322–2324
 combination antidepressant strategies, 2324–2325
 definition, 2311–2312
 indications
 brain stimulation treatment, 2327
 psychotherapy combination treatment, 2326
 limitations, 2327–2328
- management**, general principles, 2325–2326
- medication management**
 dosage and duration, 2318–2319
 emergencies, 2319
 principles, 2318
- novel agents**, 2325
- patient evaluation**
 differential diagnosis, 2315–2317
 previous pharmacological treatment, 2314–2315
- predictors**, 2312–2314
- prevalence**, 2312
- proposed algorithm for treatment**, 2325
- subtyping**, major depression, 2317–2318
- switching antidepressants**
 within class, 2319–2320
 between classes, 2320–2322
- Treatment-resistant patients**, strategies for, 2079
- Treatment-resistant schizophrenia (TRS)**
 adjuvant treatment, 2108
 clozapine, 2107
 new-generation antipsychotics, 2107–2108
- Trichotillomania (TTM)**
 diagnostic features, 1135–1136
 etiology and pathophysiology, 1136
 OCD vs., 1106
 treatment, 1136–1137
- Tricyclic antidepressants (TCAs)**, 1255, 2043, 2052, 2054, 2071, 2159
 antidepressants, perinatal depression, 2363, 2367, 2368
 anxiolytic drugs, 2159
 GAD treatment, 2164
 generalized anxiety disorder, 2164–2165
 obsessive-compulsive disorder, 2182
 panic disorder, 2172–2173
 posttraumatic stress disorder, 2176
 social anxiety disorder, 2168
 treatment-resistant depression, 2321–2322
- Trigeminal neuropathy**, inhalant abuse, 1518
- Trinucleotide repeats**, 869
- Triple P Positive Parenting program**, 1772
- Tristomania**, 2606
- TRT** *See* Testosterone replacement therapy (TRT)
- TS** *See* Tourette's syndrome (TS)
- TSC** *See* Tuberous sclerosis (TSC)
- T-tests**, research design, 2585
- TTM** *See* Trichotillomania (TTM)
- Tuberous sclerosis (TSC)**, 387
- Tuberous sclerosis complex (TSC)**, 681
- Turner syndrome**, chromosomal anomalies, 680
- Twin studies**, schizophrenia, 799

- Two-compartment mathematical model, for drug distribution, 2029
- Type 2 diabetes mellitus (T2DM), 2114–2115
- Tyrosine hydroxylase, 215
- UCLA Hoarding Severity Scale (UHSS), 1100
- Ultra-rapid metabolizers (UMs), 2047
- Ultrasonic bladder volume alarm, 1255
- Uncomplicated bereavement, 1760
- Unconscious conflict, 465
- Undifferentiated somatoform disorder, 1207
- United Nations Convention on the Rights of Persons with Disabilities (UN-CRPD), 1959
- United States, history of psychiatry, 2606–2607
- Univariate approaches, research design analysis of variance, 2586 chi-square, 2586 *t*-tests, 2585
- Unspecified depressive disorder, 916
- Uremic encephalopathy, 1652
- Urinary tract infection (UTI), 1252
- Urine testing, 514
- Urine toxicological screens, 1397
- Urophilia, 1751
- UTI *See* Urinary tract infection (UTI)
- Vagus nerve stimulation (VNS), 935, 2303–2305
- Valeriana officinalis* (Valerian) anxiety disorders, 2269 insomnia, 2276
- Validity psychiatric epidemiology, 412, 415–416 research designs, 2582
- Valproic acid/valproate acute bipolar depression, 2141–2142 cognitive enhancers, AD, 2252 mood stabilizers for mania, 2136–2137 pregnancy, psychiatric symptoms risk, 2430
- Varenicline, 1627
- Variable number tandem repeat (VNTR) polymorphism, 1357
- Variance, research design, 2584–2585
- Vascular dementia, 1663
- Vascular disease, 1682–1683
- Vastigmine, cognitive enhancers in AD, 2245
- VCFS *See* Velocardiofacial syndrome (VCFS)
- Vegetative symptoms, depression, 587
- Velocardiofacial syndrome (VCFS), 681
- Venlafaxine, 2063, 2076 anxiolytic drugs, 2159 cannabis dependence, 1466 for children with SAD, 2168 panic disorder, 2171–2172 social anxiety disorder, 2168 treatment-resistant depression, 2325 XR variety for adolescents, 2164 for children, 2164 vs. duloxetine, 2164 generalized anxiety disorder, 2163 side effects, 2164
- Ventral striatum, 248–249
- Ventricles, enlarged, 803–804
- Verbal communication, 43–44
- Verbal learning and memory tests, 817
- Verbal memory, 233
- Verbal paraphasia, 1660
- VIA classification of character strengths, 492–493
- Video conferencing cost and cost savings, 2013 minimum transmission speed, 2014 recommendations for, 2013–2014 web-based, 2012
- Vietnam Era Twin Registry, 1641
- Vigabatrin, 1590
- Vigilance, 817
- Vilazodone, 2063, 2076
- Vineland Adaptive Behavior Scales, 634
- Violence, 58 and agitated patient, 49–50 vs. anger and aggression, 2508 brain lesions/injuries, 2512 classification, 2507 clinical factors associated, 2508 definition, 2506 dysfunctional anger, 2513 genetic factors and genetic syndromes, 2512 hormones induced, 2511–2512 IPV (*see* Intimate partner violence (IPV)) and mental illness intellectual disability, 2510 mood and anxiety disorders, 2510 personality disorders, 2510 schizophrenia, 2509 neurotransmitters, 2512–2513 risk, 517–518, 2507 sexual (*see* Sexual violence (SV)) substance induced alcohol, 2510 illegal drug use, 2511 treatment (*see* Aggression) WHO, 2506 in youth, 2508
- Viral infection and schizophrenia, 802
- Virtual reality therapy (VRT), 2020
- Visual hallucinations, 589
- Visual impairment, 676–677
- Visuospatial functions, 602
- Vitamin cognitive enhancement, 2278 deficiency, dementia, 1665
- Vitamin D deficiency, 2253–2254
- Vitamin E, 2275
- Vitex agnus-castus, 974
- Voice Over Internet Protocol (VOIP) phones, 2011
- Voluntary sleep loss, 1278
- Vortioxetine, 2063
- Voyeuristic disorder, 1750 *See also* Paraphilic disorders
- VRT *See* Virtual reality therapy (VRT)
- Vulnerability genes, 330 model, depression, 560 substance use disorders, 368–369
- WAIS-IV *See* Wechsler Adult Intelligence Scale IV (WAIS-IV)
- Wakefulness, 1264–1266 *See also* Insomnia
- Waking, enuresis management, 1255
- WBC testing *See* White blood cell testing
- WCST *See* Wisconsin Card Sorting Test
- Web-based video conferencing, 2012
- Wechsler Adult Intelligence Scale, 233–234
- Wechsler Adult Intelligence Scale IV (WAIS-IV), 530 Block Design subtest, 607 Wechsler Adult Intelligence Scale-Revised test, 509
- Wechsler-Bellevue Intelligence Scale, 530
- Wechsler Intelligence Scale for Children-Fourth Edition (WISC-IV), 633
- Wechsler Memory Scale test, 509
- Wechsler Preschool and Primary Scale of Intelligence-III (WPPSI-III), 633
- Weight gain and obesity, 2114
- Weight loss anorexia nervosa, 1231, 1233 psychiatric/medical causes, 1237
- Weight phobia, 1237
- Wender-Reimherr Adult Attention Deficit Disorder Scale, 750
- Wernicke-Korsakoff syndrome, 1186
- Wernicke's aphasia, 1660
- Wernicke's encephalopathy, 1653
- White blood cell (WBC) testing, 824
- White matter lesions, 625, 626
- WHODAS *See* World Health Organization Disability Assessment Schedule (WHODAS)
- Will disorders, 543–545
- Williams syndrome, 680
- Wilson's disease, 1666
- Wisconsin Card Sorting Test (WCST), 234, 281, 509
- Withdrawal/negative affect stage, addiction motivation substrate-negative, 373 stress-aversion circuitry, 373–374
- Withdrawal syndrome, 2078
- Within-illness heterogeneity, 607
- WMH Survey Initiative *See* World Mental Health (WMH) Survey Initiative

- Woodcock-Johnson-III Tests of Achievement (WJ-III), 634
- Working memory, 232, 817, 1658–1659
neuropsychological assessment, 602
- Working Memory Index, 530
- Work-ordered day, 1968
- World Health Organization Disability Assessment Schedule (WHODAS), 574
- World Medical Association (WMA), 74
- World Mental Health (WMH) Survey Initiative, 425, 429
age-of-onset distributions, 426
DSM-IV/CIDI disorders, 428
prevalence, 425–426
- World Psychiatric Association (WPA), 75
International Guidelines for Diagnostic Assessment (IGDA), 649
- Worry
GAD/OCD distinction, 1082
generalized anxiety disorder, 1076–1077
nonpathological, 1081
pathological, 1083–1084
- Writing disorders, 768
- Xaliproden, 2248
- X-linked inheritance disorders, 682–683
- X-ray imaging and CT scanners, 617–618
- Xyrem (sodium oxybate/gamma hydroxybutyrate), 2200
- XXX syndrome, 2512
- Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), 1096
- Yale Family Study of Stuttering (YFSS), 716
- Yoga
breathing, 2271, 2273
mood disorders, 2267
- Yohimbine test, 2059
- Young adulthood, 219–220 *See also* Adolescents
- Young children *See* Infants; Preschool children
- Youth and Adolescence Study (YAS), 204
- Zaleplon (Sonata), 1554
- Z hypnotics
eszopiclone, 1554
zaleplon, 1554
zolpidem, 1553–1554
zopiclone, 1554
- Zinc, mood disorders, 2266
- Ziprasidone, 2096
acute bipolar depression, 2141
adjunctive to lithium/valproate, maintenance therapy, 2150
schizophrenia, 824–825
- ZNF804A*, 801
- Zolpidem, 1553–1554
- Zoophilia, 1751
- Zopiclone, 1554
- Zotepine, 2097

